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Abstract
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder and it is the most
common cause of dementia in elderly. The disease is characterized by memory loss,
mood swings, and communication problems. This uniquely human disease has been
investigated in various mouse models mimicking different pathological hallmarks of AD,
which supplied valuable insight into disease mechanisms; however, clinical trials based
on these models failed and current treatments are unsatisfactory. To overcome the
limitations of animal models of AD, the emerging induced pluripotent stem cell (iPSC)
technology promises great potential. It offers the possibility to investigate underlying
disease mechanisms, screen for drug targets and validate therapeutic effects in
disease-relevant cell types of human origin on a patient-specific background. Current
iPSC studies to model AD have been addressing the questions of the pathological
hallmarks such as an increase in amyloid beta (Aβ) and hyperphosphorylated tau.
However, to investigate the AD-related phenomenon of neuronal hyperactivity, mature
human neuronal cultures with spontaneously active networks are necessary, and their
generation remains a challenge.
In this study, to achieve spontaneously firing mature neuronal networks, human iPS cells
were differentiated into neurons and were supported with endogenously differentiated
human astrocytes or primary cortical astrocytes (PCA) isolated from rat brains.
Neuronal activity was recorded by using multi electrode array (MEA) to detect single
spikes and network bursts. Calcium imaging of spontaneously firing networks was
performed to monitor synchronously active neurons in cultures. To trigger
hyperactivity-induced homeostatic plasticity in human networks, iPSC-derived cultures
were treated with 4-Aminopyridine (4AP), a non-selective inhibitor of voltage-gated K+
channels. It increased the network activity only in mature (burst firing) cultures. This
induced hyperactivity further led to activation of homeostatic plasticity dependent
mechanisms to reduce the firing rate. Single spike analysis suggested Na+ channel
removal from the axonal membrane as one of these compensatory mechanisms.
Moreover, repressor element-1 silencing transcription factor (REST) was identified as a
key player in this process.
To study AD-related impairments in the established model, cell-derived and synthetic Aβ
oligomers were prepared and characterized by semi-native western blot. Synthetic Aβ
oligomers were surprisingly stable when added to neuronal cultures and caused no cell
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death and no change in spontaneous network activity. However, upon 4AP treatment,
Aβ-treated networks showed impaired homeostatic plasticity and were not able to
reduce the firing rate appropriately. According to the analysis of spike properties, the
plasticity-associated reduction of axonal Na+ channels was also impaired. In Aβ-treated
cultures, nuclear REST expression was diminished at basal levels and after triggering
homeostatic plasticity by 4AP. Thus, AD-related hyperactivity may be caused by
dysfunctional homeostatic plasticity in a REST-dependent manner.
Taken together, the results of this study provided the first hint on a previously unknown
impairment of homeostatic plasticity mechanisms in AD and identified REST as a target
which might contribute to the hyperactivity phenomenon at early stages of AD. This
knowledge of plasticity impairment might expand our understanding of disease
development and REST manipulation might be a new target for potential therapeutic
strategies.
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Zusammenfassung
Die Alzheimer Erkrankung (AE) ist eine progressive, neurodegenerative Krankheit und
die häufigste Ursache für Demenz bei älteren Menschen. Sie ist charakterisiert durch
Gedächtnisverlust, Stimmungsschwankungen und Kommunikationsprobleme. Diese
ausschließlich beim Menschen vorkommende Erkrankung wurde in unterschiedlichen
Mausmodellen untersucht, die verschiedene pathologische Merkmale der AE
adressieren. Diese lieferten wertvolle Einblicke in die Krankheitsmechanismen, jedoch
scheiterten darauf basierende Klinische Studien und existierende Therapien sind
unzulänglich. Um die Einschränkungen von Tiermodellen bei der Modellierung der AE
zu überwinden, verspricht die aufkommende Technologie der induzierten pluripotenten
Stammzellen (iPSZ) großes Potenzial. Sie ermöglicht es, zugrunde liegende
Krankheitsmechanismen, Medikamentenforschung und Validierung an
krankheitsrelevanten Zelltypen menschlichen Ursprungs vor einem
Patienten-spezifischen Hintergrund durchzuführen. Bisherige iPSZ Alzheimer-Studien
haben sich vor allem mit den Fragen der pathologischen Kennzeichen der AE, wie der
Zunahme von Amyloid-beta (Aβ) und hyperphosphoryliertem Tau beschäftigt. Um das
bei der AE auftretende Phänomen der neuronalen Hyperaktivität zu untersuchen,
werden reife menschliche neuronale Kulturen mit spontan aktiven Netzwerken benötigt.
Deren Generierung stellt eine Herausforderung dar.
Um spontan feuernde reife Netzwerke zu erhalten, wurden in dieser Studie menschliche
iPS Zellen zu Neuronen differenziert. Deren Ausreifung wurde unterstützt durch
endogen differenzierte menschliche Astrozyten oder durch primäre kortikale Astrozyten
(PCA) der Ratte. Die neuronale Aktivität wurde unter Verwendung eines
Multielektroden-Arrays (MEA) gemessen, um einzelne Aktionspotenziale (Spikes) und
Netzwerk-Bursts zu detektieren. Bildgebende Kalzium-Messungen wurden an spontan
aktiven Netzwerken durchgeführt, um synchron aktive Neuronen zu detektieren. Um
mittels Hyperaktivität homöostatische Plastizität in menschlichen neuronalen
Netzwerken auszulösen wurden aus iPS Zellen hergestellte Kulturen mit 4-Aminopyridin
(4AP), einem nicht-selektiven Inhibitor spannungsabhängiger K+-Kanäle behandelt.
Dies erhöhte die Netzwerkaktivität allerdings nur in reifen Kulturen, welche ein
Burst-Feuerverhalten aufwiesen. Die induzierte Hyperaktivität führte zur Aktivierung von
Mechanismen homöostatischer Plastizität, um die Netzwerkaktivität zu reduzieren. Die
Analyse einzelner extrazellulärer Spikes deutete auf die Reduktion axonalen Na+
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Kanälen als einen dieser kompensatorischen Mechanismen hin. Eine Schlüsselrolle in
diesem Prozess kam dabei dem Repressor Element 1 Silencing Transkriptionsfaktor
(REST) zu.
Des Weiteren wurden, um AE-bezogene Beeinträchtigungen in diesem Modell zu
untersuchen, zelluläre und synthetische Aβ-Oligomere hergestellt und mit Hilfe eines
semi-nativen Western-Blots charakterisiert. Synthetische Aβ-Oligomere zeigten eine
überraschende Stabilität während der Behandlung der neuronaler Kulturen und
verursachten keinen Zelltod und keine Veränderung der spontanen Netzwerk-Aktivität.
Allerdings was in Aβ-behandelten Netzwerken die homöostatische Plastizität
beeinträchtigt und die 4AP-induzierte Hyperaktivität führte nicht zur entsprechenden
Runterregulation der neuronalen Aktivität. Die Spike Analyse deutete außerdem darauf
hin, dass die Plastizitäts-assoziierte Reduktion der axonalen Na+ Kanäle in
Aβ-behandelten Netzwerken vermindert war. Gleiches galt für die nukleare Expression
von REST im Grundzustand und nach dem Auslösen homöostatischer Plastizität durch
4AP. Demnach könnte die mit der AE verbundene Hyperaktivität durch eine
unzureichende Fähigkeit zur homöostatischen Plastizität zu Stande kommen, bewirkt
durch einen REST abhängigen Prozess.
Zusammenfassend offenbaren die Ergebnisse dieser Studie erste Hinweise auf eine
bisher nicht bekannte Beeinträchtigung eines homöostatischen Plastizitätsmechanismus
in der AE und identifizieren REST als einen wichtigen Faktor, der bei dem Phänomen
der Hyperaktivität im frühen Stadium der AE eine Rolle spielen könnte. Dieses Wissen
über Plastizitätsbeeinträchtigungen könnte unser Verständnis der Krankheitsentwicklung
verbessern. Weiterhin könnte die Manipulation von REST ein neues Ziel für potentielle
therapeutische Strategien darstellen.
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1. Introduction
1.1 Neuronal networks
The brain is the most complex organ of the human body. It consists of approximately
one hundred billion nerve cells, which are the information processing units in the brain
(Pakkenberg & Gundersen 1997). Neurons are surrounded and protected by glial cells.
Astrocytes are the most abundant glial cells in the brain. Microglial cells are the immune
defense cells and they are activated by external cues to clear waste material by
endocytosis. Ependymal cells secrete cerebrospinal fluid (CFS) to rinse the toxic waste,
produced as a result of the brain metabolism. Oligodendrocytes produce the myelin
sheet wrapping the axons of neurons (Kandel et al. 2000). Neurons are highly
compartmentalized. They are classified morphologically as multipolar, bipolar, and
unipolar. They also differ in their neurotransmitter secretion which distinguishes
excitatory pyramidal or inhibitory interneurons. Neurons are irreplaceable, amitotic, and
the longest-lived cells in the body with a very high metabolic rate using 20 % of the
calories taken by the human body to maintain neuronal signal transmission (Kandel
et al. 2000).
1.1.1 Action potential propagation and synaptic transmission
Neurons fire an impulse called action potential (AP), which is generated at the axon
initial segment upon depolarization of the neuron above the voltage threshold (Figure
1.1). The neuronal cell membrane acts as an insulator and the ion channels within the
membrane allow the ion exchange between intra- and extra- cellular space. Neuronal
membrane is 20 times more permeable to K+ ions compared to Na+ (Cohen 1973).
Therefore, a resting neuron is polarized due to the leaky K+ efflux causing negativity in
the inside of the cell (-70 mV). The higher abundance of K+ ions inside and Na+ ions
outside creates an electrochemical gradient. Depolarization of the resting neuronal
membrane via ion diffusion through ligand gated channels triggers the opening of
voltage-gated Na+ channels and the membrane depolarization. After reaching 0 mV,
voltage-gated Na+ channels close and voltage-gated K+ channels open, which leads to
K+ efflux and repolarization. After hyperpolarization, the Na+-K+ pump takes over and
the membrane reaches its resting potential (Bean 2007).
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Figure 1.1: Action potential (AP) characteristics. Illustration of commonly measured AP parameters
according to Bean et al. (2007). Resting membrane potential is at -70 mV. The threshold (the depolarization
voltage level that must be achieved for an AP firing) for firing is at -55 mV. The amplitude of an AP is defined
as the peak relative to the threshold. Maximum rising and depolarizing slopes are the values defining the
rate of rise of membrane voltage during spike rising phase and the rate of rise of membrane voltage during
spike falling phase, respectively. Spike width is most commonly measured as the width at half-maximal spike
amplitude. Afterhyperpolarization is calculated as the voltage difference to AP threshold.
The neuronal signal transmission (synaptic transmission) occurs at the connecting point
of two neurons called synapse (Figure 1.2). When an AP reaches the axonal terminal, it
triggers signal transmission via electrical or chemical synapses, which transmit ion
currents via gap junctions or neurotransmitter release to the synaptic cleft, respectively.
The chemical synapse is slower, yet more precise and selective (Kandel et al. 2000).
The AP acts according to all-or-none principle. The signal in the chemical synapse can
be modified, amplified, or inhibited. The signal passing neuron (the presynaptic neuron)
releases neurotransmitters, packed in synaptic vesicles, which are in a close vicinity to
the axon terminal. When an AP reaches the axon terminal, voltage-gated Ca2+ channels
open, Ca2+ enters the cells, synaptic vesicles fuse with the neuronal membrane,
neurotransmitters diffuse to the synaptic cleft and bind to postsynaptic receptors such as
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-Methyl-
2
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D-aspartic acid (NMDA) for glutamate. Activated receptors change the postsynaptic
membrane potential in either an inhibitory (inhibitory post synaptic potential, IPSP) or an
excitatory (excitatory post synaptic potential, EPSP) manner.
Figure 1.2: Scheme of a chemical synapse. According to Purves et al. (2001). Upon arrival of
the AP, presynaptic membrane depolarizes, voltage-gated Ca2+ channels open, and presynaptic Ca2+
levels increase. This cascade leads to the release of neurotransmitters from the membrane-docked
neurotransmitter-containing synaptic vesicles to the synaptic cleft. Others are stored in the reserve pool,
just above the docked vesicles. Released neurotransmitters bind to ionotropic or metabotropic postsynaptic
receptors and thereby lead to a change of the postsynaptic membrane potential.
Neurotransmitter-triggered postsynaptic changes are not restricted to the occurrence of
IPSP and EPSP. Long-term changes can also occur at the synapse. The structure and
therefore the function of a synapse can be altered with a mechanism called synaptic
potentiation. This activity dependent change of the synapse is the main suggested
mechanism of learning and memory (Brown et al. 1988). Long-term potentiation (LTP)
and long-term depression (LTD) are the most prominent processes. LTP occurs as a
result of presynaptic high-frequency stimulus which involves glutamate binding to NMDA
receptors, following Ca2+ influx and activation of the calcium-calmodulin-dependent
kinase II (CaMKII). The active kinase phosphorylates AMPA receptors leading to a
higher permeability of Na+ ions and increased depolarization. An elevated Ca2+
concentration in the cell can alter signaling cascades and leads to structural changes in
3
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the postsynaptic membrane. On the other hand, LTD occurs in a similar manner;
however, with a low-frequency electrical stimulation. It reduces the number of AMPA
receptors at the synapse. The occurrence of LTP and LTD in a single synapse might
lead to synapse loss and cell death via over-excitation or inhibition, respectively. To be
able to keep neuronal transmission and prevent synapse loss, neurons control their
excitability with another plasticity mechanism, namely homeostatic plasticity.
1.1.2 Homeostatic plasticity
Neuronal networks have the ability to keep their activity at a basal state to maintain
stable function when they face activity alterations during learning and development
(Figure 1.3). During development, neuronal networks are hyperactivated to maintain
strong synaptic connections, which are fine-tuned to basal states at later stages of
development. Burst firing networks of the hyper-synchronized state of the brain are
considered to be epileptic if they occur in adult brains; however, it is a sign of maturity of
dissociated cultures in vitro (Chiappalone et al. 2006). The regulation of activity by
homeostatic plasticity mechanisms occurs in a time scale of days. Those mechanisms
are considered as homeostatic when the regulation maintains an average neuronal firing
rate around some set-point value (Turrigiano 2012). There are many suggested
homeostatic plasticity mechanisms, such as synaptic scaling (Turrigiano & Nelson
2004), homeostatic regulation of intrinsic firing (Marder & Prinz 2003), adjustment of the
excitation-inhibition balance (Maffei et al. 2004), activity-dependent spine loss (Kirov
et al. 1999) and tuning of intrinsic excitability (Marder & Goaillard 2006).
Synaptic scaling
Activity-dependent increase in synaptic strength of individual synapses by Hebbian
mechanism (Abbott & Nelson 2000) can be scaled down by homeostatic mechanisms
(Turrigiano 2008) to protect cells from over-excitation. Synaptic scaling is the ability of
neurons to detect their firing rate changes through calcium-dependent mechanisms and
as a result, alter receptor trafficking. Synaptic scaling is identified as bidirectional
compensatory mechanism upon pharmacological manipulations of the network activity
(Turrigiano 1999). As a result of altered network activity, miniature excitatory
postsynaptic currents (mEPSCs), that represent the response of a postsynaptic neuron
to neurotransmitter release, show increased or decreased amplitudes. This altered
response is the result of a postsynaptic scaling mechanism, which changes the synaptic
4
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strength up or down to compensate the activity (Desai et al. 1999).
Mechanistically, selectively blocking voltage-gated Na+ channels with tetrodotoxin (TTX)
or postsynaptic AMPA receptors leads to an upscaling of the synaptic strength via
decreased Ca2+ signaling and reduced activation of calcium/ calmodulin-dependent
protein kinase type IV (CaMKIV) (Ibata et al. 2008). As a result, AMPA-type glutamate
receptors accumulate in the postsynaptic membrane. The abundance of AMPA
receptors facilitates scaling up the miniature amplitude in the postsynaptic cell. The
suppressed neuronal activity also causes enlarged active zones and increases the
number of docked vesicles, which thereby facilitates the transmitter release and
increased synaptic strength (Pozo & Goda 2010).
Figure 1.3: Homeostatic plasticity. Illustration of homeostasis of neuronal firing rate according to
Turrigiano (2012). Activity perturbations induced by different mechanisms such as learning and memory
formation might result in hyper- or hypo-active neurons. Neurons can adapt their firing rates by changing
their synaptic properties (homeostatic synaptic scaling) or their ion channels composition which controls
neuronal excitability (homeostatic intrinsic plasticity) via homeostatic mechanisms to restore the basal firing
rates.
Elevated firing rate, on the other hand, leads to an enhanced calcium influx, activated
CaMKIV signaling pathway, AMPA receptor removal and a scaling down of the synapse
(Goold & Nicoll 2010). One of the identified calcium-dependent mechanisms is the
immediate early gene Homer1a mediated signaling which includes the regulation of
mGluRs and reduction of the tyrosine phosphorylation of GluA2 (Hu et al. 2010).
Degradation of AMPA receptors upon ubiquitination is another proposed mechanism for
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synaptic scaling which is regulated by elevated Eph4A activity (Fu et al. 2011). The
enhanced firing rate also affects the presynapse causing a reduced number of docked
vesicles and thereby neurotransmitter release (Moulder et al. 2004). Moreover, vesicular
glutamate transporter v-Glut1 expression levels are also altered by homeostatic
adaptations in the presynapse which causes further changes in the vesicular glutamate
content (De Gois et al. 2005).
Intrinsic plasticity
Intrinsic plasticity is a form of homeostatic adaptation which mainly involves changes in
the number, type, and distribution of the voltage-gated ion channels on the neuronal cell
membrane. Extended blockage of neuronal network activity results in an upregulation of
intrinsic excitability in cortical and hippocampal neurons (Desai et al. 1999). Conversely,
increasing network activity above basal levels leads to a decrease of the excitability.
Manipulations of neuronal excitability change the membrane conductance allowing the
neuron to maintain stable output properties (Surmeier & Foehring 2004). This form of
plasticity in hippocampal neurons involves calcineurin-dependent dispersion and
changes in the gating of K+ channels, reducing the cell’s excitability (Misonou et al.
2004). Although the phenomenon of homeostatic intrinsic plasticity has now been widely
investigated, very little is known about the underlying molecular mechanisms.
Furthermore, the importance of homeostatic plasticity mechanisms during abnormal
activity patterns in neurological diseases, particularly in epilepsy and their exact role in
hyperexcitable disease states are to be elucidated.
One of the attempts to investigate the molecular role players in intrinsic plasticity has
brought to light the REST/NRSF (Repressor Element-1 Silencing Transcription Factor/
Neuron-Restrictive Silencer Factor) protein in a 4AP model of increased activity (Pozzi
et al. 2013). In addition to its role in reducing Na+ channels as a result of intronsic
plasticity, REST has been further shown to decrease the presynaptic vesicle pool
(Pecoraro-Bisogni et al. 2017). The involvement of REST in various neurodegenerative
diseases such as Huntington’s disease (Zuccato et al. 2003), Alzheimer’s disease (Lu
et al. 2014), and finally as a candidate biomarker for plasma-based diagnoses of AD
(Ashton et al. 2017) has been reported with some controversial results. Collectively,
these studies outline that alterations in REST-dependent homeostatic plasticity may play
a role in especially early stages of neurodegenerative diseases.
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1.2 Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is the most common form of dementia and it is characterized
by progressive memory loss followed by personality changes, visuospatial deficits, loss
of language skills and sometimes depression. One in ten people aged 65 and one in
three over 85 years are affected by dementia. In 2015, there were 47.5 million people
suffering from dementia and 70% of them were AD patients according to the Alzheimer’s
Association. By 2050, the projections point out that there will be 135.5 million people with
dementia and approximately 95 million of them will be suffering from AD (Qiu & Fratiglioni
2017). AD is classified as early onset familial AD (FAD) where a single mutation in one
of the PSEN2 (Levy-Lahad et al. 1995), PSEN1 (Sherrington et al. 1995) or APP (Goate
et al. 1991) genes causes AD in an autosomal dominant manner and late onset sporadic
AD (SAD) where several risk factors, both genetic and environmental, are thought to
result in AD.
Figure 1.4: Alzheimer’s disease brain. Illustration of healthy vs AD brain according to Holtzman et al.
(2011). AD brain shows massive atrophy, cortical thinning, and larger ventricles compared to healthy brain.
Extracellular insoluble amyloid plaques and intracellular accumulation of neurofibrillary tangles are the main
pathologies of AD.
1.2.1 Symptoms and diagnosis
Alzheimer’s disease has been first described by the German psychiatrist Alois Alzheimer
(Alzheimer 1907). During the course of the disease, the patient first shows indications of
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short term memory impairment such as forgetting simple words and misplacing things
which were followed by losing the ability to process logical thoughts, showing erratic
mood changes, paranoia and hallucinations. In later stages of the disease, deepest
memories of the patient are erased and finally, heart rate and breathing control centers
cease to function. Persistent and progressive memory loss and other cognitive deficits
along with massive brain atrophy and pathological hallmarks of AD (Figure 1.4) results
in impaired social and functional activities of daily life of a patient. Since AD is a
condition which has a considerable impact on society, early diagnosis is crucial to inform
and support patients and caregivers and to decide on suitable treatment strategies.
To date, there is no single test to diagnose Alzheimer’s disease. However, there are
several methods and tools to determine whether the patient might have Alzheimer’s
dementia or any other dementia-causing disorders. Traditionally, the post mortem
investigation of AD-related hallmarks (plaques and tangles, see Figure 1.4) following a
progressive cognitive deterioration of the patient was the main diagnosis of AD. Today,
the diagnosis is mainly based on clinical assessments about overall health, the ability to
carry out daily activities, and changes in behavior and personality since the disease is
foremost characterized by early anterograde amnesia and as the disease progresses
this is followed by a retrograde amnesia (Salmon & Bondi 2009). To evaluate cognitive
status of the patient, Mini-Mental State Examination (MMSE) is commonly used
(Tombaugh & McIntyre 1992). For the biochemical examination, the presence of Aβ and
tau in the cerebrospinal fluid (CSF) is scanned (Blennow et al. 2010) since the senile
plaques consist of the 42 amino acid long amyloid-beta peptide Aβ42 (Glenner & Wong
1984) and the hyperphosphorylated tau protein accumulates as tangles (Grundke-Iqbal
et al. 1986). The tangle pathology mainly follows the transentorhinal, hippocampal, and
extensive neocortical involvement reflecting the disease progression (Braak & Braak
1991). Furthermore, brain imaging analyses such as computed tomography (CT),
magnetic resonance imaging (MRI), and positron emission tomography (PET) are also
used routinely. The Pittsburg compound B (PiB) is a radioactive analog of the
fluorescent amyloid dye Thioflavin which crosses the blood brain barrier (BBB) and
allows in vivo imaging of Aβ with PET (Klunk et al. 2004). The studies using PiB
confirmed the early Aβ deposition in the brain decades before the existence of any
clinical symptoms of AD (Zhang et al. 2013).
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1.2.2 Molecular neuropathology
Two major pathologies of AD are the extracellular senile plaques and intracellular
neurofibrillary tangles (NFT) as first indicated by Alois Alzheimer (Alzheimer 1907). The
extracellular senile plaques consist of a byproduct of the amyloid precursor protein
(APP) which is extensively processed to release an active peptide ligand in AD (Allsop
et al. 1988). APP is a type-1 transmembrane protein found in all mammals and it shares
structural similarities with other family members called APLPs (APP like proteins, APLP1
and APLP2) (Müller & Zheng 2012). Even though they also share similar functions, they
do not completely overlap since the single knockout (KO) mice of any of the members
are viable but triple KO mice die early. On the other hand, Down syndrome patients
(trisomy 21, APP is overexpressed) get AD early in life (Salehi et al). APP also functions
as a signal protein which might have a role in axon formation and neurogenesis in adults
(Müller & Zheng 2012). It has been indicated that neuronal stem cells subjected to APP
antibodies showed decreased differentiation suggesting its function as an adhesion
molecule of the developing brain (Sosa et al. 2017).
Figure 1.5: Proteolytic cleavage of APP. ccording to Zhang et al. (2011). Membrane-tethered APP (Holo
APP) is cleaved by α- and γ-secretases via the non-amyloidogenic pathway. α-secretase cleavage releases
neuroprotective sAPPα fragment. γ-secretase cleaves the C83-fragment resulting in the extracellular release
of P3 and intracellular release of AICD. On the other hand, β-secretase cleavage via the amyloidogenic
pathway allows the release of sAPPβ in the extracellular space and further γ-secretase cleavage leads to
intracellular release of AICD and the release of Aβ in the extracellular space. Hydrophobic Aβ peptide further
forms dimers and oligomers, and accumulate in non-soluble fibril forms. AICD: amyloid intracellular domain.
APP is processed by two main pathways (Figure 1.5): the non-amyloidogenic pathway
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which primarily involves α-secretase (ADAM10) and the amyloidogenic pathway which
involves β-secretase (Beta-Amyloid precursor protein Cutting Enzyme, BACE). In the
non-amyloidogenic pathway, α-secretase cuts APP within the Aβ sequence and gives
rise to the 83 residue-long C-terminal fragment (CTFα, C83) and the N-terminal
fragment (NTFα) which is further cleaved by γ-secretase (a four-protein complex
consisting of Presenilin1 or 2, nicastrin, PEN-2, and APH-1) into sAPPα and P3
fragment (Zhang et al. 2011). On the other hand, when APP is cleaved by the
membrane bound β-secretase into the 99 residue CTF (C99) and NTF which is
consecutively cut by γ-secretase into a heterogeneous group of Aβ peptides with
various lengths between 38-43 amino acids and slightly different characteristics (Selkoe
2001). Furthermore, N terminally truncated or modified isoforms of the Aβ peptide were
found (Portelius et al. 2010) which have different toxicity inducing abilities (Deshpande
et al. 2006).
One of the main N-terminally truncated forms of Aβ is the pyroglutamylated
([Pyr3]Aβ3−42) form which was found in frontal and entorhinal cortices of post mortem
adult brains with AD (Mandler et al. 2014). A previous study pointed out that
[Pyr3]Aβ3−42 is more frequently found in plaques of sporadic AD cases (Güntert et al.
2006). Furthermore, only [Pyr3]Aβ3−42 or [Pyr3]Aβ3−42-containing Aβ1−42 oligomers
showed prion-like activity with higher cytotoxicity compared to Aβ1−42 only oligomers in
neuronal cultures and this effect was eliminated in the cultures of tau-knockout neurons
(Nussbaum et al. 2012). This brings us to the neurofibrillary tangle pathology of AD.
The second hallmark of AD is the neurofibrillary tangle pathology which is found as
bundles of abnormal fibers composed of the microtubule-associated protein tau
intracellularly in neurons of the affected brain regions of AD patients (Buée et al. 2000).
Microtubules are the neuronal cytoskeletal proteins and tau regulates the stability of the
neuronal cytoskeleton which is vital to vesicle transport (Grundke-Iqbal et al. 1986).
Total tau and phosphorylated tau levels are increased in both the brains and the CSF of
patients with Alzheimer’s disease (De Strooper & Karran 2016). In neurodegeneration,
tau is hyperphosphorylated and loses the ability to stabilize the neuronal cytoskeleton.
Hence, structural modification of neurons and impaired cellular transport mechanisms
are followed by cell death (Gendron & Petrucelli 2009). However, the mechanism of
increased and aggregated tau which is whether it is due to increased production or
impaired clearance and the relation of tau with Aβ (directly downstream or in parallel)
are not known.
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1.2.3 The amyloid cascade hypothesis
The amyloid cascade hypothesis was first proposed in 1991 by John Hardy and Gerald
Higgins. It suggests that the Aβ production as a result of APP dysmetabolism is the
initiating factor, followed by aggregation of overproduced Aβ which contributes to
neurofibrillary tangle formation, synaptic disruption, and ultimately dementia (Hardy &
Allsop 1991) (Figure1.6). The 25-year old hypothesis has been leading the field of
Alzheimer’s disease research (Hardy & Selkoe 2002). This hypothesis mainly stems
from familial genetic mutations which cause an increased Aβ production and additional
harmful effects of Aβ on brain cells.
In recent years, growing evidence on Aβ deposition and AD challenged the leading
hypothesis and hence some modifications of the hypothesis have been proposed. The
main criticisms are the poorly correlated plaque load and dementia. Severity of
dementia rather correlates with the number and location of neurofibrillary tangles than
with the extent of senile plaque depositions (Bierer et al. 1995), and AD-like neurological
symptoms occur prior to plaque deposition (Hsia et al. 1999). Furthermore, evidence on
the pathological role of soluble oligomeric Aβ species such as synapse loss and
memory impairment (Terry et al. 1991) supported the idea that plaques might be inert
end products and possibly protect the brain from the toxic soluble Aβ species.
There is another challenging relationship between the plaques and the neurofibrillary
tangles. It has been shown that even though the plaque load does not alter, transgenic
mice with APP and tau mutations suffer from a more severe tau pathology than only tau
expressing mice (Ashe & Zahs 2010). This contributed to the view that neurofibrillary
tangles are downstream to Aβ pathology but not downstream to plaque formation.
Overall, although Aβ may not be the main culprit in AD pathology, Aβ deposition can be
the signifying point of the irreversible pathological changes. Thus, it is critical to
understand the mechanisms of Aβ-related alterations to find the optimal time point for
interventions before the take over of the irreversible pathological cascade which may
help to prevent further progression of the AD.
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Figure 1.6: Amyloid cascade hypothesis. According to Selkoe & Hardy (2016). Altered Aβ metabolism
in FAD or SAD leads to increased levels of soluble Aβ which is thought to be the initial step for the
pathological downstream effects such as early synaptic alterations, inflammation, oxidative stress, and tau
phosphorylation. Early on in this cascade, Aβ was shown to impair synaptic function. Later processes lead
to neuronal dysfunction, cell death and dementia with the plaque and tangle pathologies.
1.2.4 Synaptotoxicity
The main issue related to AD is amnesia which impairs learning and memory. Since
learning and memory are considered to be correlates of synaptic strength and plasticity,
AD’s main hallmark Aβ might primarily have an effect on synapses. This observation
stems from studies in which APP overexpressing mice show fewer synapses and
decreased spine density (Hsieh et al. 2006). Plaque bearing mice show excitatory
synapse loss near the plaques (Koffie et al. 2009), on the other hand, APP KO mice
have more synapses than wild type mice (Priller et al. 2006).
Hippocampal LTP is the main model to investigate synaptic changes (Martin et al. 2000).
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Further research on Aβ-related synaptic alterations has been carried out predominantly
in brain slices or primary neuronal cultures. FAD mutation carrying mice show LTP
deficits in an age-related manner before plaque and tangle pathology (Oddo et al. 2003).
It was reported that application of Aβ dimers isolated directly from Alzheimer brains to
hippocampal slice preparations induces synapse elimination, impair synaptic plasticity
and memory (Shankar et al. 2008). Naturally secreted Aβ oligomers lead to
hippocampal LTP inhibition in vivo (Walsh et al. 2002). Emerging cellular models of AD
with PSEN overexpressing hESC-derived neurons showed that the mEPSP frequency is
decreased (Honda et al. 2016). Overall, reported findings support the hypothesis that
AD is primarily a synaptic disease.
It has been extensively reviewed that Aβ inhibits LTP (Klein 2013), however, the exact
mechanism is not yet clear. There have been various studies showing the pathways
which Aβ acts through or interferes one of its proteins. Protein phosphatase 1 (Knobloch
et al. 2007), c-Jun N-terminal kinase, cyclin-dependent kinase 5 (cdk5), and p38
mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5
(Wang et al. 2004) were implicated in Aβ-induced LTP impairment. Moreover, Aβ
inhibits several kinases such as Erk/MAPK, CaMKII, and the phosphatidylinositol
3-kinase activated protein Akt/protein kinase B (Townsend et al. 2007) and activates
glycogen synthase kinase-3β (GSK-3β) (Takashima et al. 1996). The receptor for
advanced glycation end products (RAGE) (Arancio et al. 2004) has been implicated in
the Aβ-induced LTP inhibition.
There are also in vitro studies which suggest that LTD has a lower threshold (Hsieh et al.
2006) in APP overexpressing primary mouse hippocampal neurons and the mechanism
involved in this process is glutamate uptake (Li et al. 2009) in primary mouse
hippocampal neurons treated with Aβ. Interestingly, it has been shown that LTD can
lead to synapse elimination (Nägerl et al. 2004) and the synaptic loss is correlated with
the severity of AD-related symptoms (Scheff & Price 2003). The evidence presented in
this section suggests that Aβ indeed leads to synaptic impairment. However, it is
important to keep in mind that different Aβ preparations have different effects and acts
through various mechanisms (Ladiwala et al. 2012).
Overall, the existing literature on AD is extensive and focuses particularly on Aβ induced
synaptic failure. However, another significant aspect of AD is hyperactivity which was
neglected for many years.
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1.2.5 Hyperactivity
The main functional deficits in AD are the massive neuronal activity loss and synaptic
failure. However, recent studies with animal models as well as early stage AD patients
demonstrate that hyperactivity in various brain regions is not a coincidence. It was
reported that neurological functions of AD patients fluctuate rapidly, which cannot be
explained by neuronal loss. Instead, it is more likely that abnormal neuronal network
activity is the reason behind rapid neurological changes (Palop et al. 2006). FAD
patients showed hyperactivity and complex partial seizures before silencing of the
networks (Noebels 2011). Further studies with animal models of AD showed that
spontaneous nonconvulsive seizure activity in cortical and hippocampal networks might
be associated with impaired GABAergic synaptic inhibition (Palop et al. 2007). In
addition to decreased neuronal activity in animal models of AD, there are hyperactive
neurons exclusively near the plaques which might be due to the decreased synaptic
inhibition (Busche et al. 2008).
It has been reported that patients with sporadic and familial forms of AD share the
seizure incidence (Palop & Mucke 2009). As suggested, the main reason behind the
seizures might be the pathological accumulation of oligomeric Aβ-induced dysfunction
of inhibitory interneurons and their contribution to the network destabilization (Palop &
Mucke 2010). Further research had shown that inhibitory parvalbumin (PV) interneurons
in hAPP mice had decreased levels of voltage-gated sodium channel subunit Nav1.1
(Verret et al. 2012) leading to impaired inhibition and epileptic seizures. In vivo two
photon calcium imaging study showed that the early hippocampal hyperactivity was
detected in young mice before the formation of plaques, suggesting that soluble Aβ
species underlie this impairment. (Busche et al. 2012)
Seizures and epilepsy are not rare phenomena (Friedman et al. 2012) and the epilepsy
drug levetiracetam showed an effective reduction in abnormal spike activity detected by
electroencephalography (EEG). It reversed hippocampal remodeling, behavioral
abnormalities, synaptic dysfunction, and deficits in learning and memory in hAPP mice
(Sanchez et al. 2012). In early stages of AD, patients showed seizures and epileptiform
activity (Vossel et al. 2013). This might be linked to the dendritic neurodegeneration
caused by early hyperexcitability (Šišková et al. 2014) which has been recapitulated by
different AD mouse models showing increased hippocampal excitability in 3xTgAD
(Davis et al. 2014) and PS2APP mice (Fontana et al. 2017).
One of the main methods used to investigate network activity is the multi electrode array
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(MEA). To date, a few attempts to monitor AD-related changes by MEAs have been
made, however, they were mainly on synaptic effects of AD. It has been found that along
with LTP impairment in transgenic animals, region specific synaptic changes occur at a
young age before the occurrence of the typical amyloid or tau pathology (Chong et al.
2011). The decrease of neuronal activity by synthetic Aβ has been observed and
reversed by using memantine (Charkhkar et al. 2015). A study using AD-CSF on rat
cortical networks showed significantly enhanced burst durations (Görtz et al. 2013)
which might be the first hint of epileptic discharges related to AD. Findings on AD-related
hyperactivity bring us to the question whether enhanced neuronal activity during the
presymptomatic stages of AD provide protection against the earliest disease processes
or whether it is a pathogenic contributor to AD (Stargardt et al. 2015).
Collectively, these studies outline a critical role for hyperactivity rather than hypoactivity
during early phases of AD. Growing evidence of Aβ-related seizures from AD mouse
models and AD patients puts hyperexcitability and possible further excitotoxicity in the
focus of AD-related research (Scharfman 2012). Therefore, hyperexcitability and
epileptiform discharges in AD are long-neglected important phenomena to be
investigated for future diagnosis and therapy.
1.2.6 Current treatment
Currently, there is no drug to slow down or stop the disease progression, synaptic, loss
and neuronal atrophy; therefore, there is no cure for AD. Approved treatments are mainly
symptomatic with variable effectiveness from patient to patient and 60 % of the treated
patients face side effects like nausea, vomiting, loss of appetite, headache, confusion,
and dizziness (Kumar et al. 2015).
Basal forebrain cholinergic neurons projecting to the hippocampus and the cerebral
cortex are affected in the brains of patients with AD. Impairment in their cholinergic
transmission were correlated with a decline in learning and memory, and a deficit in
excitatory amino acid (EAA) neurotransmission (Francis et al. 1999). Therefore, a
cholinergic substitution therapy, which inhibits acetylcholinesterase to allow the
extended presence of acetylcholine at the synaptic cleft, was developed. Recently used
cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine can alleviate
cognitive symptoms of mild to moderate AD (Kumar et al. 2015).
Excitatory amino acid neurotransmission, mainly the release and uptake of the
neurotransmitter glutamate are thought to be impaired in AD. Memantine, an
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uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist is used for treatment
of moderate to severe AD. The drug blocks the current flow through NMDA receptors
and reduces glutamate-induced neurotoxicity (Johnson & Kotermanski 2006). A recent
study is implying another mechanism of memantine action in AD models, which might
reduce both insoluble Aβ and Aβ oligomer levels (Ito et al. 2017).
Investigating new treatment strategies is a continuing concern within the Alzheimer’s
field, therefore, establishing human models using emerging stem cell based assays
might provide new insights into mechanisms of AD.
1.3 Induced pluripotent stem cells (iPSCs)
In 2007, human fibroblasts were reprogrammed to generate the first human induced
pluripotent stem cells (iPSCs) (Takahashi et al. 2007) by the same method that was
successfully used a year before to create mouse iPSCs via retroviral transduction of four
transcription factor genes (Oct3/4, Sox2, Klf4, and c-Myc) (Figure 1.7) into mouse
fibroblasts to obtain embryonic stem cell (ESC)-like cells (Takahashi & Yamanaka 2006).
iPS cells have shown ES cell properties such as the capability of differentiation into cells
of all germ layers; however, they had different global gene expression patterns. Since
then, the interest in iPSC research and the number of laboratories working on iPSCs are
increasing as iPSC research does not face the ethical problems linked to human
embryonic stem cell research.
1.3.1 Induced pluripotency
During development, a fertilized egg cell (zygote) divides and reaches the 16-cell stage
(morula) which is a ball like structure with identical totipotent cells and has the ability to
develop into an organism (Moore et al. 2011). From this stage on, the morula develops
into a blastocyst which has a distinguishable outer cell layer and inner cell mass, the
source of embryonic stem cells which are pluripotent. Pluripotency is described as the
ability of a cell to develop into the three primary germ cell layers such as ectoderm,
mesoderm, and endoderm. Waddington’s epigenetic landscape metaphor (Moris et al.
2016) explains why a neuron and a smooth muscle cell have enormous structural and
molecular differences as a result of their differential transcriptomes which are regulated
by epigenetic modifications. Waddington’s hypothesis explains that a cell, which is
represented as a pebble rolling down the landscape through the hills and valleys,
changes the activity of genes during differentiation (Noble 2015). It suggests that
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differentiated cells are only separated by "hills" (epigenetic barriers) and they have the
ability to become another type of cell if the cell gains sufficient energy (epigenetic
modifications) to overcome the barrier and even go back to the starting point
(pluripotency). As the model suggests, it is possible to convert terminally differentiated
cells to the stem cell stage (induced pluripotency) via a process called reprogramming.
Figure 1.7: Applications of induced pluripotent stem cells (iPSCs). Illustration of iPSC generation,
differentiation, and applications according to Sterneckert et al. (2014). Human cells can be removed by
biopsy, cultured in a dish, and converted into iPSCs by introducing reprogramming factors (Myc, Sox2, Klf4,
and Oct4). iPSCs can be differentiated into cells of interest with or without genetic modifications which allow
researchers to investigate disease mechanisms, drug screening, and cell therapy.
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1.3.2 Neuronal differentiation
The human nervous system develops from the ectodermal layer which forms the neural
plate consists of neuroepithelial neural progenitor cells (NPCs). These cells are
progenitors of the neurons and glia and they proliferate and migrate. Invagination of the
neural plate results in the formation of the neural tube with radial glial cells and early
born neurons. Radial glial cells further give rise to post mitotic neurons during brain
development from the neural tube (Stiles & Jernigan 2010).
Neuronal differentiation from iPSCs follows human brain development. iPSCs represent
the inner cell mass of the blastocyst which have the ability to produce any cell type of the
human body. iPSCs are responsive to directed differentiation which leads to the
formation of regional or subtype specific neural progenitor cells (Mertens et al. 2016).
NPCs with a more posterior characteristic differentiate into spinal cord motor neurons or
midbrain neurons which can be initialized with SHH, RA, and FGF2 or FGF8 treatments
during the neural rosette stage, an in vitro correlate of the neural tube (Danjo et al.
2011). On the other hand, forebrain neurons develop via the inhibition of the WNT and
SMAD signaling (Shi et al. 2012) using Dickkopf-related protein 1 (DKK1), Noggin and
small molecules, such as SB431542 (Chambers et al. 2009). Dorsal forebrain structure
gives rise to excitatory cortical neuron with CTIP2 (COUP-TF-interacting protein 2)
-expressing deeper layer neurons (Chen et al. 2008) and SATB2 (special AT-rich
sequence-binding protein 2)-expressing upper layer neurons (Alcamo et al. 2008),
whereas medial and caudal ganglionic eminences give rise to cortical interneurons
however their maturation takes a remarkably long time in vitro (Maroof et al. 2013).
Differentiated post mitotic neurons also need glial support to finally gain function with
axonal and dendritic morphology and form synapses. A further astrocyte differentiation
from astrocytic progenitors through initial iPSCs with FGFs and RA (for posterior
patterning) and following ciliary neurotrophic factor (CNTF) treatment give rise to
functional astrocytes in a time frame of 6 months (Mertens et al. 2016). The maturity of
neurons can be tested via electrophysiological characterization. Although in vitro culture
systems cannot recapitulate human brain development, the generation of 3D cerebral
organoids from human iPSCs is a promising strategy to overcome this limitation.
The shortage of human neurons for experimental purposes was the main limitation for
the investigation of human specific mechanisms of neurological diseases. Recent
advances in neuronal differentiation of human iPSCs allow researchers to study
neurodevelopmental and neurodegenerative diseases at the cellular level.
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1.3.3 Application of iPSCs in AD modeling
Alzheimer’s disease has been described more than 100 years ago and a considerable
amount of literature has been published on AD using FAD mouse models. These studies
contributed to our knowledge in the area of Aβ-induced synaptic and memory deficits
however the models do not fully recapitulate distinct neurofibrillary tangle pathology.
The progress in iPSC field promotes the research of neurodegenerative diseases which
was challenging because of the lack of human material. Researchers are investigating
disease related mechanisms in patient-specific human iPSC-derived neurons in AD
field. The first described study with patient specific iPSC-derived neurons carrying
familial PSEN mutations showed elevated Aβ42 levels which were reversed by
γ-secretase modulation (Yagi et al. 2011). Another study suggested that along with the
elevated Aβ40 levels, phospho-tau(Thr 231) and active glycogen synthase kinase-3β
(aGSK-3β) were increased in both FAD and SAD models (Israel et al. 2012). Further
mechanistic study investigated the changes in endoplasmic reticulum (ER) and oxidative
stress and the results were variable depending on the response of the cells generated
from different patients (Kondo et al. 2013). Another study monitoring NSAIDs as
γ-secretase modulators showed that their effects on Aβ42 reduction failed in human
neurons derived from FAD iPSCs (Mertens et al. 2013).
To rule out the differences between the generated iPSCs as a result of the background
patients’ cells, the researchers investigated PSEN1 functions with a controlled isogenic
genetic background which was established by using genome-editing technology with
TAL effector nucleases (TALENs) (Woodruff et al. 2013). Furthermore, neurons carrying
FAD mutation in APP showed alterations in subcellular location of APP and tau
expression which was rescued by anti Aβ antibodies (Muratore et al. 2014). To note, this
study compared the electrophysiological differences in spontaneous activity using a
microelectrode array (MEA) platform and found no difference in spike shapes from
control and FAD lines. The presence of APP in endosomes has been confirmed
(Mahairaki et al. 2014) and the tau proteostasis was not only mediated through
extracellular Aβ signaling since APP mutations led to increase total and phosphorylated
tau but not PSEN1 mutations (Moore et al. 2015).
Gene expression studies with different FAD mutations from affected and unaffected
individuals revealed differential expression of 14 genes from different gene families
(Sproul et al. 2014) and genes of subunits of the proteasome complex (Hossini et al.
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2015)
Human iPSC-derived neurons from healthy individuals has been used for drug
secreening and Aβ toxicity. γ-secretase inhibitors, β-secretase inhibitors, and an NSAID
showed differential Aβ secretion levels (Yahata et al. 2011). Aβ-mediated synaptotoxicity
study using iPSC-neurons showed postsynaptic AMPA receptor density decrease and
AMPA mini amplitude decrease with no effect on cell death (Nieweg et al. 2015).
Recent developments of culturing conditions allow the use of 3D iPSC-derived
organoids or matrix-embedded 3D cultures for research. Hence, 3D cultures have a
more stable local micro environment which 2D cultures lack upon media changes.
Therefore, it may allow Aβ to form aggregates to mimic AD-like morphological changes.
To this end, the first study with human neural stem cell derived 3D cultures with FAD
background showed that Aβ plaques and hyperphosphorylated tau form and that
inhibition of Aβ processing reduced those pathologies (Choi et al. 2014). Furthermore, a
comparative study recapitulated the previously known aberrant activated p21-activated
kinase (PAK) translocation upon Aβ sensing in 3D but not in 2D cultures (Zhang et al.
2014). More recent studies with 3D organoids with FAD backgrounds showed conflicting
results where β- and γ-secretases lead to less potency reducing Aβ levels in one study
(Lee et al. 2016) and reducing amyloid and tau pathology in another (Raja et al. 2016).
Overall, these studies highlight the need for human material to model neurodegenerative
diseases. However, to recapitulate all disease-related pathologies remains challenging
and the differentiation of cultures needs to be further optimized. All in all, such studies
remain narrow in focus dealing only with molecular changes of AD and to date, no study
attempted to investigate an early electrophysiological phenomenon such as hyperactive
neuronal networks in human iPSC-derived neurons.
1.4 Aims of the study
Hippocampal hyperactivation and increased epileptic activity are common phenotypes in
the early symptomatic phase of AD patients (Vossel et al. 2017). This study aimed at
testing a hypothesis on how AD-related hyperactivity could result from increased
amyloid beta (Aβ) levels. The hypothesis is based on the findings of two
key-publications, showing that the transcriptional repressor REST (a) plays a major role
in mediating homeostatic plasticity in hyperactive neuronal networks (Pozzi et al. 2013)
and (b) is reduced in aged AD brains and Aβ treated human neurons (Lu et al. 2014).
Together, these studies indicated that increased Aβ may cause epileptic activity by
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impairing counteracting homeostatic plasticity responses in a REST-dependent manner.
This study aimed at testing the hypothesis in functionally mature human neuronal
networks derived from induced pluripotent stem cells (iPSCs).
The first part of this study focused on the development, maturation, and characterization
of human neuronal networks. To this end, human iPSCs were targeted to small molecule
directed differentiation. Post-mitotic neurons were purified and characterized to
distinguish the neuronal subtypes in the cultures. Neuronal maturation was monitored
and network parameters were extracted. Networks were used for toxicity assays.
Second, to develop a homeostatic plasticity model and to observe the homeostatic
capacity of human neuronal networks, network activity was blocked or increased
pharmacologically, the response of the networks was monitored and extracellular spike
properties were analyzed for plasticity-induced changes related to neuronal excitability.
The role of REST in neuronal homeostatic plasticity of human neurons was investigated.
Furthermore, to establish an AD model, synthetic amyloid beta (Aβ) oligomers were
prepared, characterized and their effects on cell viability, synapse function, neuronal
excitability, and network activity were investigated.
Finally, the homeostatic plasticity model was used to investigate the effect of Aβ
oligomers on hyperactivity induced homeostatic plasticity and on REST regulation as a
part of this process.
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2.1 Cell Culture
2.1.1 Human iPSC culture
Thawing hiPS cells
Human induced Pluripotent Stem (iPS) cell lines (DF6 and 8/25 were previously
described in Nieweg et al. (2015), SZ02 was reprogrammed by Shadaan Zulfiqar from
human neonatal foreskin fibroblasts, NuFF1, GlobalStem) were kept in CryoStor (Sigma
C2874) freezing medium containing cryotubes (Thermo Scientific 377267) in a liquid
nitrogen tank. iPS cells were cultured under feeder-free conditions. Cells were thawed in
a 37 ◦C water bath by shaking the vial gently. E8 medium (Table 2.1) was prepared by
adding the components freshly and used only for maximum 2 days. The cell suspension
was diluted in the pre-warmed E8 medium at a ratio of 1 part sample in 10 parts medium
and centrifuged at 118 g for 3 min. The supernatant was removed with a pipette, leaving
a small amount of medium to ensure the cell pellet is not disturbed. The cell pellet was
resuspended in 2 ml fresh pre-warmed E8. The cell suspension was distributed in one
well of a 6-well plate (Sarsted 83.3920) which was coated with Matrigel (BD 354277) at
RT 1h prior to the plating. Cells were treated with 10 µM ROCK inhibitor (Tocris 1254) to
block apoptosis, kept 37 ◦C incubator with 5 % CO2 and 95 % humidity. After 24 h,
ROCK inhibitor was removed and cells were maintained in the E8 medium with daily
medium changes.
Table 2.1: E8
Reagent Distributor Catalog no Concentration
DMEM/F-12 Invitrogen 31330-095 1X
bFGF PeproTech 100-18B 20 µg/ml
TGFβ PeproTech 100-21 2 µg/ml
ITS Table 2.2 50X
P/S Invitrogen 15140-122 100X
Ascorbic acid Sigma A8960 221 mM
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Table 2.2: ITS
Reagent Distributor Catalog no Concentration
DMEM/F-12 Invitrogen 31330-095 1X
Insulin Sigma I1882 10 mg/ml
Holo-transferrin Calbiochem 616424 20 mg/ml
Sodium selenite Sigma S5261 1.4 mg/ml
Passaging hiPS cells
iPS cells were cultured in the E8 medium under feeder-free conditions. iPSC colonies in
one well of a 6-well plate were passaged with PBS without calcium and magnesium
(PBS-/-) every 7 d. In short, cells were washed 2X with 1 ml PBS-/- and incubated for 12
min with PBS-/- and scraped by using cell spatula (Biochrom 99010). The cell
suspension was collected in E8 medium and centrifuged at 118 g rpm for 1 min. The
supernatant was removed and the cell pellet was resuspended in 9 ml fresh pre-warmed
E8 medium and cells were plated in a new Matrigel coated 6-well plate. Cells were kept
in a 37 ◦C incubator with 5 % CO2 and 95 % humidity.
Neuronal differentiation of hiPSC cells
Induction of neural lineage was initiated with a 6-day long small molecule directed
differentiation: 6 µM SB-431542 (Tocris 1614) and 1 µM DM (Tocris 3093) in N2B27
medium (Table 2.3). This strategy, known as the dual SMAD inhibition, was used to
induce neural lineage by inhibiting tumor growth factor beta (TGFβ) and bone
morphogenic protein (BMP) signaling cascades which allows rapid differentiation of
confluent, feeder free hiPSC cultures into early neurectoderm (Chambers et al. 2009).
On day 7 colonies were detached by incubating with PBS-/- for 5 min and rounding up of
the colonies from the edges was observed under the microscope. Cell aggregates were
scraped gently and collected in N2B27 medium and centrifuged at 66 g for 1 min. After
removing supernatant, the pellet was gently resuspended in N2B27 medium and
transferred into T-25 flasks (Sarstedt 83.1810.002) and kept in a 37◦C incubator with 5%
CO2 and 95% humidity for 2 weeks to obtain rounded embryoid bodies (EBs). On day
21 the EBs were plated onto a Matrigel-coated 100 mm culture dish (Sarstedt 83.1802)
containing the fresh N2B27 medium. Cells were maintained in a 37◦C incubator with 5%
23
2. MATERIALS AND METHODS
Figure 2.1: Neuronal differentiation of iPSCs. (A) iPSCs were maintained in E8 medium. Confluent
iPSCs were treated with small molecules (SB-431542 and dorsomorphin) in N2B27 medium for 1 week. EBs
were generated from detached colonies, and maintained in N2B27 medium for 2 weeks as non-adherent
cultures and plated for further differentiation for 4 weeks. Differentiated cultures were enriched for neurons by
anti-NCAM immunopanning. Further maturation of neurons was achieved by and incubated for 3-6 months
of culture for further maturation in NMM medium. (B) Representative phase contrast images of neuronal
differentiation of iPSC. iPSC: induced pluripotent stem cell, EB: embryoid body.
CO2 and 95% humidity and the medium was changed weekly. After 4 weeks,
differentiated cells with distinct processes were observed in the culture dishes and used
for neuronal enrichment via the previously described method called immunopanning
(Nieweg et al. 2015).
Immunopurification of hiPSC-derived neurons
To enrich the neuronal cultures by removing non-neuronal cells from the mixture, an
immunopurification procedure so called immunopanning was performed. Culture dishes
with bacterial quality (BD Falcon 351029) were used to prepare panning plates at least
two day before the immunopanning. Plates were incubated with goat anti mouse IgG
and IgM (Jackson labs, 115-005-068) in 50mM Tris/HCl, pH 9.5 (Sigma, T6066) at 4 ◦C
ON for the attachment of the antibody to the plastic surface. On the following day,
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Table 2.3: N2B27
Reagent Distributor Catalog no Concentration
DMEM/F-12 Biochrom FG4815 1X
NB Invitrogen 21103 1X
B27 w/o RA Invitrogen 12587-010 50X
Glutamax Invitrogen 35050-038 100X
N2 Table 2.4 50X
P/S Invitrogen 15140-122 100X
β-mercaptoethanol Invitrogen 31350-010 50 mM
Heparine Sigma H3149 10 mg/ml
Table 2.4: N2
Reagent Distributor Catalog no Concentration
DMEM/F-12 Biochrom FG4815 1X
Insulin Sigma I1882 10 mg/ml
Holo-transferrin Calbiochem 616424 20 mg/ml
Sodium selenite Sigma S5261 0.52 mg/ml
BSA Sigma S5261 10 mg/ml
Putrescine Sigma P5780 161 mg/ml
Progesteron Sigma P8783 0.62 mg/ml
antibody solution was removed, plates were washed with PBS-/-, and incubated with
NCAM antibody (DSHB, VIN-IS-53) solution at 4 ◦C ON for the attachment of the
primary antibody to the secondary antibody and kept until use.
On the day of immunopanning, NCAM solution was removed and kept at 4 ◦C. Plates
were washed with PBS-/- and incubated with 0.2% BSA (Sigma A8806) containing PanB
(Table 2.5) at RT to block antibody free areas. Cells were washed with PBS-/- and
dissociated with accutase (Sigma A6964) at 37◦C for 20 min. Detached cells were
collected in a 15 ml tube (Greiner 188271) with 0.2% BSA containing PanB solution after
scraping the plate gently and centrifuged at 223 g for 2 min. After removing the
supernatant, cells were gently triturated with a P1000 plastic pipette tip. After each
trituration step, the cell suspension was centrifuged at 30 g for 1 min to differentiate
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Table 2.5: PanB
Reagent Distributor Catalog no Concentration
Glucose Merck 1083371000 0.1 %
Na-pyruvate Invitrogen 11360 325 µM
PBS Pan Biotech P0436500
single cells from the cell aggregates. Single cell-containing supernatants were collected
in a separate tube. This process has been repeated until there was no visible pellet. The
collected single cell suspension was centrifuged at 149 g for 13 min and supernatant
was removed and the pellet was re-suspended in a 0.02% BSA containing PanB. Single
cell suspension was further distributed onto previously prepared panning plates. Cells
were kept on the panning plates for 8-10 min allowing only the attachment of neurons
because of their highly expressed NCAM profiling. Unbound cells were immediately
washed removed and weakly bound cells were removed at the end of the 20th washing
steps. After observing only the tightly attached cells under the microscope, cells were
removed by forceful flushing and collected in a new tube. Cells were counted,
centrifuged at 149 g for 13 min. The final pellet was re-suspended in NMM medium
(Table 2.6) with the density of 5000 cell/µl) and plated on previously 1 mg/ml
poly-l-ornitin (Sigma P3655)- and 10 µg/ml laminin (10 µl drop, Sigma L2020)-coated
coverslips (Assistant 1001/12). Medium was added to the well after around 30 min,
when cells had attached.
Maturation of hiPSC-derived neurons
Maturation of the cells was accomplished in NMM media enriched with 30 ng/ml BDNF
(PeproTech 450-02) and laminin. 1 µM cAMP (Sigma D0260) was also used temporarily
but did not result in an obvious improvement of neuronal maturation. For internal human
astrocytic development, the cells were also treated with 1 µM DAPT (Cayman 13197)
during the first week of maturation to stop proliferation and to allow further glial
differentiation. Medium was replaced completely at the end of the first week and partially
following weeks until experimental use of the networks.
To accelerate neuronal maturation, human neurons were co-cultured with primary rat
cortical astrocytes (PCAs) in a ratio 10:1. PCAs were dissociated by washing with
PBS-/-, incubating with trypsin, centrifuging at 184 g for 3 min, re-suspending in
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Table 2.6: NMM
Reagent Distributor Catalog no Concentration
NB Invitrogen 21103 1X
B27 Invitrogen 12587-010 50X
Glutamax Invitrogen 35050-038 100X
SATO Table 2.7 50X
P/S Invitrogen 15140-122 100X
Na-pyruvate Invitrogen 31350-010 50 mM
BDNF PeproTech 450-02 30 µg/ml
Table 2.7: SATO
Reagent Distributor Catalog no Concentration
NB Invitrogen 21103 1X
Insulin Sigma I1882 10 mg/ml
Holo-transferrin Calbiochem 616424 20 mg/ml
Sodium selenite Sigma S5261 0.4 mg/ml
BSA Sigma S5261 20 mg/ml
Putrescine Sigma P5780 161 mg/ml
Progesteron Sigma P8783 0.62 mg/ml
astrocyte medium RCAM (Table 2.8), counting the cells, centrifuging at 184 g for 3 min,
and again re-suspending in NMM to mix with human neurons. Co-cultures were treated
with 1 µM DNA synthesis inhibitor Ara-C (arabinofuranosyl cytidine, Sigma C-6645)
during the first week of maturation to kill proliferating cells. Cultures were checked
regularly from 8-12 weeks on by calcium imaging and accepted as mature cultures only
after observing synchronous activity.
2.1.2 Primary cortical neuronal (PCN) culture
Primary cortical neuronal cultures were prepared from embryonic day 18 (E18) Sprague-
Dawley rats (Charles River Laboratories). Cortical neurons were cultured on coverslips or
on 60 mm culture dishes, were maintained in NMM medium, and treated with 1 µM DNA
synthesis inhibitor Ara-C (arabinofuranosyl cytidine) during the first 3-day of maturation
to kill proliferating cells at 37 ◦C, 5 % CO2. The medium was replaced completely to end
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Ara-C treatment and partially following weeks until experimental use of the networks.
2.1.3 Primary cortical astrocyte (PCA) culture
Primary cortical astrocyte cultures were prepared from embryonic day 18 (E18)
Sprague-Dawley rats (Charles River Laboratories). Cortical astrocytes were cultured in
T25 culture flasks and were maintained in RCAM medium (Table 2.8) at 37 ◦C, 5 %
CO2. The next day, the medium was changed completely to remove all dead neurons
and replaced regularly 3-4 days after they reached 50% confluence. For splitting and
seeding for the cocultures, cells were washed once with PBS-/- to remove the growth
medium completely and incubated with trypsin to detach the cells form the culture dish.
For the cocultures, the procedure continued as described above and for splitting, 100 %
confluent cultures were split in a 1:2-1:3 ratio, cultured in T25 culture flasks and were
maintained in RCAM medium at 37 ◦C, 5 % CO2. The following day, the medium was
changed completely to remove cell debris and replaced regularly 3-4 days.
Table 2.8: RCAM
Reagent Distributor Catalog no Concentration
DMEM High glucose Invitrogen 11965-092 1X
FBS PAA A15-151 10X
L-glutamine Invitrogen 25030081 100X
P/S Invitrogen 15140-122 100X
2.1.4 CHO and 7PA2 cell culture
7PA2 cells, which stably express the V717F Alzheimer’s disease mutation and the
background Chinese hamster ovary (CHO) cells were cultured in CHOM (Table 2.9), in
case of 7PA2 cells medium was supplemented with G-418 to select APP overexpressing
cells. Every week cells were split in a 1:10-1:20 ratio. For splitting and seeding, cells
were washed once with PBS-/- to remove the growth medium completely and incubated
with trypsin (Gibco 25300-054) to detach the cells form the culture dish. To stop the
protease activity of trypsin, fresh medium was used to dilute and the cell suspension
was centrifuged at 184 g for 5 min. After discarding the supernatants, the pellet was
resuspended in fresh medium, cells were counted and diluted for further plating. After
24 h of seeding, cells were used for further experiments.
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Table 2.9: CHOM
Reagent Distributor Catalog no Concentration
DMEM Invitrogen 61965-026 1X
FBS PAA A15-151 10X
L-glutamine Invitrogen 25030081 100X
P/S Invitrogen 15140-122 100X
2.2 Amyloid-beta (Aβ)
2.2.1 Cell-derived Aβ
Soluble human Aβ oligomers were derived form 7PA2 conditioned medium. The
supernatants of 7PA2 or CHO cells were collected after 72 h, centrifuged at 184 g for 3
min to remove cell debris, filtered, aliquoted, and kept at -80 ◦C until usage. For
treatment, the 7PA2 conditioned medium was added directly to the iPSC-derived neural
cultures and immunodepleted medium (incubating 7PA2-conditioned medium with IC16
antibody coupled to NHS-sepharose bead ON at 4 ◦C) used as a control for MEA
experiments.
2.2.2 Synthetic Aβ oligomerization
Solubilization of monomeric Aβ was performed by dissolving lyophilized synthetic Aβ in
HFIP (Fluka, 52517). Aβ1−42 was aliquoted at the end concentration of 8.576 µg/ 90 µl
HFIP per tube. First 500 µl ice-cold HFIP was added in 1 mg Aβ1−42 (Bachem
4014447.1000) containing tube and incubated for 30 min at 37◦C in the water bath. The
solution was sonicated for 30 min at 37◦C in the water bath and incubated for 30 min for
final dissolving and cooled down on ice for another 30 min. Solution was transferred into
an 8-ml glass vial (neoLab 2-7232). Original tube was rinsed 3X 500 µl HFIP and
collected in the same glass vial. Then 2 ml HFIP was added and mixed. 2742 µl Aβ1−42
solution was transferred into a new glass vial for another mixture. The remaining
solution was diluted further with 2036 µl HFIP, aliquoted in 2-ml glass vials (neoLab
2-7230) and kept at -80◦C until usage. Pyroglutamylated Aβ3−42 ([Pyr3]Aβ3−42,
BioTrend BT-2987-01) was dissolved in HFIP at the final concentration of 8.19 µg/ 90 µl
HFIP per tube. First 1000 µl ice-cold HFIP was added in 100 µg [Pyr3]Aβ3−42
containing tube and above-mentioned dissolving steps were performed. Next, 345 µl
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[Pyr3]Aβ3−42 solution was transferred into a glass vial which were previously containing
2742 µl Aβ1−42 solution. The remaining solution was diluted further with 65 µl HFIP,
aliquoted in 2-ml glass vials and kept at -80◦C until usage.
For preparation of 95 % Aβ1−42 and 5 % [Pyr3]Aβ3−42 mixture (annotated as Aβ* in the
rest of the thesis), the solution in the glass vial containing 2742 µl Aβ1−42 and 345 µl
[Pyr3]Aβ3−42 was diluted with 4486 µl HFIP, mixed and aliquoted in 2-ml glass vials and
kept at -80◦C until usage. Vehicles were prepared by aliquoting 90 µl HFIP in 2-ml glass
vials and kept at -80◦C until usage.
To begin with the oligomerization protocol, vials were kept at RT to evaporate HFIP
under a nitrogen stream for 30 min. Aβ and vehicle preparations were dissolved at the
concentration of 5 µM in phenol free NB medium without supplements and incubated at
37 4◦C or 4◦C for 2 days. Oligomers were further analyzed by native, semi-native, and
SDS PAGE followed by western blot to visualize the oligomerization profiling of different
protocols. To treat the cells, prepared oligomers were further diluted to 2 µM
concentration and media supplements were added. Treatments were done by adding
prepared 2 µM Aβ oligomer solution following half medium removal from the culture
dishes.
2.3 Patch-clamp recordings
Patch-clamp recordings were performed at RT to record electrophysiological
characteristics of control, vehicle- and Aβ-treated cultures in whole cell mode.
Coverslips were placed in the measuring chamber containing the standard extracellular
solution (Table 2.10) under the phase contrast Axiovert 35M microscope (Zeiss). The
patch pipette was prepared by pulling glass capillaries (Science Products
GB150ETF-8P) using a horizontal programmable puller (Zeitz DMZ Universal Puller),
filled with standard intracellular solution (Table 2.11) and had resistances of 5-7 MOhm.
Electrophysiological data were filtered at 5 kHz and sampled at 20 kHz using Clampex
Software (Axon Instruments) digitized a Digidata 1322A (Axon Instruments). Cells were
approached via Narishige micro-manipulators (MHO-103) in presence of positive
pressure. Thereafter, the pressure was released and negative pressure was applied
along with a 3 mV stimulation pulse to obtain a Giga seal. Once the seal had been
formed, the pipette was clamped at -60 mV and corrected for fast capacitance. After the
pipette gained access to the cytosol, the cell capacitance contributed to the exponential
decay in seal test (Figure 2.2).
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Figure 2.2: Whole-cell patch clamp measurements. According to application protocol of AxolBio (2016).
(A) Micropipette with positive pressure in the bath solution. (B) Releasing the positive pressure helps
the pipette to attach the neuron and resistance increases in the neuron attached form; therefore, current
measured in oscilloscope decreases (middle). (C) Applying short pulsed suction to rupture the neuronal
membrane allows the cell cytosol and the pipette solution to connect and increase in capacitive currents
(bottom).
Table 2.10: Standard extracellular solution, pH 7.4
Reagent Distributor Catalog no Concentration
NaCl Sigma S5886 130 mM
KCl Roth HN02.1 5 mM
MgCl2 Roth HN03.1 1 mM
CaCl2 Roth HN04.1 2.5 mM
HEPES Roth HN77.3 20 mM
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Table 2.11: Standard intracellular solution, pH 7.4
Reagent Distributor Catalog no Concentration
KCl Roth HN02.1 110 mM
KOH J.T.Baker 0385 20 mM
CaCl2 Roth HN04.1 250 µM
HEPES Roth HN77.3 20 mM
EGTA Merck 1.08435.0025 10 mM
2.3.1 Current clamp recordings
For current clamp recordings, the mode was switched to current-clamp, the resting
membrane potential was noted at zero holding current, and then membrane potential
was adjusted to -60 mV. For further analysis of the spiking properties and the passive
membrane properties, 900 ms long current pulses (30 steps) were injected starting from
-50 pA in a 10 pA increasing manner. Cells were classified according to their voltage
responses including passive response, abortive response, single AP and repetitive AP.
Input-output curves were plotted as the number of spikes versus the injected current.
The amplitude was measured from the threshold to the maximum value for the first AP
of 150 pA current injection. Maximum rising slope was calculated as the first time
derivative of the amplitude. Half-width was determined as the duration of the AP at 50%
amplitude. AHP was noted as the value after the AP peak to the threshold.
2.4 Calcium imaging
Calcium imaging was carried out by using Fura-2-AM (Sigma 47989), a cell membrane
permeable, ratiometric calcium binding dye. The dye was de-esterified by cellular
esterases to yield Fura-2 free acid. The ratio signal is independent of the dye
concentration and illumination intensity which was the main advantage of using a
ratiometric dye over a single wavelength probe. Fura-2 had an emission peak at 505 nm
and changed its excitation peak from 340 nm to 380 nm in response to calcium binding.
It exerts a high signal-to-noise ratio and allows to visualize neuronal activity (Smetters
et al. 1999).
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Figure 2.3: Calcium imaging and analysis. (A) For Fura-2 AM loading, cells were incubated in Fura-2
AM (green solution) for 30 min, the membrane-permeable acetylomethylester (AM) allows the dye to enter
the cell. Extracellular dye was removed by washing. Incubation for 30 min for allowing de-esterification by
cellular esterases to trap the dye in the cells (green cells). (B) Representative false color images of calcium
bound Fura-2 AM at 340 nm excitation at baseline and 40 mM KCl response. (C) Standard deviation of 40
frames (25 frames before and 15 frames after the KCl treatment) at 340 nm excitation for the generation of
regions of interest (ROI, red frames). (D) Time series analysis of calcium transients is plotted for the selected
regions of interest. Red lines are the threshold values for each neuron calculated as the mean+5XSTD of
the silent interval of each calcium transient.
To load the dye, cells were incubated with 3 µM Fura-2 AM in HEPES-Ringer buffer
(Table 2.12) at 37◦C for 30 min. The buffer was exchanged and cells were further
incubated 20 min to allow for de-esterification of the dye (Figure 2.3). Fura-2-loaded
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cells were placed under the microscope using 20x objective lens (Table 2.13). Calcium
imaging was performed at 37◦C. Fluorescent images at 340 nm and 380 nm were taken
every 500 ms. 960 frames were recorded per coverslip, of which the first 400 frames
represented baseline recordings, followed by 500 frames after acute 4AP (Tocris 0940)
stimulation. Finally, 40 mM KCl was added to distinguish neurons from non-neuronal
cells. Each coverslip was regarded as a single network and as an independent n.
Table 2.12: HEPES-ringer buffer (HRB), pH 7.4
Reagent Distributor Catalog no Concentration
NaCl Sigma S5886 136.4 mM
KCl Roth HN02.1 5.6 mM
MgCl2 Roth HN03.1 1 mM
CaCl2 Roth HN04.1 2.2 mM
HEPES Roth HN77.3 10 mM
Glucose Sigma G70021 5 mM
Table 2.13: Equipments for CaI
Equipment Distributor
IX70 Microscope Olypmus, Hamburg, Germany
20 x Objective (oil) Olympus, Hamburg, Germany
Immersion oil Olympus, Hamburg, Germany
Polychrome IV lamp TILL Photonic’s, Gräfelfing, Germany
Lambda 10-2 optical filter changer Sutter Instruments, Novato, CA, USA
TILLvisION software TILL Photonic’s, Gräfelfing, Germany
The data analysis was done with ImageJ. Regions of interest (ROI) were selected based
on standard deviation of time projection images at 340 nm before (25 frames) and during
(15 frames) KCl addition, followed by 2.5 % RenyiEntropy thresholding. The background
was selected manually in a cell free region. Selected ROIs were analyzed for mean
fluorescent intensities from 340 and 380 images and imported in Excel. Furthermore,
the ratio of images were calculated after the background subtraction. Individual traces
were off-set by their minimal value in the first 50 frames. Active cells were defined as
cells showing at least one peak above the calculated threshold (Mean+5XSTD of a
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manually selected silent part of the transient ratio for each ROI. Transient amplitudes
were calculated from ratio traces of active cells. For the amplitude, 3 maximum values of
ratio traces before, during, and post 4AP treatments were calculated and normalized to
the pre-treatment condition. Transient frequencies were extracted from AOIs of the 340
nm / 380 nm ratio images of a field, which contained several neurons. Peaks were
manually counted in the respective traces, representing the mean ratio intensity of an
AOI.
2.5 Multi electrode array (MEA)
The MEA system (USB-MEA256-System) and the arrays used in this study were
purchased from Multichannel Systems. They are standard arrays (8X8 conformation, 59
+ 1 internal reference electrodes, W x D x H : 49 mm x 49 mm x 1 mm) with a 12 mm
high glass rings. In-house built glass lids with plastic rings were used to keep cultures
sterile during measurements. For the experiment, MEAs were washed, autoclaved,
covered with 1 mg/ml PO and 10 µ/ml laminin (20 µl drop). iPSC-derived mature
neuronal cultures were plated by removing the cultures from the glass coverslip and
transferring them on the MEAs, directly on the laminin drops. After incubating several
hours, NMM was added gently on the MEAs and incubated for 3 days.
Table 2.14: NB-Extra, pH 7.4
Reagent Distributor Catalog no Concentration
NaCl Sigma S5886 65 mM
KCl Roth HN02.1 5 mM
MgCl2 Roth HN03.1 0.8 mM
CaCl2 Roth HN04.1 0 or 1.8 mM
NaH2PO4 Sigma 71505 0.9 mM
NaHCO3 Sigma S5761 26.2 mM
HEPES Roth HN77.3 10 mM
Glycine Roth 3908.2 0.4 mM
Glucose Merck 1083371000 25 mM
Na-pyruvate Invitrogen 31350-010 1.2 mM
Glutamine Invitrogen 25030081 1X
Phenol red Sigma P0290 0.0005 %
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Figure 2.4: Extracellular recording on multi electrode arrays (MEA). (A) Illustration of standard MEA
chip. (B) Data stream of synchronously burst firing network. Examples of (C) spike and (D) burst firing
individual electrode. (E) Detected extracellular spike waveforms from an individual electrode. (F) The
correlation of intracellular AP and extracellular AP. The first time derivative of the intracellular trace is
superimposed on the extracellular trace (bottom trace, gray line). The half-maximal rising slope and the
half-width of the intracellular AP (horizontal line) is represented on the extracellular spike (Bugaysen et al.
2010). (G) Baseline correction of the mean extracellular spike. (H) Normalization of the spike amplitude to 1
for extraction of widths and post spike maximum values.
Spontaneous electrical activity was recorded from MEAs at 37 ◦C (head stage heating)
with constant 5 % CO2 for 3 min. Signals were sampled at 25 kHz and stored on hard
disc. Offline spike and burst detection were carried out by MC-Rack (Multi Channel
systems) software. Measurements were done in NMM medium. For the calcium
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dependent network activity measurements, the NB-extra solution (Table 2.14) was used.
2.5.1 Spike and burst detection
To detect spikes, a threshold of minus 5 times the standard deviation (-5XSD) of the
mean noise amplitude was set. The detection threshold was run over 200 Hz high-pass
Butterworth 2nd order filtered data stream which allowed to remove field potential since
the threshold method for spike detection was used. An active channel was defined as
channel which have fifty or more spikes per 3 minutes. Bursts were defined using the
three criteria: min 5 spikes/burst, 100 ms minimum burst duration, 10 ms inter-spike-
interval to count a spike in a burst. Data were presented as normalized mean spike or
burst rate by calculating individual spike or burst rate in Hz for each array.
2.5.2 Extracellular spike parameters
The shape of the extracellular spike closely resembles the first time derivative of an
intracellular action potential (Heinricher 2004) and therefore, the amplitude of a an
extracellular spike represents the maximum rising slope of an intracellular action
potential and thus correlates with the density of Na+ channels on the axonal membrane
(Bugaysen et al. 2010) (Figure 2.4F). On the other hand, alterations in the spike width
(Bugaysen et al. 2010) and the post-spike maximum (Speckmann et al. 2015) of the
extracellular spike correlate with K+ conductance. Quantification of extracellular spike
parameters like spike amplitude, half-width, 10 %-width, and post-peak maximum could
give hints on changes in neuronal excitability (Na+ and K+ channel densities) as part of
the homeostatic plasticity. In order to extract single spikes, raw data were filtered with
Butterworth 2nd order low-pass 2000 Hz filter and spikes were detected by identifying
the times of negative voltage deflections which drop below a threshold of minus 5 times
the standard deviations of the mean noise amplitude (-5XSD), saving the -2 to +2 ms
around the threshold crossing time. Up to 50 spikes per channel were selected from all
active channels by placing the selection tool at the threshold crossing lane (Figure
2.4E), selecting all traces that pass at this point. The extracted spikes were sorted using
visual basic for applications (VBA) editor in Excel (see Scripts and Macros). Excel
macro imported .dat files extracted from a single channel in different time points and
calculated the mean for the first 0.5 s to off-set the spike (Figure 2.4G). As the distance
between electrode and cell as well as the electrode impedance affect the spike
amplitude, amplitudes are highly variable between different MEAs and even electrodes
of the same MEA. Therefore, each channel was analyzed separately. The amplitude
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was extracted as the minimum value of the spike (Figure 2.4G). After each spike
amplitude had been normalized to -1, half width, 10 %-width and post spike maximum
values were extracted from each spike (Figure 2.4H) and compared between before,
during and after treatment conditions for each active channel.
2.6 Immunocytochemistry
Immunocytochemistry was carried out according to the standard protocol.
hiPSC-derived neurons grown on coverslips were washed once with PBS and fixed with
4 % paraformaldehyde (PFA, Table 2.15) for 13 min at RT.
Table 2.15: PFA
Reagent Distributor Catalog no Concentration
PFA Polysciences 18814 4%
PBS Pan Biotech P0436500
Table 2.16: Permeabilization buffer
Reagent Distributor Catalog no Concentration
Glycine Sigma 50045 100 mM
Triton-X100 Sigma X100 0.25 %
PBS Pan Biotech P0436500
Table 2.17: Antibody buffer
Reagent Distributor Catalog no Concentration
BSA Sigma A3059 2 %
Sucrose Merck 10176871000 5 %
PBS Pan Biotech P0436500
Cells were washed three times with PBS and permeabilized in permeabilization buffer
(see Table 2.16) for 10 min at RT and blocked with 30 % goat serum (Invitrogen,
16210064) for 1 h at RT. Cells were incubated with primary antibody (primary antibodies
used in Table 2.18) solutions ON at 4◦C with gentle rocking. The next day cells were
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washed three times with PBS and secondary antibody (secondary antibodies used in
Table 2.19) solutions were added to the wells for 1h at RT. Optionally, DNA staining
using DAPI (Sigma, D9542) was carried out during the first PBS washing step after the
removal of secondary antibodies. After two more washing steps with PBS, the coverslips
were rinsed with ddH2O, mounted on microscope slides using Fluor Safe Reagent
(Calbiochem, 345789), dried ON at RT, and kept at 4◦C until imaging.
Table 2.18: Primary antibodies for ICC
Reagent Distributor Catalog no Concentration
Tbr1 Abcam ab31940 1:500
Ctip2 Abcam ab18465 1:200
GAD67 Millipore MAB5406 1:500
Map2 Abcam ab92434 1:1000
4G8 Covance SIG-39220 1:1000
Satb2 Abcam ab51502 1:50
Rest Bethyl IHC-00141 1:300
Table 2.19: Secondary antibodies for ICC
Reagent Distributor Catalog no Concentration
anti-Ms-555 Invitrogen A21424 1:1000
anti-Rb-488 Invitrogen A11029 1:1000
anti-Rb-555 Invitrogen A21429 1:1000
anti-Ch-488 Invitrogen A11034 1:1000
anti-Ch-AMCA JIR 103-155-155 1:1000
Imaging was performed using Axiovert 200 M inverted fluorescence microscope (Zeiss)
equipped with a 12-bit monochrome CoolSNAP ES2 CCD camera (Photometrics). Four
images per coverslip were taken with 20X objective for each wavelength with constant
exposure times and the number of positive nuclei per total DAPI nuclei was calculated. n
represents the number of coverslips.
For the REST staining, imaging was performed using LSM700 confocal microscope
(Zeiss) equipped with a 63X, 1.4 NA oil objective. Five images per coverslip were taken
with 63X oil objective. Maximum intensity projections of each image were calculated
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with ImageJ. In case of MAP2 co-staining, MAP2 positive DAPI nuclei were selected and
mean nuclear and cytosolic REST immunofluorescence intensities were extracted in
ImageJ. Background was selected from the cell-free area. After background subtraction
of REST channel, nuclear versus cytoplasmic ratio was calculated. n represents the
number of cells.
2.7 Cell viability assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or in short MTT (Sigma
M2128) was used to measure cell viability in different conditions. The viable cells
converted MTT substance into purple colored formazan salt which was dissolved in
DMSO and measured by a spectrophotometer at a wavelength of 570 nm. The optical
density of the dissolved substance indicated the amount of viable cells and the degree of
cytotoxicity of the compound of interest.
Primary rat cortical neurons were isolated as described before and seeded on a 96-well
plate. After treatments of the cells with compounds such as different Aβ preparations,
7PA2 conditioned medium, LiCl (Sigma L4408), X5050 (Millipore 5.06026.0001), and
CHIR (Tocris 4423) to observe their effects on cell viability, cells were treated with 20 µM
MTT (500 µg/ml) and incubated at 37 ◦C for 30 min to allow cells to convert MTT
substrate to colored formazan crystals. After gently removal of the solution, the plate
was shock-frozen at -80 ◦C. To dissolve the colored crystals, 150 µl DMSO added into
each well of the plate and the absorbance was measured by a spectrophotometer
(Fluostar OPTIMA, BMG Labtech) at a wavelength of 570 nm.
2.8 Protein analysis
2.8.1 Total protein lysates
Protein lysates were prepared by two different methods. Human iPSCs were collected
directly in pre-boiled 2X sample buffer with fresh 50 mM DTT (Sigma D9779) by
re-suspending and post-boiling for 5 min at 95 ◦C. CHO, 7PA2 cells and rat neuronal
cultures were lysed by using RIPA buffer (Sigma R0278). Culture dishes were handled
on ice during the procedure. Cells were washed 2X with 2 ml ice-cold PBS. 200 µl RIPA
buffer with protease inhibitor cocktail (Roche 05892970001) and phosphatase inhibitor
(Roche 04906845001) was added to the cells and incubated for 5 min. Cells were
scraped and collected in microfuge tubes. Lysates were sonicated Branson Digital
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Sonifier (102c, Branson Ulstrasonic Corporation) 50% pulse for 10 s with 500 ms on/off
steps, centrifuged for 1 min at 2000 g to remove cell debris and the supernatant was
collected for further protein concentration quantification.
2.8.2 Nuclear fractionation
Nuclear fractionation was performed to investigate the translocation of REST protein
from cytosol to nucleus. For each condition, two PO-coated 6-cm tissue culture dishes
covered with 2.5 million PCN isolated from rats. Cells were treated with an inhibitor
(X5050) and activator (CHIR) of REST at the DiV 20 after spontaneous activity had been
confirmed by calcium imaging. 2 days after, medium was removed, cells were washed
twice with ice-cold PBS. Cells were collected by adding 200 µl of 0.1% NP-40
(+protease inhibitors) in PBS gentle scraping. Cell lysates were triturated, collected and
gently pipetted into microcentrifuge tubes. 100 µl of each lysate was removed and kept
in new microcentrifuge tubes as whole cell fractions. The rest of the lysates were
centrifuged at 17000 g for 1 min a 4◦C. The supernatant was transferred into a new tube
as the cytoplasmic fraction. To remove remaining cytoplasmic proteins from the nuclear
pellet, the remaining pellet was resuspended with 500 µl of 0.1% NP-40 (+protease
inhibitors), centrifuged, and the supernatant was removed. Finally, the pellet was
resuspended with 100 µl of 0.1% NP-40 (+protease inhibitors) and sonicated for 10
seconds. All fractions were stored at -80◦C until use.
2.8.3 Quantification of protein concentration
To determine the protein concentration, Pierce BCA Protein Assay Kit (Thermo Scientific
23225) was used according to the manufacturer’s instructions. A set of protein standards
were prepared in RIPA which were containing 0-200 µg / 100 µl bovine serum albumin
(BSA) for the standard curve. 10 µl of each standard and sample was pipetted into a 96-
well plate (Nunc). 1:50 mixture of reagent B: reagent A were prepared and 200 µl mixture
was pipetted into each well of the 96-well plate. The plate was incubated at 60 ◦C for 30
min. Absorption was measured at 590 nm using a microplate reader (Fluostar OPTIMA,
BMG Labtech). Sample concentrations were calculated according to the standards and
diluted with RIPA to ensure the equal amount of proteins in the samples.
2.8.4 SDS PAGE
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to
separate proteins due to their molecular weight in an electrical field. After protein
41
2. MATERIALS AND METHODS
concentrations had been determined, 10 – 15 µg protein was mixed with 4x loading
buffer (Laemmli buffer with 100 mM DTT) and heated for 5 min at 95 %C. Samples were
loaded on 4 % stacking gel (prepared with 125 mM buffer Table 2.20, 4 % acrylamide,
0.1 % APS, 0.1 % TEMED) separated on a 10-12 % polyacrylamide gel (prepared with
375 mM buffer Table 2.8.4, 10 % acrylamide, 0.1 % APS, 0.1 % TEMED).
Protein-Marker IV Prestained (Peqlab 27-2110) was used to determine the size of the
proteins. Electrophoresis was performed initially at 80 V for 20 min to allow samples to
reach the separation gel and increased later to 120 V for 1.5-2 h in running buffer (Table
2.22).
Table 2.20: Stacking gel buffer
Reagent Distributor Catalog no Concentration
Tris Roth 0188.2 0.5 M
HCl Roth 4625.2 to set pH 6.8
ddH2O
Table 2.21: Separation gel buffer
Reagent Distributor Catalog no Concentration
Tris Roth 0188.2 1 M
HCl Roth 4625.2 to set pH 8.8
ddH2O
Table 2.22: Running buffer
Reagent Distributor Catalog no Concentration
Tris Roth 0188.3 25 mM
Glycine Roth 3908.2 192 mM
SDS Roth 0183.2 0.1 %
ddH2O up to 1 l
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2.8.5 Native and semi-native tris-tricine PAGE
Semi-native tris-tricine PAGE was established to separate and visualize oligomeric forms
of Aβ by using Biorad Mini-PROTEAN system. In order to sustain high molecular weight
oligomers of Aβ, 0.1% SDS was only added to the electrophoresis buffer (Table 2.23).
150 - 200 ng Aβ oligomers were mixed with 4x native loading buffer (125 mM Tris-HCl
pH 6.8, 40 % Glycerol, 0.01 % Bromophenol blue) and the mixture was loaded on a 4
% stacking gel (prepared with 125 mM buffer Table 2.22, 4 % acrylamide, 0.1 % APS,
0.1 % TEMED) separated on 18% polyacrylamide gel (prepared with 1 M buffer Table
2.22, 4 and 18 % acrylamide, 0.1 % APS, 0.1 % TEMED). SeeBlue Plus2 Pre-stained
Protein Standard (Invitrogen LC5925) was used to determine the size of the oligomers.
Electrophoresis was performed initially at 80 V for 20 min to allow samples to reach the
separation gel and increased later to 120 V for 2.5 - 3 h in semi-native running buffer
(Table 2.23). Furthermore, native tris-tricine PAGE was perfomed as semi-native except
that the running buffer did not include any SDS.
Table 2.23: Semi-native gel buffer
Reagent Distributor Catalog no Concentration
Tris Roth 0188.2 3 M
HCl Roth 4625.2 to set pH 8.45
ddH2O
Table 2.24: Semi-native running buffer
Reagent Distributor Catalog no Concentration
Tris Roth 4855.2 100 mM
Tricine Roth 6977.2 100 mM
SDS Roth 0183.2 0.1 %
ddH2O up to 1 l
2.8.6 Western blot
After electrophoresis, separated proteins were transferred either to polyvinylidene
fluoride (PVDF) or nitrocellulose Amersham membranes (GE Healthcare 10600021,
10600002, respectively) according to the sizes of separated proteins. For analysis of
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Aβ, oligomers were blotted to a PVDF membrane. All other proteins were blotted to
nitrocellulose membranes. PVDF membranes were first activated in ethanol and then
incubated for 10 min in 1 x transfer buffer (Table 2.24) before blotting. All other materials
such as Whatman papers, sponges, and gels were incubated for 5 min in transfer buffer.
Blotting apparatus (BioRad) was filled with the membrane to the anode and gel to the
cathode in between Whatman paper and sponge layers. Blotting was performed either
25 V and 4 ◦C ON or 100 V at RT for 2 h in transfer buffer.
Table 2.25: Transfer buffer
Reagent Distributor Catalog no Concentration
Tris Roth 0188.3 25 mM
Glycine Roth 3908.2 192 mM
Ethanol Roth 5054.4 200 ml
ddH2O up to 1 l
Table 2.26: Blocking buffer
Reagent Distributor Catalog no Concentration
Roti-Block Roth A151.1 10X
ddH2O up to 20 ml
Table 2.27: TBST
Reagent Distributor Catalog no Concentration
Tris Roth AE15.2 50 mM
NaCl Roth 3957.1 150 mM
Tween 20 Sigma P1379 0.1 %
ddH2O up to 1 l
The membrane was blocked with blocking buffer (Table 2.25) under gentle shaking at RT
for 1 h. Primary antibody dilutions were prepared in blocking buffer. Membranes were
incubated with antibody solutions ON at 4 ◦C. control. The next day, membranes were
washed three times with TBST (Table 2.26) for 10 min and incubated with the
appropriate HRP-conjugated secondary antibody (diluted in blocking buffer, Table 2.8.6)
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Table 2.28: Primary antibodies for WB
Reagent Distributor Catalog no Concentration
4G8 Covance SIG-39220 1:1000
6E10 Covance SIG-39320 1:1000
βIII tubulin Covance PRB-345P 1:30000
GAPDH Calbiochem CB1001 1:20000
Rest Millipore 09-019 1:1000
SNAP25 SynSys 111011 1:1500
Lamin Abcam ab16048 1:1000
Table 2.29: Secondary antibodies for WB
Reagent Distributor Catalog no Concentration
anti-Ms-HRP SantaCruz sc-2055 1:4000
anti-Rb-HRP SantaCruz sc-2054 1:10000
for 1 h at RT. Membranes were washed three times with TBST and once with TBS
before developing with Western Bright Quantum ECL reagent (Biozym 541015)
according to manufacturer’s instructions.
2.8.7 myc-REST overexpression in HEK cells
The plasmids, msREST-myc and empty vector (kindly provided by Pietro Baldelli), were
recovered by cutting the DNA-containing circles from the filter paper and immersing the
circles in 50 µl of ddH2O in microcentrifuge tubes (Sarsted 72.706.200). After
centrifuging for 1 min at 17000 g, 1 µl plasmid was used to transform competent
bacteria. In short, 100 µl competent bacteria was mixed with 20 µl 5X KCM (Table 2.30),
80 µl ddH2O, and 1 µl plasmid DNA on ice. Mixture was incubated on ice for 20 min, at
RT for 10 min and following 1 ml LB (10 % trypton, 5% yeast extract, 10 % NaCl, pH 7.5)
addition, at 37 ◦C for 50 min at 850 rpm on the thermomixer (Eppendorf 22331). 100 µl
mixture was scraped on LB-agar plates (10 % trypton, 5% yeast extract, 10 % NaCl, 15
% agar, pH 7.5). The next day selected colonies were inoculated in 5 ml LB containing
tubes.
Plasmids were purified using the QIAGEN Plasmid Plus Mini Kit (Qiagen) according to
the manufacturer’s protocol. Plasmid DNA-concentrations were measured with a
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Table 2.30: KCM Buffer, 5X
Reagent Distributor Catalog no Concentration
KCl Roth HN02.1 500 mM
CaCl2 Roth HN04.1 150 mM
MgCl2 Roth HN03.1 250 mM
NanoVue Plus Spectrophotometer (Implem, GE Healthcare). HEK cells were seeded in
6 cm dishes (83.3901) and after they reached 90 % confluence, cells were transfected
with Lipofectamine 2000 (Invitrogen 11668019). 3 µg of DNA plasmid were diluted in
300 µl Opti-MEM (Invitrogen 31985070) and 6 µl of Lipofectamine 2000 were diluted in
300 µl Opti-MEM. Two dilutions were mixed by pippeting and the mixture was incubated
for 20 min at RT. The medium of the HEK cells were refreshed and the 600 µl mixture
were added dropwise to the dishes. Empty vector was prepared in the same way and
used as control vector. Cells were incubated for transfection for 5 h. Medium was
replaced completely. Transfection was monitored by fluorescence microscope (GFP
expression) and cells were lysed for further WB analysis.
2.9 Softwares
Softwares used in this study according to experimental set-ups:
Immunocytochemistry images were taken by ZEN software (ZEISS) and imported into
ImageJ (National Institutes of Health) for cell counting or intensity measurements.
Western blot membranes were developed by using Chemidoc-XRS software (Bio-Rad),
exported images were modified and quantified in ImageJ.
Patch clamp data acquisition was carried out using Clampex (Axon Instruments). Data
was imported in Clampfit (Axon Instruments) for extraction of parameters.
Calcium imaging data acquisition and extraction were done with TILLvisION software
(TILL Photonic), ROI selection and image processing was done by ImageJ.
MEA data acquisition and data extraction were carried out with MC_Rack (MultiChannel
systems), calculations were performed in Excel with VBA editor (Microsoft).
The data from all experiments were calculated in Excel, figures and statistical tests were
made in GraphPad Prism 6 software (GraphPad Software), Figures were combined in
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Inkscape and imported in TeXstudio.
2.10 Statistics
GraphPad Prism 6 software was used for statistical analysis. Statistical tests used in
each figure were stated in respective figure legends. Error bars represented standard
errors of the mean (SEM).
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3.1 Generation and characterization of human iPSC-derived
neuronal networks
3.1.1 Generation of human iPSC-derived neuronal networks
To generate mature human neuronal networks, human induced pluripotent stem cells
were differentiated via triggering neural induction by inhibiting TGFβ and BMP pathways
(Chambers et al. 2009) with small molecules such as SB-431542 and DM. Embryoid
bodies (EBs) were generated from induced cells for further neural differentiation in this
well-established three dimensional cell aggregate. After two weeks in suspension
culture, EBs were attached to matrigel coated dishes for further proliferation of
neurogenic progenitors and final differentiation of neurons. Differentiated neural cultures
were purified by anti-NCAM immunopanning to obtain enriched neuronal cultures
(Figure 2.1). In order to obtain functionally mature neuronal networks, neurons had to be
further cultured for three to six months (network maturation). In the first week after
immunoisolation, proliferation of persisting, NCAM-positive neural stem cells (NSCs)
was inhibited and their differentiation was induced by treatment with DAPT (10 µM for
7d). DAPT is a gamma-secretase inhibitor, which prevents notch cleavage and thus
NSC maintenance (Imayoshi et al. 2010). Eventually, these cells differentiated into
astrocytes, as after 1-2 months of maturation, neurons, as well as astrocytes, could be
detected in the immunopurified cultures. The developing cultures were evaluated by
their firing characteristics by using different strategies such as multi electrode array and
calcium imaging. Maturation of synaptically connected neural networks required a
culture time of three to six months. As maturation of the endogenous human
neuron-astrocyte cocultures was not very reliable, the culture system was optimized for
accelerated network maturation. Therefore, freshly immunoisolated neurons were plated
together rat cortical astrocytes and treated with ARAC (1 µM for 7d), in order to
eliminate proliferating NSCs. These cultures showed a higher reproducibility and
developed mature networks within 8 weeks.
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3.1.2 Characterization of neuronal subtypes
3.1.2.1 Immature neurons express deep layer cortical markers
In order to characterize the generated human neuronal networks, iPSC-derived human
neurons were immunostained for cortical markers of different layers markers, one day
after immunopanning. Tbr1 (T-box, brain, 1) and Ctip2 (chicken ovalbumin upstream
promoter transcription factor-interacting protein 2) are expressed in early-born deep
layer neurons, whereas Satb2 (special AT-rich sequence-binding protein 2) is an upper
layer marker. GAD67 (glutamic acid decarboxylase 67) was used to identify GABAergic
interneurons. MAP2 (microtubule-associated protein 2), which is abundant in soma and
dendrites (Caceres et al. 1984), served as the pan-neuronal marker (Figure 3.1A). In
three independent experiments, the percentage of MAP2 positive neurons, expressing
each marker was quantified. Due to the early developmental stage of the cultures,
excitatory neurons exhibited mainly deep layer cortical characteristics (Figure 3.1B).
Only 15% of the neurons were GABAergic interneurons.
Figure 3.1: Characterization of human iPSC-derived immature neurons. (A) Fully differentiated
neurons express pan-neuronal marker MAP2 (green) and cortical markers Tbr1, Ctip2 (deep-layer markers),
and Satb2 (upper-layer marker), as well as GABAergic marker GAD67 (red). (B) Quantification of neurons
expressing Tbr1 (black bar; 76.7±3.9), Ctip2 (red bar; 40±7.9), Satb2 (green bar; 5±0.8) and GAD67 (grey
bar; 15±0.9), n=3. Scale bar represents 50 µm. All values are represented as mean, error bars show
standard error of mean (SEM).
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3.1.2.2 Interneurons remain functionally immature
To investigate whether interneurons present in the human cortical-like neuronal
networks gained functional maturity, I performed gabazine treatments in combination
with multi electrode array (MEA) measurements after 5 months of network maturation.
Figure 3.2: Analysis of interneuron function in cortical-like actively firing neuronal networks.
Neuronal cultures that had reached a maturity stage, where synchronous bursting was detectable, were
tested for the presence of functional interneurons by treatment with the GABA-A receptor antagonist
gabazine. (A) Representative voltage traces recorded on MEAs before, during and after washout of 20
µM gabazine. (B) Bar graphs represent normalized (mean±SEM) activity parameters measured by MEA
recording of neuronal cultures incubated for 5, 10 and 20 min with gabazine and after washout. Each
measurement was normalized to the baseline value, recorded before the gabazine treatment (pre). No
significant differences were observed (one-way ANOVA followed by Bonferroni’s test), n=5 MEAs.
At this stage, networks showed an activity pattern with synchronous burst firing. MEA
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cultures were incubated with the GABA-A receptor antagonist for up to 20 min and
recorded before, during and after treatment. Although 15% of GABAergic interneurons
were present in the immature cultures immediately after panning, no significant change
in firing rate nor any of the other activity parameters was detected (Figure 3.2).
In the immature brain, GABA is excitatory and only becomes inhibitory after delayed
expression of a chloride exporter, which leads to a shift in the reversal potential for
chloride ions (Ben-Ari 2002). Thus, depending on the developmental stage of the
cultures, gabazine was expected to either decrease or increase the network activity. The
absence of any response indicated non-functional GABAergic synapses or the
elimination of interneurons during network maturation.
In conclusion, hiPSC-derived neuronal networks mainly consisted of deep layer
excitatory neurons, without any functional interneurons.
3.1.3 Characterization of network parameters by MEA analysis
In order to select useful parameters for the characterization of network activity recorded
by MEAs, synaptic transmission in mature human neuronal networks was blocked by
inhibition of postsynaptic glutamate receptors (Figure 3.3) and by reducing the
extracellular calcium concentration to block presynaptic vesicle release (Figure 3.4).
Neuronal excitability was manipulated by inducing calcium concentration-dependent
changes (Figure 3.4).
To determine synaptic connectivity-dependent parameters from extracellular MEA
recordings, glutamatergic synapse transmission in mature human neuronal networks
was blocked by exposure to saturating concentrations of the NMDA receptor antagonist
APV (50 µM) and the AMPA receptor antagonist DNQX (10 µM). A partially reduced
spike frequency was observed upon APV and DNQX treatments (Figure 3.3A and C),
however, bursts and burst-dependent parameters were no longer detectable (Figure
3.3B and D). This suggests that the occurrence of bursts completely depends on
glutamatergic synaptic transmission. Individual action potentials, on the other hand, may
be caused by spontaneous (non-synaptic) depolarization of individual neurons.
In an alternative approach, I manipulated synaptic connectivity as well as neuronal
excitability by decreasing extracellular calcium concentrations. A decrease in external
calcium concentration leads to a reduced saturation of negative surface charges and
thus a reduction of the membrane potential towards a more depolarized state. Hence,
an initial decrease of extracellular calcium increases neuronal excitability (Speckmann
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et al. 2015). Further lowering of external calcium below a certain threshold leads to the
inhibition of calcium-dependent presynaptic vesicle release and thus synaptic
connectivity in neuronal networks.
Figure 3.3: Synapse dependent network activity. To determine which of the activity parameters
correlated with synaptic connectivity, iPSC-derived neural networks were recorded on MEAs before and
after application of postsynaptic glutamate receptor inhibitors. Representative voltage traces recorded upon
treatment of (A) APV (50 µM) and (C) DNQX (10 µM). Quantification of the network parameters of (B) APV
and (D) DNQX treatment. Bar graphs represent activity parameters (mean±SEM). n= 10 electrodes from 1
MEA.
To this end, mature human iPSC-derived neuronal networks were subjected to
decreasing concentrations of extracellular calcium (1.8 mM to 0 mM) in an artificial
Neurobasal-like solution and the network activity was monitored by MEA recordings
(Figure 3.4). All recordings were normalized to baseline activity, measured in
NeurobasalTM containing culture medium (NMM) with a CaCl2 concentration of 1.8 mM.
In the mammalian brain, external calcium concentrations range from 1.5 to 2.0 mM
(Egelman & Montague 1999). As expected, the initial decrease of extracellular calcium
led to an elevation of overall network activity due to increased neuronal excitability. Both
spike and burst parameters reacted in a similar way (Figure 3.4B). When approaching 0
mM external calcium, the overall activity strongly declined. Spike frequency (Figure
3.4B) reached a level comparable to baseline activity. The fact that synaptic bursts were
still present at the lowest calcium concentration may be explained by the lack of calcium
chelators and thus, residuals of the ion, sufficient to allow synaptic transmission.
However, the parameter “percentage of spikes in bursts” was reduced below baseline
52
3. RESULTS
levels, indicating an increase of synapse-independent spikes, due to increased neuronal
excitability.
Figure 3.4: Ca2+-dependent network activity. To analyze the effects of blockage of presynaptic vesicle
release on overall network activity, a calcium dose-response curve was performed in iPSC-derived neural
networks, recorded on MEAs, showing bursting activity. Therefore, NMM was replaced by a defined
extracellular solution (Table 2.14) containing 1.8 mM Ca2+ and Ca2+ was then reduced in defined steps.
(A) Representative voltage traces recorded on MEA at different Ca2+ concentrations. (B) Concentration
dependent changes in different neuronal activity parameters (mean±SEM). Each measurement was
normalized to the baseline value recorded before the treatment (neurons recorded in NMM). No significant
differences was observed (one-way ANOVA followed by Bonferroni’s test), n=3 MEAs.
Taken together, characterization of activity parameters showed that spike and burst
frequency parameters are differentially influenced by changes in the network
connectivity and neuronal excitability, where the frequency of synchronous bursts and
the percentage of action potentials appearing within bursts correlate with synapse
function. Changes in these parameters may thus give the first hint on underlying
mechanisms when analyzing treatment responses in human neuronal networks.
3.1.4 Characterization of network parameters by calcium imaging analysis
Calcium imaging is another method to monitor network connectivity, whereby
synchronous calcium oscillations of individual neurons represent synaptic activity across
neurons (Figure 3.5). To determine that the occurrence of Ca2+ transients was
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exclusively the outcome of synaptic activity, human iPSC-derived neuronal networks (5
months of network maturation), showing synchronous calcium transients were treated
with inhibitors of postsynaptic receptors (30 µM DNQX, 5 µM APV and 20 µM
gabazine). Spontaneous synchronous calcium transients were completely eliminated
which indicates that their occurrence depends on the synaptic communication (Figure
3.5B). At the end of measurements, KCl (40 mM) was added to select and quantify the
results only from neuronal ROIs (Figure 3.5B), which showed immediate sharp
increases in the signal. Cells were determined as firing or silent as described in
methods (2.5). Before application of inhibitors around 80% of the neurons were active,
whereas all neurons were silenced after the treatment (Figure 3.5C).
Figure 3.5: Synchronous calcium oscillations in mature iPSC-derived neuronal networks. (A)
Representative false color images of intracellular calcium concentrations visualized at 340 nm. Blue and red
showing low and high calcium concentrations, respectively. Images were taken at baseline, after application
of synaptic inhibitors (30 µM DNQX, 20 µM gabazine and 5 µM APV), and KCl (40 mM). (B) Calcium
transient traces imaged from one field. Each trace was offset-corrected and represents the ROI of a single
neuron. Neurons were identified by their KCl responsiveness at the end of each measurement and ROIs
were generated as described under 2.4. (C) Percentage of silent and synchronously firing neurons before
(baseline) and during (inhibitors) inhibitor treatment. n = 1 coverslip
In conclusion, it was confirmed that calcium imaging is a valuable method to monitor
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human iPSC-derived neuronal network activity to support MEA recordings and
investigate the changes in the network activity.
3.1.5 Assay development using human iPSC-derived neuronal networks
for synaptotoxicity testing
To develop assays using human iPSC-derived neuronal networks to test synaptotoxicity,
botulinum neurotoxin type A (recombinant BoNT/A, toxogen GmbH, Hannover,
Weisemann et al. (2015)) treated networks were subjected to calcium imaging (Figure
3.6) and SNAP25 cleavage assay (Figure 3.7). To see if the two methods gave the same
results, the effects of BoNT/A exposure were compared in a dose- and time-dependent
manner.
3.1.5.1 Time- and dose-dependent effects of BoNT/A on calcium transients of
human neuronal networks
To investigate the effects of BoNT/A on spontaneous network activity (spontaneous
synchronous calcium transients) in human cultures, iPSC-derived neuronal networks
co-cultured with rat primary astrocytes (3 months of network maturation) were treated
for 2, 4 and 6 days with different concentrations of BoNT/A.
Figure 3.6: Inhibition of spontaneous synchronous network activity by BoNT/A. Synchronously
active iPSC-derived neural networks were incubated with different concentrations of recombinant BoNT/A
for 2, 4, 6 days and analyzed by Fura-2-based calcium imaging. (A) Example calcium transient traces
imaged from coverslips at different concentrations and treatment times. Each trace represents the mean
fluorescent intensity from one AOI including all neurons in the field. (B) Dose-response relations of the
blocked spontaneous calcium transient frequency for 2, 4, 6 days BoNT/A incubation. n = 3 cultures per data
point.
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Under control conditions (without toxin incubation), all investigated cultures showed
spontaneous synchronous calcium transients (Figure 3.6A, control), the frequency of
which was quantified and set as 0%-blocked activity. Incubation with BoNT/A led to
dose-dependent reduction of the calcium transient frequency (Figure 3.6). Calcium
imaging showed a complete loss in the synchronous calcium transient rate for BoNT/A
concentrations of 200 pg/ml, 100 pg/ml, and 10 pg/ml for 2, 4, and 6 day of BoNT/A
treatments, respectively (Figure 3.6).
3.1.5.2 Dose-response-curve for BoNT/A in human and rat neurons according to
SNAP25 cleavage
The SNAP25 cleavage assay is the most frequently used in vitro efficacy test method for
BoNT/A and is also used by the BoNT/A manufacturers (Cai, Singh & Sharma 2007).
Figure 3.7: SNAP25 cleavage in human and rat neurons upon BoNT/A treatment. Human iPSC-
derived and primary rat cortical neurons were incubated with increasing concentrations of BoNT/A for 2,
4 and 6 days and cell lysates were analyzed for SNAP25 and its cleavage products by western blotting.
Example blots showing (A) human and (B) rat SNAP25 immunoreactivity at different time points and
concentrations. Corresponding dose-response curves for SNAP25 cleavage in (C) human and (D) rat
neurons. EC50 (pg/ml) values are shown in the tables. Data represent mean±SEM, n = 3 biological
replicates per data point.
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To replicate the method and compare the results, human immunopurified iPSC-derived
neurons (2 months of network maturation) and rat primary cortical neurons (14 div) were
treated with different concentrations of BoNT/A for 2, 4, and 6 days and western blots
were quantified by calculating the ratio of cleaved to non-cleaved SNAP25 protein
(Figure 3.7). Exposure to BoNT/A for 2d resulted in a significant increase in SNAP25
cleavage in human compared to rat cortical neurons at much lower concentrations
(Figure 3.7 C and D, tables). Human neurons showed higher sensitivity to BoNT/A
during 2 and 4 days treatment; however, species-specific differences were eliminated
after prolonged incubation (6 days). These results might be explained by the fact that
the BoNT/A receptors responsible for internalizing the toxin might have different
structures in rat and the human neurons since The duration of the effects varies
extensively depending on dose, animal species (Pirazzini et al. 2017). Therefore, human
neurons have higher sensitivity to the toxin in early time-points. Overall, the
dose-response curves obtained from calcium imaging and SNAP25 cleavage assays
using human neurons differentiated from iPSCs showed different results, showing that
the synchronous calcium transient-based assay has higher sensitivity compared to the
SNAP25 cleavage assay. This difference in sensitivity might be explained by that
BoNT/A is taken up at the synapses and thus cleave synaptic SNAP25 first. This would
then have an effect on network activity. The total pool of SNAP25 is probably much
higher and also contains non-synaptic SNAP25, which is relevant for the SNAP cleavage
assay, but not the activity assay.
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3.2 Modeling homeostatic plasticity in human neuronal
networks
Neuronal networks have the ability to regulate activity in order to maintain their firing
rates at basal levels. The existing body of research on homeostatic plasticity was done
primarily in vivo and in vitro murine models (Desai 2003). It is still not known whether
human iPSC-derived neuronal networks share similar properties. Therefore, the first set
of questions aimed to investigate the homeostatic plasticity abilities of human
iPSC-derived neuronal networks. Their firing rates were manipulated by either blocking
action potentials with tetrodotoxin (TTX), a voltage-gated Na+ channel blocker (Figure
3.8) to silence network activity or prolonging action potentials with 4-aminopyridine
(4AP), a specific blocker of outward K+ current (Figure 3.10) to enhance network activity.
The changes in firing rates were monitored by MEA recordings and calcium imaging.
(Figure 3.16). Furthermore, the involvement of REST in 4AP-mediated homeostatic
plasticity was investigated by immunocytochemistry (Figure 3.18). REST (or NRSF), a
transcription repressor of neuronal genes, was recently described as a mediator of
homeostatic plasticity in hyperactive mouse hippocampal neurons (Pozzi et al. 2013).
Possible attempts to manipulate REST expression were examined by western blot using
primary rat cortical neurons (Figure 3.19).
3.2.1 Homeostatic plasticity in TTX-silenced mature human neuronal
networks
To examine the response of human iPSC-derived neuronal networks to TTX, which is
the mostly used homeostatic plasticity model (Turrigiano 2012), the MEA system was
used, as it enables longitudinal, non-invasive monitoring of network activity (Figure 3.8).
Endogenous cocultures of human neurons and astrocytes were extracellularly recorded
before (pre), during (acute, 1d, 2d, and 3d) and after (post 3h) TTX (1 µM) or control
treatments (Figure 3.8A, B). For quantification, the spike and burst frequency values were
normalized to pre values of each culture. The network activity of the control cultures was
stable during the course of the measurement (Figure 3.8C and D, black line). However,
cultures that underwent TTX treatment maintained a suppressed activity profile in the
presence of TTX and showed an increase in spike (Figure 3.8C, blue line) and burst
frequency (Figure 3.8D, blue line) after removal of TTX, with an average increase of
around 2 fold above the baseline. These results showed that human cultures have the
capability to alter network properties as a result of their homeostatic plasticity response.
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Figure 3.8: Homeostatic plasticity in TTX-silenced mature human neuronal networks. (A) Schematic
treatment and measurement protocol. d: day, h: hour. (B) Representative extracellular voltage traces
recorded from MEAs with hiPSC-derived mature neuronal networks incubated without (left) or with 1 µM
TTX (right) before (top), during (middle) and after (bottom) TTX treatment. Time-course of normalized mean
(C) spike and (D) burst frequencies before (pre), during (indicated by bottom line, 1 µM for 72 h) and after
(post 3h) TTX treatment. Each value was normalized to baseline activity (pre value). Data points represent
mean±SEM, n = 3 MEAs. (Two-way ANOVA followed by Tukey’s multiple comparison test **** p < 0.0001).
Normalized mean spike and burst frequencies were increased after the removal of TTX.
3.2.2 Changes in spike parameters after TTX silencing
To analyze the homeostatic response mechanism to TTX treatment at the level of a
single neuron, the recorded data from MEA experiments were further processed to
extract single action potentials (spikes). The shape of the extracellular spike closely
resembles the first time derivative of an intracellular action potential and the width of the
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intracellular and extracellular action potential are highly correlated (Henze et al. 2000,
Bugaysen et al. 2010) (Figure 2.4E). Therefore, the amplitude of a spike represents the
maximum rising slope of an action potential and thus correlates with the density of Na+
channels on the axonal membrane. On the other hand, alterations in the width
(Bugaysen et al. 2010) and the post-spike maximum (Speckmann et al. 2015) (Figure
2.4E) of the extracellular spike correlate with K+ conductance. Hence, quantification of
parameters like spike amplitude, half-width, 10%-width and post-peak maximum could
give hints on changes in neuronal excitability (Na+ and K+ channel densities) as part of
the homeostatic plasticity.
Figure 3.9: Changes in spike parameters after TTX silencing. (A) Representative mean extracellular
spikes extracted from one electrode of MEA recordings before (pre, black spikes; normalized to 1) and after
(post; normalized to pre) treatment in control (gray spike, left) and TTX (blue spike, right) treated cultures.
Effect size, shown as percent change in (B) amplitude, (C) halfwidth, (D) 10%-width, and (E) post spike max.
Mean±SEM, n > 20 electrodes from 3 MEAs. (Unpaired two-tailed t test ****p < 0.0001, ***p < 0.001, **p <
0.01).
In order to extract single spikes, raw data were filtered with a low-pass 2000 filter and
spikes were detected by the 5XSTD method. Spikes were sorted and extracted from
control and treated cultures before (pre) and after (post) treatment. Spike curves were
imported into Excel for further analysis. The in-house written macro (see Scripts and
Macros) was used to detect the mentioned parameters from each spike. As the distance
between electrode and cell as well as the electrode impedance affect the spike
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amplitude, amplitudes are highly variable between different MEAs and even electrodes
of the same MEA. Therefore, mean spike amplitudes and post-spike maximum from one
electrode were normalized to the baseline (pre, before the treatment) amplitude of the
corresponding electrode. Plasticity-dependent changes were investigated by comparing
spike parameters between before (pre) and after (post) the treatment and data are
shown as effect size (percent change). The same procedure was used for all
experiments dealing with the investigation of spike parameters.
After three days of TTX treatment, the spike amplitude was increased by 30% (Figure
3.9A and B), indicating that the density of axonal Na+ channels was increased during
homeostatic plasticity in silenced networks. Notably, in control treated cultures, no
changes could be observed, suggesting that medium changes did not affect spike.
Furthermore, half-width and 10%-width (Figure 3.9C and D) were significantly increased
and the post-spike maximum was significantly decreased (Figure 3.9E) suggesting a
reduction of K+ channels.
Taken together, changes in spike and burst frequency and the different spike parameters
indicated, that mature human iPSC-derived neural networks upregulate neuronal
excitability as homeostatic plasticity response to prolonged silencing of network activity.
3.2.3 Effect of 4AP on network activity in immature human neuronal
networks
Another significant aspect of homeostatic plasticity is that increasing network activity
leads to a decrease in neuronal excitability to come back to basal firing rates for
preventing excitotoxicity. To this end, as previously described (Pozzi et al. 2013), 4AP
was used to induce hyperactivity by blocking voltage-dependent K+ channels which
affects repolarization, prolongs action potentials, and leads to increased
neurotransmitter release. First, immature human neuronal networks (2 months of
network maturation), showing only spike firing (Figure 3.10B, pre) were treated with 4AP
(100 µM) or with vehicle for 72 h and the activity was recorded by MEA (Figure 3.10A).
Surprisingly, the networks showed no detectable change in spike frequency (Figure
3.10B). Also, 4AP treatment did not lead to the induction of bursting activity (Figure
3.10B, acute 4AP, post 1d) suggesting that the synaptic connectivity within the network
was not well developed. These results might also suggest that 4AP targets, members of
the Kv1 (Shaker, KCNA) family of voltage-activated K+ channels, were not yet
expressed by developmentally immature human neurons.
61
3. RESULTS
Figure 3.10: Effect of 4AP on network activity in immature human neuronal networks. (A) Schematic
treatment and measurement protocol. d: day. (B) Representative extracellular voltage traces recorded from
MEAs with hiPSC-derived immature neuronal networks incubated before (top), during (middle) and after
(bottom) 4AP treatment. (C)Time-course of spike frequencies recorded from neuronal cultures before (pre),
during (indicated by bottom line, 100 µM for 72 h) and one day after 4AP treatment (post 1d). Each value
was normalized to baseline activity (pre). Data points represent mean±SEM, n = 3 MEAs. (Two-way ANOVA
followed by Tukey’s multiple comparison test). Normalized mean spike frequencies showed no changes
during and after the 4AP treatment.
3.2.4 Acute 4AP effects on spike parameters in immature human neurons
Immature human neuronal cultures showed no increase in the network activity upon
4AP stimulation. 4AP was described to prolong action potential duration and thus
increase spike width, by blocking voltage-dependent K+ channels (Lin 2012). To
investigate whether 4AP affects the spike form in immature neurons, extracellular spikes
were analyzed before and during 4AP treatment in control and 4AP-treated cultures
(Figure 3.11A). Quantitative analysis showed, that 4AP-treatment did not significantly
affect spike amplitude (Figure 3.11B), half-width (Figure 3.11C), 10% width (Figure
3.11D), and post-spike maximum (Figure 3.11E), compared to control cultures. These
data implicated that 4AP targeted K+ channels were not expressed by developmentally
immature human neurons.
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Figure 3.11: Spike parameters of 4AP-treated immature human neurons. (A) Representative
normalized mean extracellular spikes extracted from one electrode of MEA recordings before (pre, black
spikes) and during treatment in control (gray spike, left) and 4AP (red spike, right) treated cultures. Effect
sizes, shown as a percent change in (B) amplitude, (C) half-width, (D) 10%-width, and (E) post spike max.
Mean±SEM, n > 5 electrodes from 3 MEAs. (Unpaired two-tailed t test). No changes were observed.
3.2.5 Homeostatic plasticity in 4AP-treated mature human neuronal
networks
In order to investigate hyperactivity-induced homeostatic plasticity in human neural
networks, the maturation time of cultures was increased, until the synchronous burst
firing activity was observed, which was shown to be reliable parameter for synaptically
well-connected networks. Human neurons were then treated with vehicle (control) or
4AP (100 µM) for up to 96 h. Longitudinal changes in network activity were monitored by
MEA recordings before (pre), during (acute, 1d, 2d, 3d, and 4d), and after (post 4d) 4AP
treatment or control treatments (Figure 3.12A). Mature networks showed spikes and
bursts during pre-measurements (Figure 3.12B, pre) and upon 4AP treatment, networks
increased the firing activity dramatically (Figure 3.12B, acute, right). Control networks
showed no change in activity pattern (Figure 3.12B, acute, left). Although individual
networks showed variable magnitude of response, the pattern of the response was
similar for the same type of treatment (Figure 3.12C). After 24 h in 4AP, the networks
displayed decreased spiking and bursting rates (Figure 3.12D and E, 1d, red line). The
firing returned to basal values at the end of 96 h (Figure 3.12D and E, 4d, red line).
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Figure 3.12: Homeostatic plasticity in 4AP treated mature human neuronal networks measured by
MEA. (A) Schematic treatment and measurement protocol. d: day. (B) Representative extracellular voltage
traces recorded from MEAs with hiPSC-derived mature neuronal networks incubated without (left) or with
4AP (right) before (top), during (middle) and after (bottom) treatment. (C) Time-course of normalized spike
rates from single MEA recordings before (pre), during (indicated by bottom line, 100 µM 4AP for 96 h) and
after (4 days post) 4AP (red) and control (black) treatment. Each value was normalized to the baseline
activity (pre value). (D) Time-course of normalized mean spike and (E) burst frequencies. Data points
represent mean ±SEM, n = 3 MEAs, * indicates significant difference between 4AP and control (Multiple t
test *p < 0.05). The normalized mean spiking rate was increased by acute 4AP treatment. After removal of
4AP, the firing rate was decreased.
Notably, 4 days after the removal of 4AP, networks still showed decreased firing rates
(Figure 3.12D and E, post 4d, red line) compared to baseline activity (pre), indicating
64
3. RESULTS
that neurons have changed their properties during 4AP treatment. In conclusion,
maturity of neuronal networks was required to study homeostatic plasticity in human
neuronal networks.
3.2.6 Acute 4AP effects on spike parameters in mature human neurons
Mature human neuronal networks responded to the 4AP treatment by increasing firing
rates (Figure 3.12). To further elucidate the changes in the cellular level, extracellular
spike waveforms were extracted from each active channel and analyzed after
normalizing the amplitudes to 1 before (Figure 3.13A, pre, black spikes) and during
control (Figure 3.13A, pre, gray spike) and 4AP (Figure 3.13A, pre, red spike)
treatments.
Figure 3.13: Acute 4AP treatment affects spike parameters in mature human neurons. (A)
Representative normalized mean extracellular spikes extracted from one electrode of MEA recordings before
(pre, black spikes, normalized to 1) and during (acute, normalized to pre) treatment in control (gray spike,
left) and 4AP (red spike, right) treated cultures. Effect size, shown as a percent change in (B) amplitude, (C)
half-width, (D) 10 % -width, and (E) post spike max. Mean±SEM, n > 20 from 3 MEAs. (Unpaired two-tailed
t test, **p<0.01 ***p<0.001).
Blocking potassium channels with 4AP did not affect the extracellular spike waveform
amplitude (Figure 3.13B). Since action potential width is modulated by potassium
channels, blocking them with 4AP showed an increase in half-width (Figure 3.13C) and
10 % width (Figure 3.13D). On the other hand, blocking potassium channels also
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affected the afterhyperpolarization of the action potential which is represented as the
post spike maximum of the extracellular spike waveforms and the second maximum
values were decreased upon 4AP treatment (Figure 3.13E).
3.2.7 Spike parameters of immature and mature human neurons
Mature (burst firing) and immature (spike firing) networks responded to the 4AP treatment
differentially both in network (Figure 3.12 and 3.10) and cellular (Figure 3.13 and 3.11)
level. To investigate whether these differences were dependent on the differences in
spike properties and could be investigated by the spike waveform analysis, extracellular
spike waveforms were compared without any treatment (Figure 3.14A). Since alterations
in the width of the extracellular spike waveform represented the changes in K+ channels,
half-width (Figure 3.14B) and 10 % width (Figure 3.14C) values of immature and mature
neurons were compared without normalizing. Both half-width and 10 % -width values
were smaller in mature cultures suggesting that smaller spike width was a correlate of
maturation and might indirectly suggest the presence of increased number of K+ channels
on the neuronal membrane.
Figure 3.14: Spike parameters of immature and mature human neurons. (A) Representative
normalized mean extracellular spikes extracted from one electrode of MEA recordings from immature (left)
and mature (right) neurons. Quantification of the (B) spike half-width, (C) 10%-width, and post spike
maximum (normalized to spike amplitude). Mean n±SEM, n > 20 electrodes from 3 MEAs. (Two-tailed t
test, **p< 0.01, ****p < 0.0001).
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3.2.8 Changes in spike parameters after 4AP induced hyperactivity in
mature human neurons
To investigate the long-term effect of 4AP on spike waveforms, single spike analysis was
performed after the removal of 4d 4AP treatment (Figure 3.15). To this end, the recorded
data from MEA experiments were further processed as previously described.
Extracellular spike waveforms were extracted from each active channel and analyzed
after normalizing the amplitudes to 1 before (Figure 3.15A, pre, black spikes) and 4 d
after the control (Figure 3.15A, post, gray spike) and 4AP (Figure 3.15A, post, red spike)
treatments. Blocking potassium channels with 4AP triggered homeostatic mechanisms
and the extracellular spike waveform amplitude was significantly reduced (Figure 3.15B).
Furthermore, 4AP treated neurons also showed a decrease in both in half-width (Figure
3.15C) and 10 % width (Figure 3.15D). However, second maximum values were not
affected (Figure 3.15E).
Figure 3.15: Change of spike parameters after 4AP induced hyperactivity in mature human
neurons. (A) Representative normalized mean extracellular spikes extracted from one electrode of MEA
recordings before (pre, black spikes) and 4 d after treatment in control (gray spike, left) and 4AP (red spike,
right) treated cultures. Effect size, shown as a percent change in (B) amplitude, (C) half-width, (D) 10%-
width, and (E) post spike max. Mean±SEM, n > 20 electrodes from 3 MEAs. (Two-tailed t test, *p<0.05,
**p<0.01).
Taken together, these results suggest that mature human-iPSC-derived neurons were
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able to change their membrane properties which could be detected by extracellular
spike waveform analysis to modulate their network activity via homeostatic plasticity
mechanisms.
3.2.9 Calcium imaging
The second method in this study which was used to identify the long term changes in
the global network activity was the calcium imaging with Fura-2AM.
Figure 3.16: Homeostatic plasticity in 4AP treated mature human neuronal networks measured by
calcium imaging. (A) Schematic treatment and measurement protocol. d: day. (B) Representative traces
of calcium transients before (top), during (middle), and after (bottom) 4AP treatment extracted from one AOI
with several neurons. (C) Percentage of synchronously firing cells before and after 4AP treatment (n = 5
coverslips from 3 different preparations). (D) Distribution of calcium transient frequencies. Sister coverslips
are indicated by symbol shape. Cultures with human astrocytes are in blue and with rat asytrocytes in black.
Normalized calcium transient (E) frequency (n > 8 coverslips from at least 4 different preparations) and (F)
amplitude (n > 25 cells from 3 different preparations) during (acute) and after (post) 4AP treatment. Each
value was normalized to the baseline value (pre) of sister coverslips and represents mean±SEM (Two-tailed
t test *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001). After removal of 4AP, the spontaneous synchronous
calcium transient rate was decreased.
It has been previously described that synchronous calcium transients represent burst
activity of MEA recordings (Shew et al. 2010). Since the downregulation of the network
activity have already been observed with MEA recordings after 48 h, calcium transient
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measurements were performed before (Figure 3.16A, pre) during (Figure 3.16A, acute
4AP), and after removal of 2 d 4AP treatment (Figure 3.16A, post 2d). 4AP treatment
affected synchronous calcium transients (Figure 3.16B). The 4AP treatment resulted in a
decrease in the percentage of active cells joining the network activity (Figure 3.16C).
Acute 4AP treatment increased the calcium transient frequency and amplitude (Figure
3.16E and F, red bars). Furthermore, after removal of 2d 4AP treatment, sister cultures
from each experiment were normalized to pre values. Calcium transient frequency was
reduced below the baseline levels (Figure 3.16E, gray bar). However, transient
amplitudes varied compared to the baseline values. Overall, homeostatic response was
possible to monitor by using calcium imaging.
3.2.10 Evaluation of cell viability upon LiCl, CHIR and X5050 treatment
REST is a translational repressor known to regulate neuronal genes and also homeostatic
plasticity as recently described (Pozzi et al. 2013). Before monitoring REST levels directly,
to test the neurotoxicity of the substances which might moduate REST levels such as
LiCl, CHIR, and the inhibitor X5050 (Charbord et al. 2013), MTT assays were performed
using primary rat cortical neurons along with the glutamate treatment to ensure the assay
quality which resulted in reduced cell viability to 50 %. The safe concentrations of used
substances were indicated as 0.5 mM for LiCl (Figure 3.17A), 100 nM for CHIR (Figure
3.17B), and 10 µM for X5050 (Figure 3.17C).
3.2.11 Changes in REST expression upon 4-AP treatment
To unravel the role of REST in 4AP-induced homeostatic plasticity, mature human
iPSC-derived neurons were stained with REST antibody and nuclei were identified with
DAPI (Figure 3.18A). REST expression levels varied cell-to-cell even without any
treatment ((Figure 3.18A, control). Upon 4AP stimulation, increase in nuclear REST
levels and nuclear to cytosolic REST ratio were observed first after 24 h, compared to
controls (Figure 3.18B, C, and D, 24h). This data was in line with the findings of MEA
recording which showed reduction in the network activity after 24 h. 48 h 4AP treatment
also showed increase nuclear REST levels and nuclear/cytosolic REST ratio (Figure
3.18B and D, 48h). However, cytosolic REST levels were comparable to control
condition at this time point (Figure 3.18C). CHIR increased both nuclear and cytosolic
REST levels, as well as the the ratio between them (Figure 3.18A,B,C, and D, CHIR).
Surprisingly, TTX treated cells showed increased REST levels both in cytoplasm and
nucleus. However, the nuclear/cytoplasmic ratio was not different compared with the
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control. In conclusion, for 4AP-related REST changes, the nuclear/cytosolic REST ratio
at 24 hours was selected as valuable read-out for the further experiments.
Figure 3.17: Decrease of cell viability upon LiCl, CHIR, and X5050 treatment. MTT assay of primary
rat cortical neurons, treated for 48 hours with different concentrations of (A) LiCl, (B) CHIR, and (C) X5050.
100 µM glutamate treatment for 15 min (and further incubation for 1.5 h) served as a positive control. All
values were normalized to control and represent mean±SEM, n=6 wells. (One-way ANOVA Tukey’s multiple
comparisons test ****p < 0.0001). LiCl caused toxicity at 1 mM, CHIR did not show toxicity, X5050 decreased
the cell viability at 50 µM and glutamate caused a 50 % reduction of cell viability parameters.
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Figure 3.18: Changes of REST expression in 4AP-treated human neurons upon manipulation of
network activity. Neurons were treated with 4AP (100 µM) to increase and TTX (1 µM) to silence network
activity. CHIR is known to upregulate REST expression and was used as a positive control (100 nM). (A)
Example confocal micrographs of control, 4AP (30 min, 90 min, 3 h, 24 h, and 48 h), CHIR (24h), and TTX
(3h) treated human neurons, immunocytochemically stained for REST (red). Nuclei were stained with DAPI
(blue). Quantification of mean fluorescent intensity of (B) nuclear and (C) cytosolic REST at the indicated
treatment timepoints. (D) Nuclear vs cytosolic REST ratio. Data are represented as single data points,
representing values from one neuron, and mean, n > 20 neurons from two coverslips. (One-way ANOVA
Dunn’s multiple comparisons test *p < 0.05, **p < 0.01, ***p < 0.001). Scale bar, 50 µm.
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3.2.12 Manipulation of REST expression levels in primary rat cortical
neurons
To further confirm the REST expression changes with another method, western blot
analysis of nuclear and cytosolic fractions was performed. In this case, primary rat
cortical neuronal cultures were used, since human networks include astrocytes and
excluding astrocytic REST levels in western blots was not possible. To investigate the
changes in REST expression levels, western blot analysis was performed using X5050
(10 µ)- and CHIR (100 nM)-treated PCNs and untreated control PCNs after fractionating
nuclei and cytosol. Since several splice variants of REST were described, mouse REST
overexpressing HEK cell lysate was used as a positive control to identify the REST band
(Figure 3.19A). Nuclear fractions were identified and REST levels were normalized to
Lamin, whereas cytosolic REST expression levels were normalized to GAPDH.
Quantification of the upper band showed no changes in REST immunoreactivity (Figure
3.19B, upper panel). However, CHIR treated cells showed increased nuc/cyto REST
ratio in the lower band (Figure 3.19B, lower panel).
Figure 3.19: Manipulation of REST expression levels in primary rat cortical neurons. (A)
Representative WB of fractionated lysates from control, X5050 (10 µM, 48h), and CHIR (100 nM, 48h)
treated primary rat cortical neurons probed with REST antibody. Total cell lysate from myc-tagged-REST
overexpressing HEK cells were run on the same gel and probed with anti-myc antibody. Arrows indicate
potential REST immunoreactivity, due to molecular weight, treatment responsiveness and nuclear/cytosolic
distribution. Lamin and GAPDH are markers for nuclear and cytosolic fractions, respectively. (B)
Quantification of REST immunreactivity in nuclear and cytosolic fractions and their ratios. Data represent
mean±SEM, n = 4 biological replicates. (One-way ANOVA Dunn’s multiple comparisons test *p < 0.05).
Taken together, a homeostatic plasticity model, based on 4AP-induced hyperactivity in
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mature and spontaneously active human neuronal networks differentiated from iPS cells
was established and the REST protein was identified as a potential player in this
mechanism. The model was ready to use for further investigations of disease-related
alterations and evaluations of potent therapeutic strategies.
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3.3 Characterization of different Aβ preparations
After characterizing human iPSC-derived neuronal networks and establishing
homeostatic plasticity models, these cultures were ready to be employed for modeling
certain aspects of Alzheimer’s disease. In order to investigate AD-related changes,
studying the effect of amyloid beta (Aβ) in human iPSC-derived neuronal networks was
the first approach since the increased amount of this peptide is found in cerebrospinal
fluid (CSF) of preclinical AD patients and it represents the central player in the amyloid
cascade (Figure 1.6), triggering early events like synaptic dysfunction.
3.3.1 Effects of cell-derived Aβ
For the generation of cell-derived Aβ species, conditioned medium was collected from
control CHO and 7PA2 (CHO:V717F in the APP751) cells. for obtaining cell-derived Aβ
species. Overexpression of APP in stably transfected 7PA2 cells was confirmed by
immunocytochemistry with the 4G8 antibody (Figure 3.20A) and 8% SDS-PAGE
followed by western blot with the 6E10 antibody (Figure 3.20B). Both methods showed a
clear APP overexpression in 7PA2 cells compared to control CHO cells.
Figure 3.20: 7PA2 cells and the conditioned medium on cell viability (A) Representative images of
7PA2 and CHO cells immunostained with 4G8 antibody for APP (red) and DAPI for nuclei (blue). (B) Western
blot analysis of 7PA2 and CHO cells immunolabelled with GAPDH and 6E10 antibody for APP. (C) Primary
rat cortical cells were exposed to control (black bar), ID (grey bar) or 7PA2 (red bar) conditioned medium for
48 h. Cytotoxicity was measured by MTT assay at an absorbance of 545 nm using a microplate reader. Data
are presented as a mean±SEM, n = 6.
To test the effects of 7PA2 conditioned medium on cell viability, an MTT assay was
performed using primary rat cortical neurons. As control, 7PA2, immunodepleted for Aβ
(ID) by incubating 7PA2-conditioned medium with IC16 antibody coupled to
NHS-sepharose bead ON at 4 ◦C, was used. 7PA2 conditioned medium and the
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immunodepleted control medium did not show any changes in cell viability (Figure
3.20C). Since no change in cell viability was observed, the next step was to evaluate the
cell-derived Aβ dependent effects on network activity in human iPSC-derived networks.
Figure 3.21: Effects of cell-derived Aβ on network activity. (A) Schematic 7PA2 od ID treatment
protocol on mature human networks. d: day. (B) Representative extracellular voltage traces recorded
from hiPSC-derived mature neuronal networks incubated with 7PA2 conditioned medium (right panel) or
immunodepleted 7PA2 conditioned medium as control (left panel). Time-course of normalized (each culture
to respective basal value) spike (B) and burst (C) frequencies of neuronal networks before (pre) and during
(1-5 d) 7PA2 or ID treatment. n = 2.
To this end, the activity of mature human networks was monitored by MEA recordings
before and during Aβ treatment (Figure 3.21A). Spike and burst frequencies of different
cultures were normalized to baseline activity (pre). Both Aβ and ID treatment induced a
trend towards reduced network activity (Figure 3.21C and D). However, immunodepleted
control conditioned medium showed an even stronger effect indicating unspecific effects
derived from components introduced by the immunodepletion procedure. Thus,
cell-derived Aβ and its ID control were not suitable to serve as a proper
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treatment/control group and next steps opted for a more defined Aβ preparation.
3.3.2 Generation and characterization of synthetic Aβ oligomers
To obtain more defined and consistent disease-related Aβ preparations, I aimed at
generating low molecular weight oligomers (Selkoe 2001) of synthetic Aβ. Another type
of Aβ was used additionally since it has been described that N-terminal truncated and
pGlu-modified Aβ species (Pyroglutamylated Aβ3−42 ([Pyr3]Aβ3−42,) are present in AD
brains in large quantities (Saido et al. 1995). The preparation of a mixture of
Aβ42:[Pyr3]Aβ3−42 (95%:5%) was prepared according to the published protocol
(Nussbaum et al. 2012). First a main issue with visualizing Aβ oligomers had to be
solved, as some polyacrylamide gel electrophoresis (PAGE) types alter the oligomer
profile. Therefore, different PAGE conditions were tested (Figure 3.22). Subsequently,
synthetic Aβ42 was subjected to different oligomerization protocols with varying
oligomerization temperature, time and solvent used to dissolve Aβ42 (Figure 3.23).
3.3.2.1 Western blot analysis of synthetic Aβ oligomers with different PAGE
conditions
SDS, used in conventional SDS-PAGE is known to solubilize Aβ fibrils or aggregates
until the dimer state, thus changing the initial oligomer profile. Therefore, native and
semi-native PAGE protocols were performed to observe the full-range oligomer profile
(Figure 3.22A).
Figure 3.22: Western blots of synthetic Aβ oligomers with different PAGE conditions (A) Native and
(B) semi-native PAGE contained 0.1 % SDS in the electrophoresis buffer and allowed identification of Aβ
monomer and low molecular Aβ oligomers such as dimer, trimer, and tetramer by conventional SDS-PAGE
molecular weight markers. V = vehicle, Aβ = Aβ1−42, Aβ* = 95 % Aβ1−42 + 5 % [Pyr3]Aβ3−42.
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Native PAGE did not contain any SDS. Semi-native PAGE contained SDS only in the
running buffer to facilitate the running of the peptides in the 18% gel (Figure 3.22B). The
vehicle sample which was used as a negative control and did not show any signal. The
semi-native condition resolved low molecular weight oligomers such as dimer, trimer,
and tetramer and monomers (Figure 3.22B) and single bands could be detected by
conventional SDS-PAGE molecular weight markers. However, in native conditions, all
different bands were observed as a single band and undefined smear (Figure 3.22A).
Overall, semi-native PAGE was a useful method to monitor oligomeric Aβ species and
was used routinely for the rest of the study to check the oligomer profile of Aβ
preparations.
3.3.2.2 Synthetic Aβ* oligomerization and oligomer stability
To establish stable low molecular weight oligomer preparations, synthetic Aβ* was first
solubilized in HFIP to generate a purely monomeric sample. Aβ* was aliquoted in glass
vials to reduce loss of the sticky peptide during resolubilization. For oligomerization,
HFIP was evaporated and Aβ* was dissolved and incubated at different conditions
(Figure 3.23A).
Figure 3.23: Synthetic Aβ* oligomerization and oligomer stability during cellular incubation time.
Semi-native WBs were probed with the 6E10 antibody. (A) Synthetic Aβ* oligomers, prepared with or without
DMSO in phenol-free Neurobasal medium, were incubated at (5 µM) for up to 7 d (1, 2, 5, and 7 d) either at
4 ◦C or 37 ◦C. (B) Western blot analysis of collected culture supernatant from primary rat cortical neurons,
treated with 1 µM Aβ* (oligomerized with the DMSO-free protocol for 2d at 4 ◦C) for up to 5 d (0, 1, 3, and 5
d). This shows, that oligomer profiles were stable during 5 days of incubation at 37 ◦C.
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Mostly, Aβ is dissolved in DMSO, which stabilizes the monomeric form (Shen & Murphy
1995). However, the presence of DMSO might cause synaptic alterations (Hanslick et al.
2009, Götte et al. 2010). Therefore, synthetic Aβ* was oligomerized at 5 µM in aqueous
solutions (phenol free neurobasal solution) or in DMSO + NB (Aβ was first dissolved in
DMSO at 5 mM briefly and further diluted in NB to 5 µM) for up to 7 d (1, 2, 5, and 7 d)
at 4 ◦C or 37 ◦C. Oligomerization products were the analyzed by a semi-native western
blot. This showed, that Aβ* oligomer profiles of DMSO+NB and only NB preparations
(DMSO with more smear-like) performed at 4 ◦C were similar (Figure 3.23A, first 8
lanes), however, the DMSO-free condition contained more low molecular weight
oligomers at any time point. It was also observed that temperature alters the oligomer
profiles of Aβ* preparations immensely (Figure 3.23A, last 8 lanes). 37 ◦C resulted in
more high-molecular weight aggregates in comparison to 4 ◦C. On the contrary,
monomeric Aβ* was the most abundant species at 4 ◦C, followed by tetramers. To be
able to observe the dimers and trimers in the preparations, longer exposure of the
membranes was necessary (data not shown). Furthermore, high molecular weight
oligomers were only observable in 5 d and 7 d preparations at 4 ◦C. Therefore, 4 ◦C
preparations of Aβ* which gave rise to low-molecular weight oligomers were used for the
rest of the study. Surprisingly low-molecular weight synthetic Aβ oligomers prepared in
this method were very stable, media collected from cells, incubated with 1 µM Aβ* over
5 days showed no decrease in Aβ* and no change in the oligomer pattern (Figure
3.23B). Taken together, the Aβ preparation used in the following experiments contained
mainly monomers and low-molecular weight Aβ oligomers.
3.3.3 Effects of synthetic Aβ* on neuronal cell viability
To test the effects of Aβ, Aβ* oligomer preparations on cell viability, an MTT assay was
performed using untreated controls or HFIP-vehicle, Aβ, Aβ* oligomer-treated PCNs for
3d and 7d (Figure 3.24A and B, respectively). No change in cell viability was observed.
To further investigate whether Aβ* oligomer-treatment alter the effect on cell viability in
less enriched medium, SATO supplement was omitted from the medium and MTT assay
was performed with 8 d long Aβ* oligomer-treated primary rat cortical neurons (Figure
3.24C). There was no change in cell viability neither in regular nor in less-enriched
conditions (Figure 3.24C).
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Figure 3.24: Effect of synthetic Aβ species on cell viability. Rat cortical cells were exposed to control
medium (black bar), HFIP-vehicle (grey bar), 1 µM Aβ (red bar) or 1 µM Aβ* (dark red bar) oligomers for
(A) 3d and (B) 7d. (C) Cell viability in presence and absence (dashed bars) of SATO supplement (Table
2.7) along with control (black bar), vehicle (grey bar), or 1 µM Aβ * oligomer (dark red bar) treatments.
Cytotoxicity was measured by an MTT assay. Data are presented as a mean ±SEM, n = 6 wells (One-way
ANOVA) No evidence of impaired cell viability was detected.
3.3.4 Effects of synthetic Aβ on electrophysiological properties of human
neurons
To investigate the effects of the Aβ oligomers on the excitability and firing behavior of
human iPSC-derived neurons, single-cell patch-clamp recordings were performed with
mature cultures treated with vehicle and Aβ (for this experiment Aβ was oligomerized by
incubation for 24h at 37◦C) and compared to control cultures with no treatment (Figure
3.25). Injected current pulses resulted in depolarization and repetitive firing in almost all
cells and representative evoked spike trains are shown for selected current steps (10,
50, 100, 150, and 200 pA current injection) of control, vehicle, and Aβ oligomer-treated
cultures (Figure 3.25A). Repetitive firing patterns of Aβ oligomer-treated neurons were
different for 50 and 100 pA current injection steps between vehicle and control neurons.
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Figure 3.25: Effects of synthetic Aβ oligomers on excitability. (A) Representative current-clamp
recordings of spike trains evoked by current injections of 10, 50, 100, 150, and 200 (bottom to top) under
control, vehicle, or Aβ conditions. (B) Action potential (AP) frequency response to depolarizing current
injections of untreated control (black), and vehicle- (gray) or Aβ- (red) treated neurons. (Two way ANOVA,
Tukey’s multiple comparison test *p < 0.05) n = 9.
All injected current pulses (-50 pA to 240 pA, 10 pA/step) were plotted against the
corresponding firing rates (input-output curve, Figure 3.25B). Firing frequency showed
reduction in 90 pA and 110 pA current injection steps in Aβ treated cultures compared to
control and vehicle (Figure 3.25B, red line).
The shape of the first AP occurring upon 150 pA current injection was characterized
from the patch clamp recordings of control, vehicle and Aβ oligomer-treated human
iPSC-derived neuronals (Figure 3.26). APs of all human neurons showed a fast rise time
to peak amplitude followed by a fast drop in voltage into afterhyperpolarization (AHP),
which then slowly recovered to resting membrane potential (Figure 3.26A). The
threshold for firing an AP was not different between treatments (Figure 3.26B). The initial
phase of AP represented by AP amplitude and maximum rising slope, which are
predominantly regulated by Na+ channels, were not changed upon long term vehicle
and Aβ oligomer treatment compared with control (Figure 3.26C and D). Furthermore,
half-width, maximum rising slope, and AHP, which are predominantly regulated by K+
channels, were not significantly different between treatments. These data suggest that
there was no difference in AP parameters between neurons upon Aβ treatment.
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Figure 3.26: Effects of synthetic Aβ oligomers on AP properties. The shape of the first AP occurring
upon 150 pA current injection was characterized. (A) Representative AP trace of control, vehicle, or Aβ
treated neurons. (B) V threshold, (C) AP amplitude, (D) maximum rising slope, (E) half-width, (F) maximum
repolarising slope, and (G) afterhyperpolarization of control (black), vehicle- (gray), and Aβ- (red) treated
cultures. No changes were observed (One-way ANOVA followed by Tukey’s multiple comparison test). n = 9.
3.3.5 Effects of synthetic Aβ* on spontaneous network activity of human
neurons
In order to examine the effects of synthetic Aβ* oligomers on spontaneous activity,
mature human iPSC-derived networks were treated with HFIP-vehicle or Aβ* and were
extracellularly recorded by MEA. Firstly, to be able to use the vehicle-treated cultures as
a control for the rest of the experiments, the network activity alterations were
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investigated in vehicle-treated human iPSC-derived neuronal cultures and compared to
the network activity of control cultures (Figure 3.27). Since the vehicle was prepared by
evaporating HFIP (in which Aβ* was monomerized) under N2 stream for 30 min and
followed by addition of phenol-free neurobasal medium to the tube, evaluation of traces
of HFIP on the network activity was necessary to exclude vehicle effects. MEA
recordings revealed that treatment of vehicle did not alter spike and burst frequency
(Figure 3.27A and B), burst duration (Figure 3.27C), as well as the spike rate in bursts
(Figure 3.27), compared to control cultures. Therefore, HFIP-vehicle was used for the
rest of the study as a control for the synthetic Aβ* oligomer-related MEA recording
experiments.
Figure 3.27: Effects of vehicle HFIP treatment on spontaneous activity in mature human neuronal
networks. HFIP vehicles were prepared according to the Aβ oligomerization protocol and MEA cultures
were treated by replacing half of the medium with vehicle containing fresh medium. Time-course of the
normalized (A) spike frequency, (B) burst frequency, (C) burst duration, and (D) spike rate in bursts extracted
from MEA recordings of human neuronal cultures, incubated for 4, 24, 48, and 72 h in the absence (control,
black lines) and presence of vehicle (gray lines). Each value was normalized to the baseline value (before
treatment). Data represent normalized mean±SEM, n = 3 MEAs.
Next, synthetic Aβ* oligomer-dependent effects were studied. Long-term changes in
network activity upon synthetic Aβ* oligomer treatment were monitored for up to 8 days
of treatment (1d, 2d, 3d, 4d, 5d, and 8d) (Figure 3.28A). Mature networks showed spike
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and burst activity during pre measurements (Figure 3.28B, pre). Both vehicle- and
synthetic Aβ* oligomer-treated networks showed no change in activity pattern (Figure
3.28B, 4d and 8d). Time-course analysis also revealed that synthetic Aβ*
oligomer-treated networks showed no detectable changes in spike (Figure 3.28C) and
burst (Figure 3.28D) rates compared to vehicle-treated control networks. Overall,
synthetic Aβ* oligomers did not alter network activity in human neuronal networks.
Figure 3.28: Effects of synthetic Aβ* oligomers on spontaneous activity in mature human neural
networks. (A) Schematic Aβ* treatment and measurement protocol. d: day. Red arrowheads indicate the
half medium changes with Aβ* treatments. (B) Representative extracellular voltage traces recorded from
MEAs with vehicle (left) or Aβ* (right) treated cultures. Time-course of normalized (C) spike and (D) burst
frequencies before (pre) and during (1, 2, 3, 4, 5, and 8 d) vehicle or Aβ* treatment. Each value was
normalized to the baseline activity (pre). Data represent normalized mean±SEM, n = 3 MEAs. (Two-way
ANOVA followed by Tukey’s multiple comparison test). Normalized mean spike and burst frequencies showed
no changes during Aβ* treatment.
Finally, to examine the long-term effect of synthetic Aβ* oligomers on spike properties,
single spike analysis was performed before, at 1 d and 5 d of Aβ* treatment (Figure
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3.29). To this end, the recorded data from MEA experiments were further processed as
described before. Extracellular spikes from each active channel were normalized to the
mean spike amplitude from the same electrode measured before the treatment (Figure
3.29A, -1d, black spikes. Quantification of spike parameters such as amplitude,
half-width, 10 %-width and post-spike peak did not show any significant changes after 1
d and 5 d Aβ* treatment, compared to vehicle treated cultures (Figure 3.29B-E).
Figure 3.29: Spike parameters of synthetic Aβ* oligomer-treated mature human neurons. (A)
Representative normalized mean extracellular spikes extracted from one electrode of MEA recordings before
(-1d, black spikes) and during (1d, light gray spikes and 5d, dark gray spike) vehicle or Aβ* oligomer
treatment. Effect size, shown as percent change in (B) amplitude, (C) spike half-width, (D) 10 % -width,
and (E) post spike maximum. Data represent mean±SEM, n > 20 electrodes from 3 MEAs.
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The results in this chapter indicated that high molecular weight or aggregated synthetic
Aβ did not impair neuronal excitability (Figure 3.25 and Figure 3.26) and low molecular
weight Aβ * oligomers did not affect the overall network activity (Figure 3.28) or spike
properties (Figure 3.29) in human iPSC-derived neuronal networks. The lack of changes
in burst activity suggested, that synapse number or efficiency were not affected by
synthetic Aβ * oligomers. The next chapter, therefore, moves on to investigate alteration
in homeostatic plasticity alterations upon synthetic Aβ* oligomer treatment.
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3.4 Effect of synthetic Aβ* on 4AP-induced homeostatic
plasticity
After establishing a hyperactivity-based homeostatic plasticity model in human
iPSC-derived neuronal networks and characterizing Alzheimer disease-related Aβ*
oligomers, the next step was to combine these approaches to study potential
homeostatic plasticity alterations in AD. To this end, mature human iPSC-derived
neuronal networks underwent long-term synthetic Aβ* oligomer exposure and later they
were subjected to 4AP stimulation. Their ability to induce homeostatic plasticity in
response to 4AP stimulation was monitored by MEA recording and calcium imaging
(Figure 3.30 and Figure 3.33). Their response to acute and long-term 4AP stimulation
and the ability to change the firing properties were investigated by spike analysis (Figure
3.31 and Figure 3.32). The involvement of REST was studied using
immunocytochemistry and calcium imaging (Figure 3.34 and Figure 3.35).
3.4.1 Changes in homeostatic plasticity upon synthetic Aβ* treatment in
mature human neuronal networks
To investigate the effect of Aβ* oligomers on hyperactivity-induced homeostatic
plasticity, mature hiPSC-derived neurons, which were pre-treated with Aβ* oligomers
(oligomer preparation: 5 µM for 2 d at 4 ◦C) or vehicle for 8 days, were subjected to 4AP
stimulation and the network activity was monitored by MEA recordings (Figure 3.30A).
Networks showed burst pattern activity before 4AP treatment (Figure 3.30B, pre). Both
vehicle and Aβ* oligomer-treated networks displayed increased activity upon 4AP
stimulation (Figure 3.30B, acute 4AP). After 24 h in 4AP, vehicle-treated networks
showed decreased spike rates which continued decreasing until 96 h. After removal of
4AP, the spike frequency was reduced, compared to baseline levels. Low activity levels
sustained for at least 72 h after 4AP removal (Figure 3.30B, post1d and Figure 3.30C,
black lines). Aβ* treated networks were also able to decrease their firing rates; however,
the initial decrease was lower and even after 96 hours, the plasticity response was only
partial and did not reach the levels of vehicle-treated networks (Figure 3.30B, post1d
and Figure 3.30C, red lines). To conclude, Aβ* treatment leads to an impaired
homeostatic network response to induced hyperactivity in human iPSC-derived neuronal
networks.
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Figure 3.30: Effect of Aβ* oligomers on homeostatic plasticity in mature human neuronal networks.
(A) Schematic treatment and measurement protocol. Human neurons were pretreated with vehicle and
oligomeric Aβ* for 8 days, with a half medium change and Aβ* refreshment after 6 days. Red arrowheads
represent the medium changes. Homeostatic plasticity was then induced by 4AP treatment for 4 days.
Network activity was analyzed before, during and after 4AP treatment. (B) Representative voltage traces
from MEA recordings before (top), during (middle) and after (bottom) 4AP treatment in vehicle (left) and Aβ*
(right) treated cultures. (C) Time-course of normalized spike frequencies from single MEAs before (pre),
during (bottom line, 100 µM for 96 h) and after (post 1d, 2d, 3d) 4AP treatment. Each value was normalized
to the baseline activity (pre value).
3.4.2 Effects of Aβ* oligomers on 4AP-induced changes in spike
properties
To evaluate the effects of Aβ* oligomers on homeostatic plasticity, spike properties were
investigated during acute treatment and after the removal of Aβ*. First, it was tested,
whether both vehicle and Aβ*-treated cultures responded to 4AP stimulation in a similar
manner (Figure 3.31). Representative normalized extracellular spikes of vehicle and
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Aβ*-treated neurons before and during 4AP stimulation are shown in Figure 3.31A.
Quantification of spike parameters revealed that the spike amplitude (Figure 3.31B) was
not changed by 4AP treatment in vehicle and Aβ* pre-treated cultures. Acute 4AP
stimulation resulted in increased spike half-width (Figure 3.31C) and 10 % width (Figure
3.31D) and decreased post-spike maximum (Figure 3.31E) in both conditions. However,
the increase in 10 % width was slightly lower in Aβ*-treated cultures (Figure 3.31D, red
bar).
Figure 3.31: Effects of Aβ* oligomers on 4AP-induced acute changes in spike parameters. (A)
Representative normalized mean extracellular spikes extracted from one electrode of MEA recordings before
(pre, black spikes, normalized to 1) and during (acute, normalized to pre) 4AP treatment in vehicle (gray
spike, left) and Aβ* (red spike, right) treated cultures. Effect size, shown as percent change in (B) amplitude,
(C) half-width, (D) 10 %-width, and (E) post spike max. Mean±SEM, n > 20 electrodes from 2 MEAs.
(Two-tailed t test, *p<0.05).
Once it was confirmed that vehicle and Aβ* oligomer-treated human neurons responded
to the acute 4AP stimulus in a similar manner, plasticity-dependent changes were
investigated by comparing spikes before and after 4AP treatment (Figure 3.32).
Extracellular mean spike amplitudes from one electrode of vehicle and Aβ*-treated
neurons were normalized to the mean spike amplitude before 4AP treatment (Figure
3.32A). As expected, blocking potassium channels with 4AP triggered homeostatic
mechanisms and the amplitude of vehicle-treated neurons was decreased in the post
4AP condition compared to the values before treatment (Figure 3.32A, post 4AP, gray
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spike). However, this change was significantly diminished in Aβ*-treated neurons
(Figure 3.32A, post 4AP, red spike and Figure 3.32B). In both conditions, 4AP-treated
neurons showed a decrease in half-width (Figure 3.32C) and 10 %-width (Figure 3.32D)
and the post-spike maximum was not affected (Figure 3.32E). Overall, indicated by the
data on spike properties, Aβ*-treated human iPSC-derived neurons were not able to
fully adjust their excitability in response to 4AP-induced hyperactivity.
Figure 3.32: Effects of Aβ* oligomers on 4AP-induced plasticity-dependent changes in spike
parameters. (A) Representative normalized mean extracellular spikes extracted from one electrode of MEA
recordings before (pre, black spikes, normalized to 1) and 1 day after removal of 4AP (1 day post, normalized
to pre) 4AP in vehicle (gray spike, left) and Aβ* (red spike, right) treated cultures. Effect size, shown as
percent change in (B) amplitude, (C) half-width, (D) 10 %-width, and (E) post spike max. Mean±SEM, n >
20 electrodes from 2 MEAs. (Two-tailed t test, *p<0.05).
3.4.3 Effects of Aβ* oligomers on 4AP-induced plasticity-dependent
changes in synchronous calcium transients
To explore the plasticity-dependent changes in calcium transients of human
iPSC-derived networks, pre-treated with vehicle or Aβ* for 6-8 days, Fura 2-based
calcium imaging was performed (Figure 3.33A). Calcium transients were imaged before
and at acute 4AP treatment from the same coverslip. Activity in 2 day 4AP-treated
cultures (2d post) was imaged from sister coverslips.
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Figure 3.33: Effects of Aβ* oligomers on 4AP-induced plasticity-dependent changes in
synchronous calcium transients. (A) Schematic treatment and measurement protocol. d: day.
Red arrowheads indicate the half medium changes with Aβ* treatments. (B) Representative traces of
spontaneous calcium transients before (top), during (middle), and after (bottom) 4AP stimulation of vehicle
and Aβ*-treated cultures extracted from one AOI with several neurons. (C) Distribution and mean of calcium
transient frequencies at different treatments. Sister coverslips are indicated by symbol shape. Normalized
calcium transient (D) frequency and (H) amplitude of vehicle and 6 days Aβ* treated networks. Aβ* values
were normalized to the vehicle treated sister coverslips. Data represent mean±SEM, n = 6. (Two-tailed t test,
**p < 0.01). (E,F) Normalized calcium transient frequency and (I,J) amplitude during (acute) and after (post)
4AP treatment in vehicle and Aβ*-treated cultures. Each value was normalized to the baseline value (pre)
of the respective vehicle or Aβ*-treated sister coverslips, data represent mean±SEM, n= 6-8 coverslips.
(Two-tailed t test *p < 0.05). After removal of 4AP, the spontaneous synchronous calcium transient rate
was decreased in vehicle-treated cultures (G) Percentage of synchronously firing cells before and after 4AP
treatment in vehicle and Aβ*-treated cultures. Data represent mean±SEM, n > 3 coverslips. (Multiple t test
**p < 0.01).
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The general activity state, that is the presence of synchronous calcium transients, which
is a prerequisite for functionality of the 4AP plasticity paradigm was confirmed in 2d post
samples by reapplication of 4AP at the end of the measurement. Only cultures, that
enhanced transient frequency upon 4AP reapplication, were taken into account. This set
of experiments was performed on endogenous neuron-astrocyte cocultures and
cocultures of human neurons and rat astroctyes. Both cultures systems yielded variable
calcium transient frequencies, which are displayed in Figure 3.33C. For quantitative
comparison, each value was normalized to the values received from sister coverslips at
baseline activity (pre). Interestingly, calcium transients of Aβ*-treated cultures showed a
decreased transient frequency compared to vehicle-treated sister networks (Figure
3.33B, pre, and Figure 3.33D). Upon 4AP treatment (Figure 3.33B, acute and Figure
3.33E and F, red bars) both conditions showed a similar increase in their calcium
transient frequency. However, after 2 days of 4AP, a decreased calcium transient rate
was only observed in vehicle treated cultures (Figure 3.33E and F, grey bars). Upon
4AP-induced hyperactivity, the number of active cells was only decreased in vehicle
treated cultures (Figure 3.33G). The transient amplitude which was extracted from active
cells showed a tendency to be increased in Aβ* as compared to vehicle treated cultures
(Figure 3.33B, pre, and Figure 3.33H). After removal of 4AP, in Aβ*-treated cultures the
amplitude was slightly reduced compared to vehicle treated cultures (Figure 3.33J). In
conclusion, these data confirm the preliminary results from MEA recordings, showing
that in presence of Aβ*, the homeostatic response was impaired and cells were not able
to change their properties to adjust overall network activity.
3.4.4 Changes in REST expression upon synthetic Aβ* treatment in
mature cultures
REST was previously reported to be upregulated in the aging brain. However, this
upregulation was found to be impaired in the brain of AD patients (Lu et al. 2014),
suggesting that dysregulation of REST may play a role in the pathogenesis of AD. Here,
I wanted to address, whether Aβ*, a well-established causative factor in AD etiology,
exerts its effect on homeostatic plasticity by impairing REST upregulation during periods
of hyperactivity. Therefore, mature human iPSC-derived neurons were treated with
vehicle or synthetic Aβ* oligomers and REST expression was compared to untreated
controls (Figure 3.34A) by immunocytochemistry.
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Figure 3.34: Effects of synthetic Aβ* on 4AP-induced changes in REST expression. Mature human
neurons were treated with control medium, HFIP-vehicle and Aβ* for 8 days. Subsequently, these cultures
were further cultured for 24 h in the absence (untreated) or presence of 100 µM 4AP. Three of the Aβ*
treated cultures were additionally treated with 100 nM CHIR in parallel to the 4AP treatment (Aβ* + CHIR).
(A) Schematic treatment and analysis protocol. (B) Example confocal micrographs of control, vehicle, Aβ*,
and Aβ* + CHIR treated human neurons after 24 h with or w/o 4AP. Neurons were immunocytochemically
stained for REST (red). Nuclei were stained with DAPI (blue). Quantification of the mean fluorescent intensity
of (C) nuclear and (D) cytosolic REST under different conditions. (E) Nuclear vs cytosolic REST ratio. Data
are represented as single data points, representing values from one neuron and mean, n > 20 neurons from
3 coverslips. (Two-way ANOVA Tukey’s multiple comparisons test *p < 0.05, **p < 0.01, ***p < 0.001, ##p <
0.01). Scale bar, 50 µm.
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Representative merged confocal images (REST, red; Nuclei, blue) of each treatment
was displayed (Figure 3.34B) before (untreated, upper panel) and after 24 h 4AP
treatment (4AP, lower panel). The nuclear/cytosolic ratio of REST expression showed a
reduction in Aβ*-treated cultures (Figure 3.34E). Furthermore, 4AP did not lead to an
increase of nuclear/cytosolic REST in Aβ*-treated cultures, whereas control and vehicle
cells responded to the 4AP stimulation with a comparable increase in nuclear/cytosolic
REST (Figure 3.34E). CHIR is known to increase REST expression within 24 h (Figure
3.18). Therefore, to rescue the Aβ*-related REST alterations and impaired increase of
nuclear/cytosolic REST, Aβ* pre-treated neurons were subjected to CHIR treatment for
24 h, in parallel to 4AP or control treatment. CHIR treatment increased
nuclear/cytoplasmic REST ratios in Aβ* treated cells (Figure 3.34E). However, CHIR
and 4AP co-treatment did not lead to a further increase of nuclear/cytosolic REST.
3.4.5 Effect of CHIR on 4AP-induced changes in the calcium transient
frequency in human mature neurons
In parallel to studying the effect of CHIR on 4AP-induced upregulation in Aβ*-treated
cultures, I also wanted to address how CHIR affects homeostatic plasticity at the activity
level. Therefore, vehicle or Aβ* (6 days) pre-treated human iPSC-derived networks were
subjected to a 48 h CHIR and 4AP co-stimulation. In vehicle treated cultures, CHIR
treatment (post +CHIR, 3.35B) did not lead to a further decrease in network activity
upon 4AP removal (post, 3.35B). However, compared to the activity after removal of 4AP
(post, 3.35D) in Aβ* pre-treated cultures, CHIR lead to a non-significant increase in
activity (post + CHIR, 3.35D). To conclude, the pharmacological intervention to rescue
REST levels and thereby impaired homeostatic plasticity by CHIR treatment was not
successful at the level of REST induction and thus, did not improve homeostatic
plasticity in Aβ*-treated cultures.
Taken together, Aβ* treatment showed no effect on cell viability and spontaneous
activity. However, when the network was shifted towards hyperactivity by 4AP treatment,
Aβ*-treated cultures were incapable of changing the excitability of single neurons for
re-setting the firing rates to basal levels. Additionally, general REST expression and
plasticity-dependent regulation of REST expression were impaired by Aβ*, which
indicated an important role of REST in AD-related plasticity dysfunction. As a
consequence, REST dysregulation may lead to prolonged periods of hyperactivity, which
may explain the frequent occurrence of epileptic activity in the brain of Alzheimer
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patients.
Figure 3.35: Effect of CHIR on 4AP-induced changes in the calcium transient frequency in human
mature neurons. (A) Schematic treatment and measurement protocol. (B) Representative traces of
spontaneous calcium transients. Quantification of calcium transient frequencies in (C) vehicle and 6 days (D)
Aβ* treated networks before, during and after 48 h of 4AP treatment and after 48 h of CHIR + 4AP treatment.
Data represent mean±SEM, n = 3 coverslips. Aβ*+CHIR treated cultures showed increased frequency after
the removal of 4AP (post +CHIR) compared to before 4AP treatment (pre) only in Aβ*-treated cultures.
(One-way ANOVA Dunn’s multiple comparisons test, *p < 0.05).
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4.1 Human iPSC-derived neuronal networks: cell types,
network activity, and assay development
Neurological disease modeling until this decade mainly relied on animal models and
non-neuronal human cell lines because of the lack of human material. However,
although the contribution of those models to our understanding disease mechanisms
cannot be denied, developed drugs by using the models failed in clinical trials.
Fortunately, ten years ago, the first successful reprogramming attempt was made by
using human cells to create stem cell-like cells (Takahashi et al. 2007) which could be
further differentiated into neurons for disease modeling (Yagi et al. 2011). However, the
maturity of differentiated human neurons from iPSCs is still debated and establishing
networks with spontaneous activity is challenging and requires long-term culturing.
Moreover, it has been shown that murine astrocytes help human iPSC-derived neurons
to develop spontaneous network activity (Odawara et al. 2014).
In this study, human iPSC-derived neurons were differentiated and the cell type
composition was characterized by immunocytochemistry. Functional maturation was
evaluated by MEA recordings and by calcium imaging and correlated with synchronous
network activity. Finally, the eligibility of human networks for toxicity assays was
investigated by western blot and calcium imaging upon BoNT/A treatment.
4.1.1 Differentiation and characterization of human iPSC-derived neuronal
networks
Establishing mature human neuronal networks from iPSCs is a critical step for disease
modeling. In this study, to obtain networks with cortical identity, iPSCs were directed
towards the neural lineage by dual SMAD inhibition to induce neuroectoderm formation
(Chambers et al. 2009) alone or in combination with the tankyrase-inhibitor XAV939
(Huang et al. 2009) which was replaced recombinant DKK1 for forebrain fate
determination by inhibiting WNT. After differentiation, immature postmitotic neurons
were enriched by NCAM immunopanning (Nieweg et al. 2015). Immature post mitotic
neurons showed the expression of mainly deep-layer cortical markers which overlaps
with the finding of other studies, showing dorsal forebrain characteristic (Chen et al.
2008). and, to a lesser extent, upper layer cortical markers (Figure 3.1) which overlaps
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with the findings of the studies of dorsal forebrain characteristics (Chen et al. 2008,
Alcamo et al. 2008). This result may be explained by the fact that these are early born
neurons and longer culturing of the networks might give rise to more upper layer
neurons. Interestingly, although cortical induction would not allow the generation of
GABAergic interneurons, a few GAD67-positive GABAergic interneurons were observed
in the immature cultures. The reason for this is not clear but it may have something to do
with the fact that GABA acts as excitatory transmitter to depolarize the young neurons
via chloride permeable channels (Cherubini et al. 1991).
After neuronal enrichment by NCAM immunopanning of hiPSC-derived neurons were
either treated with DM and PD for internal glial development, or cocultured with rat
cortical astrocytes for maturation. Cocultures were treated with AraC to kill all
proliferating cells. Cultures were incubated for at least eight weeks post immunopanning
to ensure morphological and functional maturation. During the normal development of
the nervous system, electrophysiological development of the neurons is the critical step
for maturation (Spitzer 2006). Since the cultures were mainly consisted of excitatory
neurons and, to a lesser extent, GABAergic interneurons, the network activity was
monitored by MEA recordings with gabazine treatment (Figure 3.2). Gabazine inhibits
chloride flux across the cell membrane and thus inhibiting neuronal hyperpolarization.
Surprisingly, although GAD67 expression in the cultures was observed, gabazine
treatment did not cause any alterations in the network activity. There are several
possible explanations for this result. Since the cortical forebrain GABAergic cells mainly
develop from medial and caudal ganglionic eminences, the forebrain fate direction
eliminated the GABAergic development. However, this does not explain the presence of
GAD67 expressing neurons in the cultures to begin with. Another explanation would be
that the inhibitory input caused changes in the network activity which was under the
detection limits of MEA recordings. A further possible explanation for this result may be
the lack of adequate glial support for functional inhibitory interneuron development. It is
possible to overcome the problem of lacking inhibitory interneurons by differentiating
them from iPSCs separately (Liu et al. 2013) and coculture them with the excitatory
pyramidal neurons. However, this issue was not addressed in this study and a future
study investigating the inhibitory interneuronal input to the network activity would be very
interesting.
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4.1.2 Network activity
The major aim of generating human iPSC-derived neurons is to better model
neurological diseases. Since neurons do not function as a single entity, it is necessary to
have functional synapses and networks to be able to study neuronal function. The
synchronous burst firing is a sign of the maturity in dissociated neuronal networks in
vitro (Chiappalone et al. 2006). For networks to function, synapses have to be
maintained via synaptic transmission which occurs via the calcium influx
dependent-vesicular release upon the arrival of an AP to the presynaptic terminal (Llinás
1991). Therefore, extracellular calcium ion dependent-network activity changes were
monitored by MEA recordings (Figure 3.4). Contrary to expectation, increasing
extracellular Ca2+ reduced the frequency of synchronous network bursts to almost zero.
A possible explanation for these results may be the surface charge effect which is a
negative charge masking effect by divalent ions, mainly Ca2+ on the outside of the cell
membrane (Hille 1978). Lowering extracellular Ca2+ concentration showed first
increased than reduced spikes and synchronous network bursts probably first removing
the surface charge effect but then inhibiting the vesicle release. Overall, calcium is an
important player in network activity and the stable extracellular calcium ion levels have to
be maintained for stable firing rate acquisition during MEA recordings.
The functional maturation of human iPSC-derived neurons was closely correlated with
the presence of fully functional AMPA and NMDA receptors. AMPA and NMDA receptors
mediate learning-related neuroplasticity and AMPA receptors are important because of
their involvement in synaptic scaling, a form of homeostatic plasticity (Pozo & Goda
2010). Moreover, overactivity of NMDA receptors was implicated in neurodegenerative
diseases. Therefore, to ensure that the recorded neuronal activity was a result of the
synaptic connectivity, extracellular network activity changes were monitored by MEA
recordings upon introducing APV and DNQX (Figure 3.3). As expected, inhibition of
NMDA and AMPA type glutamate receptors by APV and DNQX resulted in strong
reduction of synchronous bursts suggesting that the occurrence of bursts are exclusively
mediated by excitatory synaptic transmission. Thus, NMDA and AMPA receptors were
pharmacologically functional in these cells. On the other hand, individual action
potentials also appear to be caused by spontaneous (non-synaptic) depolarization of
individual neurons since they were only partially reduced. These findings are in line with
the findings of synchronously burst firing long-term human iPSC-derived cultures from
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another group (Odawara et al. 2016).
Network activity can be monitored by calcium imaging since synchronous calcium
transients are associated with neuronal bursting (Opitz et al. 2002). As an alternative to
MEA recordings, calcium imaging with Fura-2-AM was used to visualize spontaneous
network activity of human iPSC-derived neuronal cultures. It was ensured that during
measurements, environmental temperature was set to 37◦C since the synaptic
transmission is temperature dependent (Hardingham & Larkman 1998). To distinguish
the neurons from astrocytes, KCl was applied at the end of each recording because
astrocytes give a delayed response. Application of APV, DNQX, and gabazine blocked
the occurrence of spontaneous synchronous calcium transients indicating that they are
exclusively outcome of the synaptic activity.
In conclusion, the MEA and calcium imaging assays using pharmacologically
manipulated hiPSC-derived cortical neuronal networks showed that synchronous burst
firing is the main outcome of synaptic activity. Nonetheless, the spike frequency is also
affected by synaptic blockage and allows an insight into the network activity. Finally,
synchronously burst firing human iPSC-derived neuronal networks provide a powerful
tool to study pharmacological and toxicological characteristics of a compound of
interests.
4.1.3 BoNT/A toxicity assays
The botulinum neurotoxin type A (BoNT/A) is a lethal substance produced by the
bacteria Clostridium botulinum which is used to treat neuromuscular disorders, chronic
pain, and in cosmetics (Jankovic 2004). BoNT/A is a useful compound in the
pharmaceutical industry however it needs to be carefully titrated. The main method for
testing BoNT/A activity is an in vivo mouse bioassay (MBA), in which intraperitoneally or
intravenously injected BoNT/A leads to the death of a mouse due to respiratory arrest
with the sensitivity limit at 20 pg/ml (0.13 pM BoNT/A) (Schantz & Johnson 1990).
BoNT/A is known to act on the SNAP25 and its cleavage leads to the inhibition of
neurotransmitter release (Rossetto et al. 2014). Therefore, to investigate the synaptic
impairments of the in vitro cultures, the SNAP25 cleavage assay is the most frequently
used in vitro test for BoNT/A activity (Cai, Reinisch & Ferro-Novick 2007).
In this part of the study, human iPSC-derived neuronal networks were subjected to
BoNT/A for toxicity testing using calcium imaging to monitor synchronous calcium
transients as functional synaptic output and western blot for SNAP25 cleavage. It was
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observed in calcium imaging experiments that 200 pg/ml BoNT/A after 48 h (also 100
pg/ml BoNT/A after 96 h and 10 pg/ml BoNT/A after 120 h) resulted in complete network
silencing. However, western blot results suggested that indicated concentrations only
caused less than 50% of the SNAP25 cleavage. Interestingly, the SNAP25 cleavage
assay indicated different sensitivity levels for 48 and 72 h BoNT/A but not 120 h
treatments in human networks in comparison with the rat primary cortical cultures.
Overall, such a synapse-specific effect of BoNT/A might also cause the altered cleavage
of human SNAP25.
In summary, the results have shown that detection of synchronous network activity and
SNAP25 cleavage assay using iPSC-derived human neuronal networks provide an
alternative to animal-related BoNT/A toxicity screening. However, further optimization of
the human iPSC-derived neuronal cultures would be beneficial to obtain more accurate
and reproducible results.
4.2 Homeostatic plasticity models with human iPSC-derived
neuronal networks
This study is the first one to address the homeostatic network plasticity in human
iPSC-derived cultures. Homeostatic plasticity is a fundamental mechanism through
which the neuronal networks regulate their activity pattern. The underlying processes
include presynaptic and postsynaptic alterations as well as modulations of intrinsic
excitability (Turrigiano 2012). The existing body of research on homeostatic plasticity
was done primarily in vivo and in vitro murine models and it is still not known whether
human iPSC-derived neuronal networks share similar properties. In this part of the
study, responses to chronic manipulations of human neuronal network activity over
several hours to days were monitored by MEA recordings and calcium imaging.
4.2.1 Silencing model with TTX
One of the main homeostatic plasticity mechanisms is the modulation of intrinsic
excitability (Turrigiano 2011). Network silencing-driven homeostatic changes upon
long-term TTX treatment, a voltage-gated Na+ channel blocker, were previously
investigated in rat cortical neurons and the findings include an increase in voltage-gated
Na+ current and a downregulation of the persistent K+ current (Desai et al. 1999). It has
been reported that chronic TTX treatment of OHSCs induces plasticity and upon
removal of TTX, the impact of synaptic plasticity results in spontaneous seizures
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(Bausch et al, 2006). In human iPSC-derived neurons, voltage-gated Na+ currents were
fully blocked by 1 µM TTX (Haythornthwaite et al. 2012). Our findings from the blockage
of voltage-gated Na+ current and overall network activity using 1 µM 72 h TTX treatment
in human iPSC-derived neuronal networks showed an increase in spontaneous spike
and burst activity in MEA recordings (Figure 3.8). These findings suggest that the
network activity of human iPSC-derived cultures can be manipulated by TTX. As a result
of homeostatic plasticity response to TTX-induced network silencing, human networks
have the capability to increase their firing rates.
Extracellular recordings with MEA allow us to monitor changes non-invasively during the
course of long-term experiments. Recorded traces contain information of single
extracellular spike properties. It has been reported that intracellular spike parameters
can be extracted from extracellular spike properties and the negative phase of the
extracellular spike coincides with the depolarization of the intracellular spike (Henze et
al. 2000). In this study, to eliminate the differences which might occur because of the
distance between the electrode and the cell, each electrode was analyzed and
compared separately. Single extracellular spike analysis showed an increase in the
spike amplitude, in widths, and a decrease in the second maximum (Figure 3.9). The
amplitude of the spike depends on the abundance of voltage-gated Na+ channels
whereas, the width of the spike represented the changes in K+ channels. Hence, it could
be hypothesized that the homeostatic response of human iPSC-derived neurons to TTX
blockage was an increase in voltage-gated Na+ channels and a decrease in
voltage-gated K+ channels to increase neuronal excitability. However, this model was to
prove the concept of homeostatic plasticity in human iPSC-derived neuronal networks.
More detailed analysis at the single cell level by patch clamp recordings should be
further performed to support the findings of extracellular spike analysis. Furthermore, to
see the opposite effects, hyperactivity-induced homeostatic plasticity was investigated in
human neuronal networks.
4.2.2 Hyperactivity model with 4AP
Increasing neuronal activity is followed by a reduction in intrinsic excitability due to an
increase in K+ leak currents (O’Leary et al. 2010) and a decrease in Na+ currents, Na+
channel expression and overall network activity (O’brien et al. 2010, Pozzi et al. 2013).
In this study, network hyperactivity-driven homeostatic changes with long-term
4-Aminoprydine (4AP) treatment, a voltage-gated A-type K+ channel blocker, were
investigated in human iPSC-derived immature (spike firing) and mature (burst firing)
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networks (Figure 3.10 and 3.12). 4AP acts by blocking the delayed rectifier type K+
channels, allowing for excessive neuronal depolarization. Network activity analysis
revealed that only mature human networks responded to the acute 4AP treatment and
that the overall network activity was downregulated within 24 h. These results are
consistent with an earlier study that 4AP-treatment acutely caused epileptiform activity
in rat organotypic hippocampal slice cultures (Albus et al. 2008). The different
responses observed in mature and immature human neuronal networks to 4AP
stimulation might be attributed to the lack of A-type K+ channel expression in immature
neurons. Another possible explanation for this result is that although the A-type K+
channels were present in the immature neurons, the synaptic connectivity of immature
human networks was not fully developed. Therefore, extracellular spike analysis was the
next step to examine the effects of acute 4AP in detail.
Extracellular spike amplitude was not altered by acute 4AP treatment in both immature
and mature neurons (Figure 3.11 and 3.13), indicating that Na+ channels were not
affected. It is known that 4AP increases the width of action potential by blocking
voltage-gated K+ channels (Lien & Jonas 2003). In this study, the increase in spike width
and the decrease in second maximum values were only present in the mature human
neurons. These results are likely to be related to the presence of A-type K+ channels in
the mature neuronal membranes. In a recent study, 10 mM 4AP inhibited the initial,
transient phase of outward K+ currents in human neurons (Haythornthwaite et al. 2012).
Furthermore, immature and mature neuronal differences were observed in extracellular
spike properties (Figure 3.14) where the spike widths of immature neurons were larger
compared to mature neurons. This result is in agreement with a decrease in the
extracellular spike half-width that is observed during the maturation of primary mouse
cortical neurons (Weir et al. 2015). Moreover, long-term effects of 4AP treatment with a
decrease of the amplitude and an increase of the spike-width were obtained after the
removal of 4AP (Figure 3.15). These results indicated the decrease of Na+ channels
and the increase of K+ channels and support previous research in hyperactivity related
homeostatic plasticity which links the decreased intrinsic excitability and increase in K+
leak currents (O’Leary et al. 2010).
Long-term changes in networks were investigated by calcium imaging (Figure 3.16). In
fact, 4AP treatment resulted in an acute increase in the synchronous calcium transient
frequency followed by a reduction after removal of 4AP after 2 d supporting the findings
of MEA recordings. This combination of findings provides some support for the
conceptual premise that mature human iPSC-derived neuronal cultures are useful tools
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for homeostatic plasticity-related research.
4.3 Effects of Aβ on human iPSC-derived neuronal networks
Alzheimer’s disease is the most common neurodegenerative disease and the main culprit
of the disease is the senile plaque forming amyloid-beta (Aβ). Even though Aβ has
been the main focus of AD research, important questions regarding the physiological and
neurotoxicological role of it still remain. Recently, small soluble oligomeric Aβ species are
considered to be the toxic mediators of the disease (Sengupta et al. 2016). The present
study characterized the cell-derived and synthetic Aβ species and investigated the effects
of them in the human iPSC-derived neuronal cultures at cellular and network levels.
4.3.1 Characterization of cell-derived Aβ
Cell-derived Aβ was collected from the conditioned medium of stably APP
overexpressing 7PA2 cells. Cell-derived Aβ did not cause changes in cell viability
measured with an MTT assay in primary rat cortical neurons. However, the network
activity of mature human cultures showed instability in immunodepleted control
conditioned medium making impossible to use it as an experimental control.
4.3.2 Dissolving and oligomerizing synthetic Aβ
In this study, to establish better defined oligomer preparations and eliminate the
batch-to-batch differences of cell-derived Aβ, synthetic Aβ was used. The Aβ peptide is
hydrophobic and tends to aggregate; therefore, dissolving the synthetic Aβ peptide is
complicated. Purchased Aβ arrives as lyophilized powder and monomerization is
necessary to dissolve pre-existing aggregates for further use in the experiments. These
aggregates could work as seeds and accelerate the aggregation which then might cause
experimental inconsistencies. Furthermore, visualizing the Aβ oligomer profile is
another difficulty since the mainly used method is SDS-PAGE and SDS-PAGE is not a
reliable method for characterization of Aβ oligomers. SDS alters the oligomer profile of
Aβ preparations by breaking down higher oligomers or even inducing artificial
oligomerization (Bitan et al. 2005). This study addressed both of those issues. First of
all, another type of Aβ was used since it has been described that N-terminal truncated
and pGlu-modified Aβ species (Pyroglutamylated Aβ3−42 ([Pyr3]Aβ3−42,) in particular
are present in large quantities in the AD brains (Saido et al. 1995). The preparation of
[Pyr3]Aβ3−42 was performed according to the published protocol (Nussbaum et al.
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2012). For the monomerization of all synthetic Aβ species, HFIP was used which is the
main solvent for dissolving Aβ (Fa et al. 2010). Native and semi-native methods were
used to investigate the oligomeric state of preparations and semi-native was preferred
since it includes small amount of SDS to help peptides to run but not dissolve them.
Semi-native WBs with Aβ1−42 and the Aβ* were compared and the results of these two
preparations were similar. It was not possible to separate single bands by native WB.
Moreover, different solvents were used such as DMSO and NB phenol free. Phenol plus
NB medium was avoided because phenol seems to interfere with oligomerization (Ono
et al. 2012). Furthermore, using DMSO to dissolve Aβ creates problems because
DMSO is toxic to cells. Studies have shown that DMSO caused cell loss in an in vitro rat
hippocampal culture preparation at 0.5 % concentration and 0.06 % DMSO had a
negative effect on the neurite network (Hanslick et al. 2009, Götte et al. 2010). A
temperature effect was also observed since all chemical reactions depend on the
temperature. 37 ◦C preparations showed fibrillar forms in semi-native WB. The lanes
were more like a smear in the WB and it was not possible to distinguish sizes. Therefore,
the 4 ◦C preparation of Aβ was selected. Finally, the duration of oligomerization was
optimal at 2 d where monomer and also some tetramer was detectable in phenol-free
NB. It was surprising that after treating the human iPSC-derived neurons with Aβ*
oligomers, there was no further oligomerization. This inconsistency may be due to the
phenol plus media and retinoic acid in the B27 supplement which might block further
oligomerization even at 37 ◦C. The final concentration of Aβ or Aβ* used for cellular
incubation was 1 µM. This concentration is much higher compared to ELISA
(enzyme-linked immunosorbent assay) reports of human brain extracts which shows 1
ng/ml Aβ in CSF (Hulstaert et al. 1999). Even though the used concentration was much
higher, it was necessary to use Aβ for modeling AD-related changes in a shorter time
window and it is also widely used concentration.
4.3.3 Effects of Aβ on neurons
Characterized Aβ and Aβ* oligomers were used in cell viability assays using primary rat
cortical neurons. In this study, the oligomer preparations did not cause any alterations in
cell viability. This outcome is contrary to that of Nussbaum et al. (2012) who found
cytotoxicity of Aβ* using the same concentration. This might be explained by differences
of Aβ* resistance of mouse and rat neurons. Moreover, Aβ was used to see the
differences in excitability of human iPSC-derived neurons. Patch-clamp input-output
curve showed delayed response in early current injection steps. A possible explanation
103
4. DISCUSSION
for this result may be the masking effect of Aβ oligomers on the neuronal membrane
which interferes with channel function for AP firing. However, it seems to be overcome
by more current injection. Single AP analysis showed no differences in any parameters
which suggest that the properties of the channels did not change upon Aβ treatment.
4.3.4 Effects of Aβ on spontaneous activity
A strong relationship between early phases AD and network hyperactivity has been
reported in the literature (Busche et al. 2012) suggesting that primary neuronal
dysfunction is mediated by amyloid pathology related hyperactivity. In this study,
spontaneously active human iPSC-derived neuronal networks were subjected to Aβ*
treatment (Figure 3.28). Long-term Aβ* treatment did not affect spontaneous firing rates
of human networks. The result seems to be consistent with other research which found
no alteration in the spike rate of 1 µM Aβ-treated mouse cortical cultures (Charkhkar
et al. 2015). Another study showed that the application of CSF obtained from individuals
with MCI did not change the global network activity of rat cortical neurons compared to
healthy controls (Görtz et al. 2013). Furthermore, control and FAD iPSC-derived
neuronal networks with the London (V717I) APP mutation did not differ in their
spontaneous activity (Muratore et al. 2014). Spike analysis of Aβ oligomer-treated
neurons showed no significant differences in spike parameters (Figure 3.29). These
findings are in line with the findings of Muratore et al. (2014) in FAD vs control neurons.
In the present study, long-term Aβ* oligomer treatment resulted in the decreased
synchronous calcium transient frequency and a trend to increased calcium transient
amplitude. To note, calcium imaging in this study was used to optically detect AP evoked
calcium increase (so called ’calcium transients’) which is occurring via the calcium influx
through the voltage-gated calcium channels as a result of action potential generation
(Grienberger & Konnerth 2012). Otherwise, calcium alterations are linked to AD (LaFerla
2002) and oligomeric Aβ is known to increase calcium load in neuronal cell bodies and
dendritic spines (Arbel-Ornath et al. 2017).
4.3.5 Effects of Aβ on homeostatic plasticity
Previous results of this work demonstrated that Aβ* oligomers showed no significant
changes in the spontaneous network activity. Therefore, this study focused on the
homeostatic response of Aβ* oligomer-treated networks when there was a hyperactivity
situation (Figure 3.30). Vehicle and Aβ* oligomer-treated networks reacted similarly to
4AP stimulation by increasing network activity. However, the increase in the 10 %-width
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showed reduction in Aβ* oligomer-treated neurons compared to spike waveform of
vehicle-treated neurons. The most interesting finding was that the decrease in firing
rates of Aβ* oligomer-treated cultures did not reach the levels of vehicle-treated ones.
This outcome was supported by calcium imaging since the decrease in spontaneous
synchronous calcium transient frequency was not observed Aβ* oligomer-treated
cultures. Furthermore, the percentage of active cells contributing to neuronal networks
were not reduced in the Aβ* oligomer-treated cultures (Figure 3.33). The outcome
suggests that the decrease in neuronal excitability as a result of the homeostatic
network plasticity did not occur in Aβ* oligomer-treated cultures. The elevated
voltage-gated Na+ expressions, especially voltage-gated Na+ 1.6 subtype, was observed
in cultured mouse neurons treated with Aβ or the brains of APP/PS1 mice compared to
control groups which might suggest an intrinsic neuronal hyperexcitability as the
underlying mechanism of epileptiform activity in AD (Wang et al. 2016). This is the first
study to show the relationship between homeostatic plasticity and AD-related Aβ*
oligomers using iPSC-derived human neuronal networks. This finding, while preliminary,
suggests that homeostatic plasticity was impaired in Aβ* oligomer-treated human
neuronal cultures.
4.4 REST as a key role player in Aβ-induced homeostatic
plasticity impairment
REST (Repressor Element-1 Silencing Transcription Factor, also known as NRSF,
Neuron-Restrictive Silencer Factor) is a transcription inhibitor which orchestrates many
neuron specific genes (Zhao et al. 2017). REST is important regarding this study for two
main reasons. Firstly, its role in homeostatic plasticity was shown in a 4AP model of
increased activity (Pozzi et al. 2013). Involvement of REST in homeostatic response
mechanism has been reported in another study which shows that REST deletion caused
epileptogenesis (Hu et al. 2011). The study of Pozzi et al. (2013) showed that REST
expression increases after 96 h of 4AP treatment in mouse hippocampal cultures, in
contrast, REST upregulation reached its peak within 24 h in human iPSC-derived
neuronal cultures. Furthermore, kainaic acid treatment leads to an increase in REST
mRNA in hippocampus suggesting the important role in neuronal activity dependent
processes (Baldelli & Meldolesi 2015). The splice isoforms of REST are indicated in
epilepsy related gene expression which may therefore relevant to the progression of
epileptogenesis (Spencer et al. 2006). Secondly, aging related-REST increase in human
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neurons were not observed in AD brains (Lu et al. 2014). The reduced nuclear REST
expression in neurons of the prefrontal cortex has been correlated with Alzheimer’s
disease progression in both humans with AD (Lu et al. 2014) and mouse model of AD
(12 month-old APP23 mice) (Van Acker et al. 2017). It is also known that REST
regulates Na+ channel expression (Chong et al. 1995). With respect to those studies,
the role of REST in homeostatic plasticity impairment was investigated by using Aβ*
oligomer-treated human neuronal cultures. In this study, the increase in nuclear/cyto
REST levels upon 4AP treatment was not observed in Aβ* oligomer-treated whereas
this was the case in both untreated control or vehicle-treated human iPSC-derived
neurons. Findings in this study are in line with the previously shown REST impairment in
AD and indicate that Aβ oligomers are directly responsible for REST expression
alterations. To note, in this study, the alterations in REST levels were not investigated at
mRNA level by RT-q-PCR or at protein level by western blot since cultures include
astrocytes and REST is expressed in GFAP-positive astrocytes (Kohyama et al. 2010)
which would interfere the outcome of those experiments. Furthermore, REST is
controlled by the canonical Wnt pathway (Nishihara et al. 2003). It was shown that
Wnt-beta-catenin/REST signaling plays critical and collaborative roles in neuroprotection
in prion diseases and associated neurodegenerative diseases, as transient REST
elevation maintained homeostasis and plasticity in neurons (Song et al. 2016). CHIR
treatment showed increased REST levels possibly by blocking GSK-3β which is
upstream of REST. However, REST expression upon CHIR and 4AP treatment was not
fully recovered in Aβ* treated cultures. It was shown that the activity of GSK-3β is
increased in AD and that somatodendritic accumulation and activation of GSK-3β is an
early event preceding and accompanying the formation of NFT and of other tau-positive
inclusions (Leroy et al. 2007). Furthermore, PSEN1 mutation destabilizes β-catenin
(Zhang et al. 1998). REST is also implicated in epigenetic regulations with the
interaction of long-non coding RNA (Wu et al. 2013). Thus, a cascade, where Aβ leads
to the activation of GSK-3β which further leads to a reduced REST expression may
eventually explain the link between increased levels of Aβ and impaired homeostatic
network plasticity. REST deficiency would then cause prolonged periods of hyperactive
states, which may be detectable as epileptiform activity in AD patients. In conclusion,
although both the involvement of REST in homeostatic plasticity and the loss of REST in
AD neurons has been shown before, the outcome of this thesis combines both
phenomena for the first time and concludes that REST might be a key player in
AD-related network dysfunction. A deeper understanding of REST activation and the
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upstream and downstream molecular mechanisms in neurodegeneration are crucial for
developing a therapeutic strategy.
4.5 Conclusion and outlook
AD research has focused on the Aβ peptide for many years; nonetheless, important
questions regarding this peptide still remain. Recent studies confirmed Aβ-related
epileptiform activity in patients with memory decline (O’brien et al. 2010) and mild
cognitive impairment (Dickerson et al. 2005). Aβ-related hyperactivity has also been
described in cognitively normal elderly (Oh et al. 2015). Human iPSC-derived neurons
have been emerging as valuable research tools in the field of neurodegenerative
diseases. Several studies, reviewed in Arber et al. (2017), thoroughly demonstrated
successful neuronal differentiation from SAD and FAD patient-derived iPSCs and
reported differential Aβ production upon pharmacological interventions. However, so far,
the AD-related electrophysiological changes in the cellular and synaptic levels were only
addressed using iPSC-derived neurons by Nieweg et al. (2015). Therefore, this is the
first study which has reported the AD-related network alterations using human
iPSC-derived neurons.
The major limitation of this study is the number of cultures developing spontaneous
synchronous network activity. Therefore, further optimizations of culture conditions are
required. Since astrocytes are important for neuronal maturation, they would accelerate
the generation of active cultures. However, the presence of astrocytes in direct coculture
systems prevents to study neuron specific changes in bulk-molecular approaches.
Recently, indirect-contact co-cultures of neurons and astrocytes were developed (Clarke
& Barres 2013) and would be useful to overcome this issue. Another step towards a
more physiological AD model would be the generation of 3D cultures allowing plaque
formation in the dish, as described by Choi et al. (2014). This study aimed at generating
a valuable model that allows a mechanistic insight at the phenomenon of hyperactivity in
the early phase of AD. The study presented in this dissertation provides a powerful new
model of homeostatic plasticity utilizing human iPSC-derived neuronal networks. This
study also demonstrates the usage of this model to mimic AD-related hyperactivity. It
shows that increased levels of Aβ lead to impaired homeostatic plasticity, resulting in
prolonged periods of neuronal hyperactivity. Moreover, it describes REST as a potential
molecular player in the Aβ-induced process, hinting at a novel therapeutic target.
REST is controlled by the canonical Wnt pathway (Nishihara et al. 2003), where
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activation of Wnt signaling leads to increased REST expression. Wnt activation also
exerts homeostatic effects by stabilizing the aberrant network activity (Oliva & Inestrosa
2015). Moreover, activation of GSK-3β was shown to be AD-related (Leroy et al. 2007)
and GSK-3β interferes with the Wnt signaling pathway through β-catenin degradation.
Thus, the observed downregulation of nuclear REST expression by Aβ could be
explained by the Aβ-induced activation of GSK-3β. Further studies need to be carried
out in order to understand the effects of those proteins in Aβ-related homeostatic
plasticity impairments.
Finally, while other studies using human iPSC-derived neurons have attempted to
analyze the Aβ-related molecular and cellular changes, this study looked at AD from an
electrophysiological perspective and has thrown up many questions in need of further
investigations which would collectively improve our understanding of AD pathogenesis
and help to find new targets to develop effective therapeutics.
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6. Abbreviations
4AP 4-aminopyridine
Aβ amyloid beta
AD Alzheimer’s disease
AM acetoxymethyl
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AP action potential
APP amyloid precursor protein
APV D,L-2-amino-5-phosphonovaleric acid
AraC arabinofuranosyl cytidine
BCA bicinchoninic acid
BDNF brain derived neurotrophic factor
BMP bone morphogenic protein
BoNTA botulinum neurotoxin type A
BSA bovine serum albumin
CaI calcium imaging
CaMK calcium-calmodulin-dependent kinase
CHO chinese hamster ovary
CNS central nervous system
CSF cerebro spinal fluid
CTIP2 chicken ovalbumin upstream promoter transcription factor-interacting protein 2
DAPI 4’,6-diamidino-2-phenylindole
DM dorsomorphin
DMSO dimethyl sulfoxide
DNQX 6,7-dinitroquinoxaline-2,3-dione
DTT DL-dithiotreitol
EB embryoid body
EPSP excitatory postsynaptic potential
EthD-1 ethidium homodimer
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FAD familial Alzheimer’s disease
GABA γ-aminobutyric acid
GAD67 glutamate decarboxylase 67
GAPDH glyceraldehyde-3-phosphate-dehydrogenase
HFIP hexafluoro-2-propanol
IP immunoprecipitation
iPSC induced pluripotent stem cell
LTD long term depression
LTP long term potentiation
MAP2 microtubule associated protein 2
MEA multi electrode array
mEPSCs miniature excitatoty postsynaptic currents
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NCAM neuronal cell adhesion molecule
NMDA N-methyl-D-aspartate
NMM neuronal maturation medium
NPC neuronal progenitor cell
PAGE polyacrylamide gel electrophoresis
PBS-/- phospate buffer saline without calcium and magnesium
PD PD0325901
PFA paraformaldehyde
PI Propidium iodide
PVDF Polyvinylidenfluoride
REST regulatory element 1 silencing transcription factor
RNA Ribonucleic acid
ROCK Rho-associated coiled-coil containing protein kinase
ROI region of interest
RT room temperature
SAD sporadic Alzheimer’s disease
SDS sodium dodecyl sulfate
S.E.M. standard error of the mean
SNAP25 synaptosomal-associated protein 25
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TBR1 T-box brain 1
TBS tris buffer saline
TEMED tetramethylenethylendiamin
TGFβ tumor growth factor beta
TTX tetrodotoxin
VBA visual basic for applications
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7.1 Visual basic data extraction
Sub resetfile()
Dim ws As Worksheet
Application.DisplayAlerts = False
Application.ScreenUpdating = False
For Each ws In ActiveWorkbook.Worksheets
If ws.Name <> "options" And ws.Name <> "summary" Then ws.Delete
Next
With Sheets("summary")
.Range(.Rows(2), .Rows(100)).ClearContents
End With
Sheets("options").Select
Application.ScreenUpdating = True
Application.DisplayAlerts = True
End Sub
Sub extractinfo()
Dim thiswb As Workbook, addRes As String
Dim MyObj As Object, MySource As Object, file As Variant, caseN As Integer, ActN As
Integer, pos As Double, max As Variant, thisfilename, archivo As String
Dim RepDate As Date, entN, i, j As Integer, sig As Boolean
Dim Nfilas As Single, sname As Name
Application.ScreenUpdating = False
thisfilename = ThisWorkbook.Name
Set thiswb = ActiveWorkbook
folder = Sheets("Options").Range("C4")
beg = Sheets("Options").Range("C5")
lenbeg = Len(beg)
minval = Sheets("Options").Range("C7")
exception = Sheets("Options").Range("C6")
file = Dir(folder & "\")
n = 2
While (file <> "")
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If Left(UCase(file), lenbeg) = UCase(beg) And Right(UCase(file), 4) = ".DAT" And
InStr(file, exception) = 0 Then
Application.ScreenUpdating = False
newtab = Mid(file, lenbeg + 1, Len(file) - lenbeg - 4)
Sheets.Add After:=ActiveSheet
ActiveSheet.Name = newtab
With ActiveSheet.QueryTables.Add(Connection:="TEXT;" & folder & "\" & file,
Destination:=Range("$A$1"))
.Name = Right(file, Len(file) - 4)
.FieldNames = True
.RowNumbers = False
.FillAdjacentFormulas = False
.PreserveFormatting = True
.RefreshOnFileOpen = False
.RefreshStyle = xlInsertDeleteCells
.SavePassword = False
.SaveData = True
.AdjustColumnWidth = True
.RefreshPeriod = 0
.TextFilePromptOnRefresh = False
.TextFilePlatform = 850
.TextFileStartRow = 1
.TextFileParseType = xlDelimited
.TextFileTextQualifier = xlTextQualifierDoubleQuote
.TextFileConsecutiveDelimiter = False
.TextFileTabDelimiter = True
.TextFileSemicolonDelimiter = False
.TextFileCommaDelimiter = False
.TextFileSpaceDelimiter = False
.TextFileColumnDataTypes = Array(1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1)
.TextFileDecimalSeparator = "."
.TextFileThousandsSeparator = " "
.TextFileTrailingMinusNumbers = True
.Refresh BackgroundQuery:=False
End With
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Nrows = Sheets(newtab).Cells(Rows.Count, 1).End(xlUp).Row
Ncols = Sheets(newtab).Cells(3, Columns.Count).End(xlToLeft).Column
With ActiveWorkbook.Worksheets(newtab).Sort
.SortFields.Clear .SortFields.Add Key:=Range("B4", Cells(Nrows, "B")),
SortOn:=xlSortOnValues, Order:=xlAscending, DataOption:=xlSortNormal
.SetRange Range("A3", Cells(Nrows, Ncols))
.Header = xlYes
.MatchCase = False
.Orientation = xlTopToBottom
.SortMethod = xlPinYin
.Apply
End With
valfound = False
For i = 4 To Nrows
If Cells(i, "B") >= minval And valfound = False Then
valfound = True
first50 = i
End If
Next i
Cells(Nrows + 2, "A") = "Average"
Cells(Nrows + 3, "A") = "(Num_Spikes>50)"
Range(Cells(Nrows + 2, "B"), Cells(Nrows + 2, Ncols)).FormulaR1C1 = "=AVERAGE(R"&
first50 & "C:R" & Nrows & "C)"
Sheets("summary").Cells(n, "A") = newtab
n = n + 1
End If
file = Dir
Wend
With Sheets("summary")
.Range("B2", .Cells(n - 1, "M")).FormulaR1C1 = _
"=INDIRECT(ADDRESS(MATCH(""Average"",INDIRECT(RC1&""!A:A""),FALSE),
MATCH(R1C,INDIRECT(RC1&""!3:3""),FALSE)„,RC1))"
End With
Application.ScreenUpdating = True
End Sub
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7.2 Visual basic spike parameters
Sub sumarize_unit(ByVal tab_name As String, ByVal Ncols As Integer, ByVal i As Integer)
With Sheets("summ_u" & i)
n = .Cells(2, .Columns.Count).End(xlToLeft).Column + 1
.Cells(1, n) = tab_name
For j = 2 To 9
.Cells(j, n).FormulaR1C1 = _
"=AVERAGEIFS(" & tab_name & "!R" & j & "C2:R" & j & "C" & Ncols & "," & tab_name &
"!R11C2:R11C" & Ncols & ",""Unit=" & i & " "")"
Next j
End With
With Sheets(tab_name)
Nrows = .Cells(.Rows.Count, 1).End(xlUp).Row
chartname = "Unit" & i & " graph"
If n = 2 Then
Charts.Add.Name = chartname
With Charts(chartname)
.ChartArea.Clear
.ChartType = xlLine
End With
Charts(chartname).SetSourceData Source:=.Range(.Cells(13, Ncols + 1 + i),
.Cells(Nrows, Ncols + 1 + i))
Charts(chartname).SeriesCollection(1).XValues = .Range(.Cells(13, 1), .Cells(Nrows,
1))
Charts(chartname).SeriesCollection(1).Name = tab_name
Charts(chartname).SetElement (msoElementChartTitleAboveChart)
Charts(chartname).ChartTitle.Text = "Unit" & i & " average spikes"
Sheets(chartname).Move Before:=Sheets("options")
Else
Charts(chartname).SeriesCollection.NewSeries
Charts(chartname).SeriesCollection(n - 1).Name = tab_name
Charts(chartname).SeriesCollection(n - 1).Values = .Range(.Cells(13, Ncols + 1 + i),
.Cells(Nrows, Ncols + 1 + i))
End If
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End With
End Sub
Sub test()
For i = 0 To 5
Sheets("options").Cells(i + 7, "G") = 0
Next i
End Sub
Sub resetfile()
Dim ws As Worksheet
Dim chrt As Chart
Application.DisplayAlerts = False
Application.ScreenUpdating = False
Charts.Add
For Each ws In ActiveWorkbook.Worksheets
If ws.Name <> "options" And ws.Name <> "summ_u1" And ws.Name <> "summ_u2"
And ws.Name <> "summ_u0" Then ws.Delete
Next
For Each chrt In ActiveWorkbook.Charts
chrt.Delete
Next
With Sheets("summ_u0")
.Range(.Columns(2), .Columns(100)).ClearContents
End With
With Sheets("summ_u1")
.Range(.Columns(2), .Columns(100)).ClearContents
End With
With Sheets("summ_u2")
.Range(.Columns(2), .Columns(100)).ClearContents
End With
Sheets("options").Select
Application.ScreenUpdating = True
Application.DisplayAlerts = True
End Sub
Sub extractinfo()
Dim thiswb As Workbook, addRes, restfile, newtab As String
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Dim Ncols, z As Integer
Dim MyObj As Object, MySource As Object, file As Variant, caseN, ActN As Integer, pos
As Double, max As Variant, thisfilename, archivo As String
Dim ws As Worksheet, Err As Boolean
Dim curr_chart As ChartObject
Dim RepDate As Date, entN, wchart, hchart, x, y, chartxrow, a, orig_len, umarg, lmarg,
sum_col As Integer, sig As Boolean
Dim Nfilas As Single, sname As Name
Dim ser_range As Range
Dim ex_u0, ex_u1, ex_u2 As Boolean
Dim min_val As Double
Application.ScreenUpdating = False
thisfilename = ThisWorkbook.Name
Set thiswb = ActiveWorkbook
With Sheets("Options")
folder = .Range("C4")
If Right(folder, 1) <> "\" Then folder = folder & "\"
beg = .Range("C5")
lenbeg = Len(beg)
keyword = .Range("C6")
max2_timeframe = .Range("C8")
End With
ex_u0 = False
ex_u1 = False
ex_u2 = False
file = Dir(folder & "\")
n = 2
x = 0
y = 0
sum_col = 2
first = True
While (file <> "")
Err = True
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If Left(UCase(file), lenbeg) = UCase(beg) And Right(UCase(file), 4) = ".DAT" And
InStr(file, keyword) <> 0 Then
Application.ScreenUpdating = False
restfile = Mid(file, lenbeg + 1, Len(file) - lenbeg - 4)
a = InStr(restfile, "_")
If a < 3 Then a = InStr(3, restfile, "_")
newtab = Left(restfile, a - 1)
orig_len = Len(newtab)
While Err = True
Err = False
For Each ws In ActiveWorkbook.Worksheets
If ws.Name = newtab Then Err = True
Next
If Err = True Then
If Len(newtab) = orig_len Then
newtab = newtab & "_1"
Else
newtab = Left(newtab, orig_len) & "_" & Val(Right(newtab, 1) + 1)
End If
End If
Wend
Sheets.Add After:=Sheets("summ_u2")
ActiveSheet.Name = newtab
With ActiveSheet.QueryTables.Add(Connection:="TEXT;" & folder & file,
Destination:=Range("$A$1"))
.Name = Right(file, Len(file) - 4)
.FieldNames = True
.RowNumbers = False
.FillAdjacentFormulas = False
.PreserveFormatting = True
.RefreshOnFileOpen = False
.RefreshStyle = xlInsertDeleteCells
.SavePassword = False
.SaveData = True
.AdjustColumnWidth = True
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.RefreshPeriod = 0
.TextFilePromptOnRefresh = False
.TextFilePlatform = 850
.TextFileStartRow = 1
.TextFileParseType = xlDelimited
.TextFileTextQualifier = xlTextQualifierDoubleQuote
.TextFileConsecutiveDelimiter = False
.TextFileTabDelimiter = True
.TextFileSemicolonDelimiter = False
.TextFileCommaDelimiter = False
.TextFileSpaceDelimiter = False
.TextFileColumnDataTypes = Array(1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1)
.TextFileDecimalSeparator = "."
.TextFileThousandsSeparator = " "
.TextFileTrailingMinusNumbers = True
.Refresh BackgroundQuery:=False
End With
With Sheets(newtab)
.Rows("1:10").Insert Shift:=xlDown, CopyOrigin:=xlFormatFromLeftOrAbove
.Range("A8") = "Baseline"
.Range("A9") = "Norm. Minimum"
.Range("A2") = "max2"
.Range("A3") = "Peak latency"
.Range("A4") = "Amplitude"
.Range("A5") = "Half-width"
.Range("A6") = "70% Width"
.Range("A7") = "90% Width"
Nrows = .Cells(Rows.Count, 1).End(xlUp).Row
Ncols = .Cells(11, Columns.Count).End(xlToLeft).Column
time_delta = Abs(.Cells(18, 1) - .Cells(19, 1)) ’increment of time between two random
points
For k = 2 To Ncols
Select Case Mid(.Cells(11, k), 6, 1)
Case "0"
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ex_u0 = True
Case "1"
ex_u1 = True
Case "2"
ex_u2 = True
End Select
Next k
pos_1milisec = Application.Match(-0.001, .Columns(1), 0)
.Cells(11, Ncols + 1).FormulaR1C1 = "Unit=0 "
.Cells(11, Ncols + 2).FormulaR1C1 = "Unit=1 "
.Cells(11, Ncols + 3).FormulaR1C1 = "Unit=2 "
For n = 0 To 2
If (n = 0 And ex_u0 = True) Or (n = 1 And ex_u1 = True) Or (n = 2 And ex_u2 = True)
Then
.Range(.Cells(13, Ncols + 1 + n), .Cells(Nrows, Ncols + 1 + n)).FormulaR1C1 =
"=ROUND(SUMIF(R11C2:R11C" & Ncols & ",R11C,RC2:RC" & Ncols &
")/COUNTIF(R11C2:R11C" & Ncols & ",R11C),5)"
End If
Next n
.Range(.Columns(Ncols + 1), .Columns(Ncols + 3)).Font.Bold = True
For i = 2 To Ncols + 3
If i <= Ncols Or (i = Ncols + 1 And ex_u0 = True) Or (i = Ncols + 2 And ex_u1 = True)
Or (i = Ncols + 3 And ex_u2 = True) Then
baseline = Application.Average(.Range(.Cells(13, i), .Cells(pos_1milisec, i)))
.Cells(8, i) = baseline
Set ser_range = Sheets(newtab).Range(Sheets(newtab).Cells(13, i),
Sheets(newtab).Cells(Nrows, i))
Set ser_range2 = Sheets(newtab).Range(Sheets(newtab).Cells(100, i),
Sheets(newtab).Cells(150, i))
Set ser_range3 = Sheets(newtab).Range(Sheets(newtab).Cells(120, i),
Sheets(newtab).Cells(Nrows, i))
norm_min = Application.Min(ser_range2) - baseline
.Cells(9, i) = norm_min
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For k = 13 To Nrows ’with this loop we normalize the spike
.Cells(k, i) = (.Cells(k, i) - baseline) / Abs(norm_min)
Next k
min_val = Application.Min(ser_range2)
peak_time_pos = Application.Match(min_val, ser_range2, 0) + 100
max2_timeframe_pos = peak_time_pos + Int(max2_timeframe / time_delta)
peak_tim = .Cells(peak_time_pos, 1)
max_t = min_val
For j = 100 To Nrows
If .Cells(j, i) >= max_t And j >= peak_time_pos And j <= max2_timeframe_pos Then
max_t = .Cells(j, i)
Next j
.Cells(2, i) = max_t
.Cells(4, i) = -norm_min
max2_tim_pos = Application.Match(max_t, ser_range3, 0) + 120
.Cells(3, i) = .Cells(max2_tim_pos, 1) - peak_tim
For k = 0 To 2
Select Case k
Case 0
magicpoint = -0.5
Case 1
magicpoint = -0.3
Case 2
magicpoint = -0.1
End Select
j = peak_time_pos
While Not (.Cells(j, i) <= magicpoint And .Cells(j - 1, i) >= magicpoint)
j = j - 1
Wend
t1 = .Cells(j, 1)
t2 = .Cells(j - 1, 1)
v1 = .Cells(j, i)
v2 = .Cells(j - 1, i)
x1 = (magicpoint - v1) / (v2 - v1) * (t2 - t1) + t1
j = peak_time_pos
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While Not (.Cells(j, i) <= magicpoint And .Cells(j + 1, i) >= magicpoint)
j = j + 1
Wend
t1 = .Cells(j, 1)
t2 = .Cells(j + 1, 1)
v1 = .Cells(j, i)
v2 = .Cells(j + 1, i)
x2 = (magicpoint - v1) / (v2 - v1) * (t2 - t1) + t1
.Cells(5 + k, i) = x2 - x1
Next k
End If
Next i
.Rows("5:7").NumberFormat = "_-* #,##0.000000_-;-* #,##0.000000_-;_-* ""-""??_-;_-
@_-" End With
For z = 0 To 2
If (z = 0 And ex_u0 = True) Or (z = 1 And ex_u1 = True) Or (z = 2 And ex_u2 = True) Then
Call sumarize_unit(newtab, Ncols, z)
Next z
End If
file = Dir
Wend
Application.ScreenUpdating = True
End Sub
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9. Appendix
Experiment Cell line Age Coculture/Treatment Figure
MEA
TTX 8/25(PAN9) 11 m no/DM 3 µM for 7 d 3.8 and 3.9
4AP immature DF6(PAN22) 4 m no/DM 3 µM for 7 d 3.10, 3.11, 3.14
4AP immature DF6(PAN24) 4 m no/DM 3 µM for 7 d 3.10, 3.11, 3.14
4AP mature 8/25(PAN9) 9-10 m no/DM 3 µM for 7 d 3.12, 3.13, 3.15
7PA2 8/25(PAN9) 7 m no/DM 3 µM for 7 d 3.21
7PA2 8/25(PAN9) 8 m no/DM 3 µM for 7 d 3.21
Control/Vehicle 8/25 8 m no/AraC 5 µM for 5 d 3.27
Gabazine 8/25(PAN9) 8 m no/DM 3 µM for 7 d 3.2
AP5/DNQX 8/25 6 m no/AraC 5 µM for 5 d 3.3
Calcium 8/25 6-7 m no/AraC 5 µM for 5 d 3.4
Aβ* 8/25(PAN9) 8 m no/DM 3 µM for 7 d 3.28 and 3.29
Aβ* 8/25(PAN9) 12 m no/DM 3 µM for 7 d 3.28 and 3.29
Aβ* + 4AP 8/25(PAN9) 12 m no/DM 3 µM for 7 d 3.30, 3.31, 3.32
CaI
DNQX + APV SZ01(PAN1) 2 m yes/DAPT 1 µM for 7 d 3.5
4AP DF6(PAN6) 3 m no/DM 3 µM for 7 d 3.16, square
4AP DF6(PAN6) 3-4 m yes/AraC 1 µM for 7 d 3.16
paralelogram
4AP DF6(PAN6) 3-4 m no/DAPT 1 µM for 7 d 3.16 tilted square
4AP SZ02(PAN13) 5 m yes/AraC 1 µM for 7 d 3.16 hexagon
Aβ + 4AP DF6(PAN6) 3 m no/DM 3 µM for 7 d 3.33 circle
Aβ + 4AP DF6(PAN6) 3-4 m yes/AraC 1 µM for 7 d 3.33 square
Aβ + 4AP SZ02(PAN13) 5 m yes/AraC 1 µM for 7 d 3.33 triangle
ICC
4AP Timecourse SZ02(PAN13) 4 m yes/AraC 1 µM for 7 d 3.18
Aβ + 4AP SZ02(PAN13) 5 m yes/AraC 1 µM for 7 d 3.35
PatchC
Aβ DF6(PAN2) 4 m no/AraC 5 µM for 5 d 3.25 and 3.26
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